Conditions: Pneumonitis SARS-CoV Infection
Keywords: COVID-19
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 132
Healthy volunteers: no

Brief summary:
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection

Detailed description:
This Phase II randomized, double-blind, placebo-controlled, study will assess 2 different doses of GLS-1027 in the prevention of severe pneumonitis among those hospitalized with PCR confirmed SARS-CoV-2 infection. Subjects will be randomized at a 1:1:1 ratio to either Standard of Care (SOC) plus placebo, or SOC plus GLS-1027 at either 120 mg or 360 mg daily. Clinical status will be monitored through 56 days from the initiation of treatment.

Arms:
arm 1: One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily arm 2: Three 120 mg pills of GLS-1027 given by mouth once daily arm 3: Three Placebo pills given by mouth once daily

Interventions: intervention 1: GLS-1027 intervention 2: Placebo
Intervention descriptions: intervention 1: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity. intervention 2: Placebo looks like GLS-1027

Protocol document:
Prot_000.pdf: 
 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-1- 
 
 
 
 
Brief protocol title 
GLS27-005 
 
 
Formal protocol title 
Safety, Tolerability, Efficacy and Dose Response of GLS-
1027 in the Prevention of Severe Pneumonitis caused by 
SARS-CoV-2 Infection  
 
 
 
Regulatory Sponsor: 
GeneOne Life Science Inc.  
535 Pennsylvania Ave., Suite 200 
Fort Washington, PA 19034 
(610) 707-5671 
 
 
IND Protocol Number: 
150401 
 
 
Clinical Trials.gov #: 
NCT04590547 
 
 
 
Version Summary 
Initial version:  
Version 3.0 
11 Dec 2020 
Amendment:  
 
 
 
 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-2- 
 
 
 
CONFIDENTIAL 
The information in this document is considered privileged and confidential by GeneOne 
Life Science, Inc. and may not be disclosed to others except to the extent necessary to 
obtain Institutional Review Board/Ethics committee approval and informed consent, or as 
required by local regulatory authorities. Persons to whom this information is disclosed 
must be informed that this information is privileged and confidential and that it must not 
be further disclosed without the written permission of GeneOne Life Science, Inc. Any 
supplemental information added to this document is also confidential and proprietary 
information of GeneOne Life Science, Inc. and must be kept in confidence in the same 
manner as the contents of this document. 
 
 
 
  
 
 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-3- 
 
 
PROTOCOL ACKNOWLEDGEMENT 
 
 
I have read this Protocol and agree that it contains all necessary details for carrying out the study 
described. I understand that it must be reviewed by the Institutional Review Board or Independent 
Ethics Committee overseeing the conduct of the study and receive approval or a favorable opinion 
before implementation. 
 
The signature of the Principal Investigator and Sponsor below constitute their approval of this 
protocol and provide the necessary assurances that this study will be conducted according to the 
Declaration of Helsinki, GCP, ICH guidelines, local legal and regulatory regulations as well as to 
all stipulations of the protocol in both the clinical and administrative sections, including statements 
regarding confidentiality. 
 
 
 
 
_________________________________ 
 
 
_________________ 
Investigator’s printed name and signature 
 
 
Date 
 
 
 
 
11 Dec 2020 
_________________________________ 
 
 
_________________ 
Medical Monitor 
 
 
 
 
 
Date 
 
 
 
Protocol Number: GLS27-005 
Version Number: 3.0 / Version Date: 11 Dec 2020 
 
 
 
  
 
 
 
 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-4- 
 
 
TABLE OF CONTENTS 
 
PROTOCOL ACKNOWLEDGEMENT ................................................................................................... 3 
TABLE OF CONTENTS ........................................................................................................................... 4 
CLINICAL PROTOCOL SYNOPSIS ....................................................................................................... 8 
1. 
INTRODUCTION .............................................................................................................................. 13 
1.1 
Background and Rationale .................................................................................................. 13 
1.1.1 
Pre-clinical experience with GLS-1027 ..................................................................... 14 
1.1.2 
Human experience with GLS-1027............................................................................. 20 
1.2 
Investigational Agent ............................................................................................................ 21 
1.4 
Risk/Benefit Assessment ..................................................................................................... 22 
2. 
HYPOTHESIS AND STUDY OBJECTIVES ................................................................................ 23 
2.1 
Hypothesis ............................................................................................................................... 23 
2.2 
Primary Objectives and Outcome Variables ................................................................... 23 
2.3 
Exploratory Objectives ......................................................................................................... 23 
3. 
STUDY DESIGN ............................................................................................................................... 23 
3.1 
Safety Monitoring ................................................................................................................... 24 
3.2 
Data and Safety Monitoring Board (DSMB) ..................................................................... 24 
4. 
SELECTION AND ENROLLMENT OF PARTICIPANTS .......................................................... 24 
4.1 
Recruitment of Participants ................................................................................................ 24 
4.2 
Inclusion Criteria for enrollment ........................................................................................ 24 
4.3 
Exclusion Criteria for enrollment ....................................................................................... 25 
4.4 
Discontinuation/Withdrawal of Study Participants ....................................................... 25 
4.5 
Treatment with dexamethasone post-enrollment .......................................................... 26 
5. 
STUDY PRODUCT .......................................................................................................................... 26 
5.1 
Investigational Product ........................................................................................................ 26 
5.2 
Packaging and Labeling ....................................................................................................... 27 
5.3 
Handling of Study Drug ........................................................................................................ 27 
5.4 
Dispensing of Study Drug.................................................................................................... 27 
5.6 
Preparation of Investigational Product ............................................................................ 27 
5.7 
Record of Investigational Product Disposition at Site ................................................. 28 
5.8 
Return and Destruction of Investigational Product ...................................................... 28 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-5- 
 
 
6. 
STUDY PROCEDURES AND TREATMENTS ............................................................................ 28 
6.1 
Procedures by Visit (also see Table S2) .......................................................................... 28 
6.1.1 
Day 1: Review Study and Eligibility Criteria; Obtain Informed Consent, 
Enrollment ........................................................................................................................................ 28 
6.1.2 
Day 2 (PK sub-study participants ONLY) ................................................................. 28 
6.1.3 
Day 2 through 29 (or until discharge or death) ...................................................... 28 
6.1.4 
Day 56 ................................................................................................................................ 29 
6.2 
Timing and Evaluations ........................................................................................................ 29 
6.2.1 
Informed Consent (Day 1) ............................................................................................ 29 
6.2.2 
Enrollment (Day 1) ......................................................................................................... 29 
6.2.3 
Safety Assessments ...................................................................................................... 30 
6.3 
Assessment of Laboratory Abnormalities....................................................................... 31 
6.4 
Assessment of Clinical Adverse Events .......................................................................... 31 
6.5 
Plasma for PK sub-study and/or trough level determination of GLS-1027 ............ 31 
6.6 
Serum and PBMCs for immunology assessments ....................................................... 31 
7. 
EVALUATION OF SAFTY AND MANAGEMENT OF TOXICITY ............................................ 31 
7.1 
Safety Parameters .................................................................................................................. 31 
7.1.1 
Adverse Events (AEs) ................................................................................................... 31 
7.1.2 
Serious Adverse Events (SAEs) ................................................................................. 32 
7.1.3 
Suspected Unexpected Serious Adverse Drug Reactions (SUSARs) .............. 33 
7.1.4 
Assessing Severity (Intensity) .................................................................................... 33 
7.1.5 
Causal Relationship of Investigational Product to Adverse Events ................ 33 
7.1.6 
Abnormal Laboratory Values ...................................................................................... 34 
7.1.7 
Pregnancy During Study .............................................................................................. 34 
7.1.8 
Decreases in renal function during study ............................................................... 34 
7.1.9 
Post-study Reporting Requirements ........................................................................ 34 
7.2 
Methods and Timing for Collection and Recording of Safety Data .......................... 34 
7.3 
Safety and Toxicity Management ....................................................................................... 35 
7.3.1 
Events Requiring Expedited Reporting .................................................................... 35 
7.3.2 
Reasons to Discontinue Treatment ........................................................................... 35 
7.3.3 
Unblinding ........................................................................................................................ 37 
8. 
STATISTICAL METHODS and CONSIDERATIONS ................................................................ 37 
8.1 
Data Sets to be Analyzed ..................................................................................................... 37 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-6- 
 
 
8.2 
Sample Size ............................................................................................................................. 37 
8.3 
Randomization ........................................................................................................................ 38 
8.4 
Demographic and Other Baseline Characteristics ........................................................ 38 
8.5 
Safety Analysis ....................................................................................................................... 38 
8.5.1 
Adverse events ............................................................................................................... 38 
8.5.2 
Laboratory Data .............................................................................................................. 38 
8.6 
Efficacy Analysis .................................................................................................................... 39 
8.7 
Other Analysis ........................................................................................................................ 39 
8.8 
Interim Analysis ...................................................................................................................... 40 
8.9 
Missing Values ........................................................................................................................ 40 
9. 
DATA COLLECTION, MONITORING, AND AE REPORTING ................................................ 41 
9.1 
Confidentiality ......................................................................................................................... 41 
9.2 
Source Documents ................................................................................................................ 41 
9.3 
Data Collection ....................................................................................................................... 41 
9.4 
Record Retention ................................................................................................................... 41 
9.5 
Safety and Quality Monitoring and Record Availability ............................................... 41 
9.6 
Adverse event (AE) Reporting ............................................................................................ 42 
9.6.1 
Study Reporting Period of Adverse Events ............................................................ 42 
9.6.2 
Study Reporting Period for Serious Adverse Events ........................................... 42 
9.6.3 
Notification of Serious Adverse Events ................................................................... 43 
9.7 
Study Termination ................................................................................................................. 43 
10. 
PUBLICATION OF RESEARCH FINDINGS ........................................................................... 44 
11. 
LIST OF ABBREVIATIONS ....................................................................................................... 44 
12. 
REFERENCES ............................................................................................................................. 45 
13. 
APPENDICES ............................................................................................................................... 47 
 
List of Figures 
FIGURE 1.1.1.1-1: PULMONARY LPS-INDUCED INFLAMMATION IS INHIBITED BY GLS-1027 ......... 15 
FIGURE 1.1.1.1-2: PULMONARY LPS-INDUCED INFLAMMATION IS INHIBITED BY GLS-1027 ......... 16 
FIGURE 1.1.1.2-2: GLS-1027 LOWERS PM2.5 INDUCED LUNG INFLAMMATION AND AIRWAY 
RESISTANCE .................................................................................................................................................. 18 
FIGURE 1.1.1.3-1: SARS-COV CASE-FATALITY RELATIVE TO PROVINCIAL AIR POLLUTION 
INDEX  .............................................................................................................................................................. 19 
FIGURE 1.2-1: STRUCTURE OF GLS-1027 ....................................................................................................... 21 
FIGURE 1.2-2: STRUCTURE OF MICROCRYSTALLINE CELLULOSE ....................................................... 22 
 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-7- 
 
 
List of Tables 
TABLE 5.2-1. GLS-1027 AND PLACEBO DRUG PRODUCT VIAL LABELS .............................................. 27 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-8- 
 
 
CLINICAL PROTOCOL SYNOPSIS 
Title of study: Safety, Tolerability, Efficacy and Dose Response of GLS-1027 in the Prevention of 
Severe Pneumonitis caused by SARS-CoV-2 Infection 
Number of study participants: 132 
Study Phase: II 
Study Type: Randomized, double-blind, placebo-controlled  
Research Hypothesis: GLS-1027 will be safe, well tolerated and reduce the incidence of treatment 
failure as characterized by 1) advancing to WHO COVID-19 Classification level ≥6 which includes the 
need for intubation with mechanical ventilation, initiation of extracorporeal mechanical oxygenation 
(ECMO), or death, in SARS-CoV-2 infected hospitalized patients, 2) need for institution of salvage 
therapy 72 hours after study entry with either an IL-6 monoclonal antibody or dexamethasone (≥6 
mg/day), 3) withdrawing consent from the study, 4) becoming lost to follow-up, or 5) discontinuation 
of treatment for any reason other than decrease in renal function or pregnancy. 
Primary study objectives and outcome variables:  
 Incidence of serious adverse events relative to treatment group 
 Incidence of treatment failure within 28 days from enrollment 
Exploratory study objectives and outcome variables: 
 Assess the number of days requiring ICU care relative to treatment group 
 Assess the number of days of mechanical ventilation relative to treatment group 
 Assess incidence of WHO COVID-19 Classification levels relative to baseline serum IL-6 level 
 Assess incidence of WHO COVID-19 Classification levels relative to baseline serum ferritin level 
 Assess incidence of WHO COVID-19 Classification levels relative to baseline CRP  
 Assess trough level of GLS-1027 relative to serum creatinine 
 Assess the maximal level of Positive End-Expiratory Pressure (PEEP) for subjects who are 
intubated relative to treatment group.  
 Assess the number of days of PEEP > 5 cm H2O for subjects who are intubated relative to 
treatment group 
 Incidence of progression to  WHO COVID-19 Classification level 6, or 7, or 8 (individually) 
 Assess SARS-CoV-2 IgM antibody responses relative to treatment group 
Table S1: Dosing arms and treatment regimen 
Group 
N 
Treatment assignment 
Study drug 
dose 
Treatment 
schedule 
1 
44 
Placebo + SOC 
0 mg 
Daily 
2 
44 
GLS-1027 + SOC 
120 mg 
Daily 
3 
44 
GLS-1027 + SOC 
360 mg 
Daily 
 
Study design: 
Phase II randomized, double-blind, placebo-controlled, study to assess 2 different doses of GLS-
1027 in the prevention of treatment failure among participants admitted to hospital with PCR 
confirmed infection with SARS-CoV-2 (WHO classification 3 or 4). The enrollment period will extend 
to 72 hours from hospital admission. Participants will be randomized at a 1:1:1 ratio to either SOC 
plus placebo, or SOC plus GLS-1027 at either 120 mg or 360 mg daily. Participants will be 
administered drug until discharge or death for a maximum treatment period of 28 days. Clinical status 
will be monitored through 56 days from the initiation of treatment.  


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-9- 
 
 
Sample Size: 
Based early literature reports [1], it is anticipated that approximately 50% of subjects hospitalized with 
PCR-positive SARS-CoV-2 infections (WHO COVID-19 Classification level 3 or 4) will progress to 
WHO COVID-19 classification level of 6 or greater as defined by one or more of the following: the need 
for intubation or mechanical ventilation (level 6), the need for ECMO (level 7), or any cause death (level 
8). The sample size estimate for this proof of concept is based on Fisher’s Exact two-sided test for 2 
proportions using NQuery 8 (www.statsols.com).  
 
Although the interim analysis will utilize masked treatment assignments, the O’Brien Fleming group 
sequential sample size estimation confirms that a single interim look would retain a cumulative exit 
probability of 70% with a cumulative alpha =0.05 after the final analysis using the target enrollment of 
132 (44 per group) to detect a reduction of those reaching the endpoint of treatment failure, which 
includes advancing to WHO COVID-19 Classification level ≥6 from 50% (SOC treated) to 25% in either 
treatment group of SOC plus GLS-1027. Other conditions also qualify a subject as treatment failure 
include: need for salvage therapy with IL-6 monoclonal antibody; or institution of salvage therapy with 
dexamethasone (≥ 6 mg/day), withdrawing consent from the study, becoming lost to follow-up, or 
discontinuation of treatment for any reason other than renal function or pregnancy.  This study is not 
powered to assess statistically significant differences between GLS-1027 doses.  
Study assessments: 
Adverse events will be monitored and recorded throughout hospitalization from the point of enrollment. 
Daily assessments of vital signs and clinical laboratory parameters will be reviewed and recorded. 
Follow-up clinical status will be assessed to Day 56.  The first 15 persons enrolled will be included in a 
pharmacokinetic sub-study assessment to determine elimination of GLS-1027, while trough levels will 
be monitored throughout the study.  
Efficacy will be assessed by evaluating the difference in the proportion of treatment failures by group.  
Treatment failure will be defined as any of the following:  
1) progression to WHO COVID-19 classification level of 6 or greater within the 28 days of treatment 
initiation,  
2) need for salvage therapy with IL-6 monoclonal antibody; or institution of salvage therapy with 
dexamethasone (≥ 6 mg/day),   
3) withdrawing consent from the study,  
4) becoming lost to follow-up, or  
5) discontinuation of treatment for any reason other than renal function or pregnancy. 
A masked interim analysis will be performed when 22 subjects in each group have been assessed for 
the primary endpoint of treatment failure.  The interim analysis is intended for blinded safety assessment. 
Unless safety is of concern, the study will not be stopped for futility and enrollment will continue to the 
targeted sample size of 132. 
Study population: 
Inclusion criteria for enrollment: 
1. Age 18 years or older 
2. Able to provide consent  
3. Able and willing to comply with study procedures 
4. Enrollment within 72 hrs of hospitalization with a diagnosis of PCR confirmed SARS-CoV-2  
5. WHO COVID-19 classification level 3 or 4 
Exclusion criteria for enrollment: 
1. Pregnant or lactating 
2. SpO2 less than 90% on room air or less than 95% if on supplemental oxygen 
3. Calculated GFR < 60 (Cockcroft-Gault)  


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-10- 
 
 
4. Meets hospital COVID-19 treatment algorithm for treatment with dexamethasone at a dose of 6 
mg/day for a 10-day course. A single bolus dose of 6 mg of dexamethasone given in the 
Emergency Department and continued at a dose of ≤ 3.5 mg/day or less is allowed. 
5. Meets treatment algorithm criteria for treatment with toclizumab or other anti-IL-6 agent 
6. Treatment with an anti-IL-6 inhibitor, anti-IL-1 inhibitor, anti-TNF monoclonal antibody, or anti-
JAK inhibitor (see Appendix A exclusionary period for specific drugs)  
7. Participation in a COVID-19 clinical trial that includes prescription of a drug with anti-cytokine 
activity 
8. Treatment within the past 60 days with a chemotherapeutic agent 
9. Current treatment with systemic corticosteroids at a dose equivalent of 20 mg/day or greater of 
prednisone or prednisolone, 16 mg/day or greater of methylprednisolone, or 4 mg/day or 
greater of dexamethasone  
10. Diagnosis of leukemia or lymphoma  
11. WHO COVID-19 classification level of 5 or greater (use of high-flow oxygen, non-mechanical 
ventilation such as CPAP, mechanical ventilation)  


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-11- 
 
 
Table S2: Schedule of Events per Study Day 
Tests and Observations 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
56m 
Clinical Evaluations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obtain written Informed Consent  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confirm Eligibility Criteria 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical History  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Review Medical Record 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
WHO COVID-19 Classification (Appendix B) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Safety Evaluations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Record Adverse Events  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Record Vital Signs a 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Record Hematology b 
X 
X 
X 
X 
X 
X 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
Record Basic Metabolic Panel, LFTs c 
X 
X 
X 
X 
X 
X 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
Record other labs d (for days available) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Record Procalcitonin (baseline value) e 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Record admission CXR  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Record if care given in ICU setting  
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Record whether nasal O2 prescribed and dose 
level (L/min) f 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Record whether CPAP prescribed and 
expiratory pressure g 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Record if mechanically ventilated and level of 
PEEP, % FiO2 h 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Record if treated by ECMO 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Record admission ECG 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Related Procedures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Administer assigned study drug i 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
(X) 
 
Perform urine pregnancy test 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Perform ECG (12-lead) j 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collect serum for CPK, GGT k 
X 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collect blood for plasma for PK assessment l 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collect blood for plasma for trough drug 
measurement (AM blood draw) 
 
X 
X 
X 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
X 
 
 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-12- 
 
 
Collect blood for serum (10mL red top,3 tubes) 
X 
 
 
X 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
X 
 
 
Collect blood for PBMCs (10mL ACD; 3 tubes) 
X 
 
 
X 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
X 
 
 
Blood volume for serum, PBMCs 
60 
 
 
60 
 
 
5 
 
60 
 
 
 
 
 
 
60 
 
 
 
 
 
 
60 
 
 
 
 
60 
 
 
 
a Vital signs to be recorded daily to include maximal and minimal: temperature, respiratory rate, heart rate, systolic and diastolic blood pressure 
b Hematology labs to be collected as necessary and recorded: Hemoglobin, hematocrit, platelets, neutrophils, band forms, lymphocytes, eosinophils 
c Basic metabolic panel labs to be collected as necessary and recorded: Sodium, potassium, CO2 (bicarbonate), creatinine, BUN, glucose, liver function tests 
(LFTs) that should be recorded include AST, ALT, bilirubin (direct), alkaline phosphatase, LDH, albumin . These labs are performed daily per the hospital COVID 
algorithm. 
d Other labs to be recorded as available: Ferritin, CRP, IL-6, troponin, D-dimer 
e Procalcitonin: record only initial measurement or within 48 hours of admission and/or SARS-CoV-2 diagnosis (may be performed prior to date of enrollment) 
f Record maximal daily level of O2 by nasal cannula prescribed, if applicable 
g Record maximal daily level of end expiratory pressure delivered by CPAP prescribed, if applicable 
h Record maximal daily level of PEEP and delivered FiO2 by mechanical ventilation, if applicable 
i Study drug administration will commence on the day of enrollment if treatment can be administered before 10 pm and then with AM medications thereafter, If, 
study drug cannot be administered prior to 10 pm on the day of enrollment, then the 1st day of treatment will occur on the day after enrollment.  
j Perform a 12-lead ECG on the 2nd day of treatment with study drug between 75 and 90 minutes post-administration on day 2; and on day 15 (± 2 days) 
k Serum is collected for CPK and GGT on day 1 and day 7, and weekly thereafter, if values on day 7 are abnormal until return to normal 
l PK assessment will be performed for the initial 15 subjects enrolled. Blood (5 ml) will be collected for plasma collection at baseline (pre-treatment), and then at 1, 
2, 4, and 8 hr. Trough measurements will be obtained as indicated for all study participants  
m The clinical record should be reviewed through to Day 56 as relevant to denote date of discharge, date of death, or clinical status (WHO COVID-19 Classification 
Level) at Day 56  
 
 
 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-13- 
 
 
1. 
INTRODUCTION 
This study will examine whether GLS-1027 is safe, tolerated and can reduce the risk 
treatment failure among patients admitted to hospital with confirmed Severe Acute 
Respiratory Syndrome coronavirus type 2 (SARS-CoV-2) infection and who require 
supplemental oxygen and assess if there appears to be a dose dependent response. 
1.1 
Background and Rationale 
SARS-CoV-2 is a novel coronavirus first recognized in November 2019. Since discovery, 
greater than 60 million confirmed cases and greater than 1 million deaths have been 
documented globally, and greater than 13 million cases and greater than 250,000 deaths 
in the US, as of 30 November, 2020. Although coronaviruses typically cause a self-limited 
upper respiratory infection in the winter months, SARS-CoV-2 represents the third highly 
pathogenic coronavirus to emerge over the past 2 decades. SARS-CoV similarly was first 
recognized in 2002 and over the two-year period between 2002-2003 there were 
approximately 8,000 cases with a mortality rate of 10% and resulted in outbreaks and 
cases worldwide. The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has 
resulted in fewer than 3,000 cases but with a mortality rate of 36-38%. Cases of MERS-
CoV have been largely restricted to inhabitants of or travelers to the Arabian peninsula or 
neighboring countries.  
Clinically, each of the pathogenic coronaviruses cause lower respiratory tract illness. For 
SARS-CoV-2, clinical illness typically starts with a viral prodrome characterized by 
malaise, muscle aches, and headache that can progress to a febrile illness with 
diaphoresis. Less usual, but pathognomonic signs are anosmia, ageusia, conjunctivitis, 
and perniosis. While most individuals will recover, progression to increasing respiratory 
compromise requiring oxygenation, high-flow oxygenation, intubation and mechanical 
ventilation, extracorporeal mechanical oxygenation (ECMO), or death may occur. Other 
complications of severe disease include renal failure and arterial thrombosis that may 
present as stroke, myocardial infarction, or peripheral arterial obstruction. Early studies 
reported that approximately 50% of those who require supplemental oxygenation after 
admission to hospital progress to needing mechanical ventilation at some time during 
hospitalization [1]. It is generally considered that as the level of acuity of admitted patients 
has increased, this percentage of those progressing to severe disease is likely higher. 
The mortality rate of those requiring mechanical ventilation has been reported as 50-80% 
[1] including recent data reported from New York City. Risk factors for severe disease and 
death include older age, diabetes mellitus, hypertension, cardiac disease, and chronic 
obstructive pulmonary disease. As was reported for both SARS-CoV and MERS-CoV, the 
fatality rate in men exceeds that for women.  
Pulmonary disease associated with SARS-CoV-2 infection is characterized by a marked 
inflammatory component that was not described for either SARS-CoV or MERS-CoV. In 
fact, at presentation, minimally symptomatic patients may present with marked interstitial 
inflammatory changes on chest radiography presenting as “white-out” as described by 
colleagues treating infected patients in Seoul, Korea. Of interest, a similar presentation 
of severe pulmonary inflammatory disease despite a relatively low level of virus has been 
observed in ferrets). This inflammatory pneumonitis has been ascribed inflammatory 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-14- 
 
 
cytokine release. related to the release of multiple cytokines including TNFα, IL-1β, IL-6 
and can lead to capillary leakage, hypotension, and myocardial dysfunction.  
Treatment with anti-IL-6 monoclonal antibodies (mAb) such as tocilizumab or siltuximab 
for severe SARS-CoV-2 infection. Although anti-IL-6 mAbs appeared to be potentially 
beneficial, later studies did not bear this out. Moreover, anti-IL-6 mAbs are parenterally 
administered, difficult and expensive to manufacture, and are associated with potential 
serious adverse events including severe hypersensitivity and risk for opportunistic 
infection. A recent report provides critical insights as to why treatment directed against a 
single cytokine may be insufficient finding that the inflammatory effects were related to 
combinations of cytokines, especially TNFα plus IFNγ, whereas individual cytokines were 
not pathogenic [2].  
GLS-1027 is an oral medication with high bioavailability that has inhibitory activity against 
multiple inflammatory cytokines including IL-6, IL-1β, TNFα, IL-17, and IL-23 and 
decreases Th17 T cell activity. As reviewed below, in pre-clinical studies, GLS-1027 is as 
potent in preventing inflammatory changes as dexamethasone. GLS-1027 is being 
assessed for the prevention of progression of severe respiratory disease among patients 
admitted to the hospital with documented SARS-CoV-2 infection and who require 
supplemental oxygen. The hypothesis being tested is whether daily oral treatment of 
GLS-1027 for those admitted to hospital at WHO COVID-19 Classification level of 3 or 4 
will significantly reduce the number of SARS-CoV-2 infected patients who fail treatment. 
Pre-clinical and clinical experience with GLS-1027 are presented in the sections below.  
1.1.1 Pre-clinical experience with GLS-1027 
There is extensive literature regarding the use of GLS-1027 in either in vitro or in vivo 
animal models of inflammatory and autoimmune diseases with greater than 25 papers 
published by more than 15 groups of investigators. In the scientific literature, the GLS-
1027 molecule is also known as VGX-1027 or GIT-27. For simplicity, the summaries 
below will only use the designation of GLS-1027. Those papers relevant to this study are 
presented in detail below. 
In vitro, GLS-1027 was shown to prevent development of carragenen-induced pleuritis in 
mice with treatment effects similar to a monoclonal antibody against TNFα [3] and was 
equal to dexamethasone to prevent the development of collagen-induced arthritis [3] in 
mice and to prevent LPS-induced uveitis in rats [4]. The therapeutic effect of GLS-1027 
correlated with inhibition of IL-1β, IL-6, and TNFα.  
Unpublished data have also shown that GLS-1027 can successfully treat dogs with 
steroid-resistant autoimmune uveitis.  
Of note, dexamethasone is the only treatment that has prevented progression of COVID-
19 disease that has borne the test of time.  
 
1.1.1.1. GLS-1027 protects mice from LPS-induced acute lung injury 
Zhang et al. studied a model of lipopolysaccharide (LPS) induced acute lung injury in 
mice [5]. Following intranasal infusion of 10 μg of LPS mice were treated intraperitoneally 
an hour later with either atractylenolide I at doses of 5, 10, or 20 mg/kg or GLS-1027 at 
0.5 mg/mouse (approximately 20 mg/kg).  


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-15- 
 
 
 
 
Figure 1.1.1.1-1: Pulmonary LPS-induced inflammation is inhibited by GLS-1027 
Effects of AO-I on histopathological changes in lung tissues in LPS-induced ALI mice. Mice were given an 
intraperitoneal injection of AO-I (5,10 and 20 mg/kg) 1h after administration of LPS. Lungs tissues from each 
experimental group were processed for histological evaluation at 6h after LPS challenge. Representative histological 
changes of lung obtained from mice of different groups. A:Control group, B:LPS group, C:LPS + AO-I (5mg/kg) group, 
D:LPS +A O-I (10mg/kg) group, E:LPS + AO-I (20mg/kg) group, F: LPS + VGX-1027 (0.5mg/mouse) (Hematoxylin and 
eosin staining, magnification 200). 
As shown in Figure 1.1.1.1-1 (Fig 1 from paper), compared to control untreated mice 
(Panel A), LPS induced significant inflammatory changes with thickened interstitial 
membranes and small alveolar spaces. Whereas atractylenolide showed a dose-related 
effect with near-normal lung histology at the highest dose (Panel E), animals treated with 
GLS-1027 had normal lung histology (Panel F). GLS-1027 treatment was also associated 
with significant decreases in neutrophil and macrophage influx into the lungs relative to 
LPS. Importantly, the anti-inflammatory effect of GLS-1027 was associated with 
significantly lower levels of IL-6, IL-13, TNFα, and IL-1β (Figure 1.1.1.1-2 panels A-D 
respectively, called VGX-1027 in Fig 5 from paper). The inflammatory changes related to 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-16- 
 
 
SARS-CoV-2 infection are expected to mirror the pathogenesis of LPS induced lung injury 
demonstrating a potential benefit of GLS-1027 treatment.  
 
 
 
 
 
Figure 1.1.1.1-2: Pulmonary LPS-induced inflammation is inhibited by GLS-1027 Effects of AO-I and GLS(VGX)-
1027 on TNF-α, IL-6, IL-1β, IL-10, IL-13, and MIF production in the BALF of LPS-induced ALI mice. BALF was collected 
a t 6 h following LPS challenge to analyze the inflammatory cytokines TNF-α, IL-6, IL-1β, IL-10, IL-13 and MIF. The 
values presented are mean +- S.D. (n = 12 in each analysis) of three independent experiments. P# <0.01 vs control 
group, P* < 0.05, P** < 0.01 vs LPS group. 
 
1.1.1.2. Lung inflammation induced by PM2.5 particulates is prevented by GLS-1027; 
Potential role for particulate enhancement of SARS-CoV and SARS-CoV-2 
related disease 
Xu et al. examined whether GLS-1027 could prevent PM2.5 particulate induced lung 
inflammation [6]. The deleterious pulmonary effects of air pollution are associated with fine 
particular matter of a size less than 2.5 μm, referred to as PM2.5, which leads to multiple 
respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), 
and lung cancer.  
A 
B 
C 
D 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-17- 
 
 
Mice pretreated with GLS-1027 (25 mg/kg given intraperitoneally) were exposed to PM2.5 
particulates (7.8 mg/kg) over two consecutive days. Whereas PM2.5 exposed, untreated 
mice developed significant inflammatory changes in the lungs and bronchi consisting of 
infiltration of mononuclear cells and thickened alveoli, PM2.5 exposed, GLS-1027 treated 
animals did not akin to PBS treated controls. Bronchoalveolar lavage fluid demonstrated 
that alveolar inflammation was associated with marked increases in TNFα, IL-1β, and IL-
6; increases blocked by GLS-1027 as correlated with mRNA transcriptional reductions 
(Figure 1.1.1.2-1, Fig 3 from paper).  
 
Figure 1.1.1.2-1: GLS-1027 inhibits PM2.5 induced inflammatory cytokine expression Effect of PM 2.5 (7.8 mg/kg) 
exposure and of VGX-1027 (25 mg/kg) pretreatment on individual and mean levels of TNF-α (A), IL-1β (B) and IL-6 (C) 
in bronchoalveolar lavage (BAL) fluid. *P < 0.05, **P < 0.01, ***P < 0.001 compared with PBS-pretreated PM2.5-instilled 
mice 
The therapeutic effect of GLS-1027 in PM2.5 exposed mice yielded lower pulmonary 
inflammation scores (Figure 1.1.1.2-2, panel A; VGX-1027 in Fig 4E from paper). 
Moreover, GLS-1027 treatment lowers PM2.5 induced airway resistance (Figure 1.1.1.2-
2, panel B; VGX-1027 in Fig 1C from paper) – a factor that is a critical determinant in 
being able to effectively oxygenate persons after airway intubation. GLS-1027 also 
reduced levels of IL-18, caspase-1 and NLRP3 inflammasome mRNA.  
A.
B.
C


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-18- 
 
 
  
 
  
Figure 1.1.1.2-2: GLS-1027 lowers PM2.5 induced lung inflammation and airway resistance Effect of PM2.5 (7.8 
mg/kg) exposure and of VGX-1027 (25 mg/kg) pretreatment on lung inflammation (A) and airway resistance (B). A. 
Individual and mean values of inflammation scores measured from H&E-stained sections. *P<0.05, **P<0.01, 
***P<0.001 compared with PBS-pretreated PM2.5-instilled mice. B. Individual and mean airway resistance at 256 mg/mL. 
*P<0.05, **P<0.01, ***P<0.001 compared with PBS-pretreated PM2.5-instilled mice. 
 
1.1.1.3. Particulate exposure is associated with increased mortality SARS-CoV and 
SARS-CoV-2 
Lung pollution has also been associated with greater morbidity and mortality with severe 
coronavirus infection. Cui et al. examined the mortality during the 2002-2003 SARS-CoV 
epidemic in China [7]. They found a 2-fold increase in mortality between regions 
experiencing either short-term or long-term exposure to environmental particulates 
yielding an air pollution index > 100 relative to an index < 75. Moreover, analysis of 
Chinese provinces reveals a near linear relationship (R2 = 0.86) between air pollution 
index and SARS-CoV case fatality rate (Figure 1.1.1.3-1; Fig. 1 from paper). A similar 
association is being anecdotally reported for SARS-CoV-2 infection and has been 
postulated by many as a risk factor for greater mortality.  
A.
B.


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-19- 
 
 
                                          
 
Figure 1.1.1.3-1: SARS-CoV case-fatality relative to provincial air pollution index The correlation and 
association between short-term exposure to ambient air pollution and case fatality of SARS in People's Republic of 
China.  
The data showing that GLS-1027 reduces airway inflammation related to PM2.5 air 
pollution provides a potential second important anti-inflammatory effect of GLS-1027 that 
may be associated with lower progression to severe pulmonary disease. Moreover, the 
fact that PM2.5 exposure was associated with greater airway resistance, an effect blocked 
by GLS-1027 in mice, raises the possibility that, for those individuals who progress to 
requiring mechanical ventilation, continued GLS-1027 treatment may increase ventilatory 
effectiveness and possibly reduce the level of positive end-expiratory pressure (PEEP) 
required to maintain oxygenation status. Note, that in general, higher levels of PEEP are 
considered as a negative prognostic factor for survival. Thus, an additional exploratory 
goal of this study will be to determine whether those patients who do progress to 
intubation and mechanical ventilation differ in the level of PEEP required relative to 
treatment group. 
  
1.1.1.4. Biomaterial induced thrombosis is TLR2/4 mediated  
Langadec et al. investigated the pathogenesis of biomaterial induced thrombosis [8]. 
Some observations from this study have relevance to the use of GLS-1027 in SARS-CoV-
2 disease. The study showed that pathogenesis of thrombogenesis was initiated through 
a classic inflammatory response involving NF-κB translocation resulting in induction of 
TNFα and pro-IL-1β release, the latter then cleaved to IL-1β through caspase-1 cleavage. 
In addition, there is formation of the NLRP3 inflammasome that together with the 
inflammatory cytokines IL-1β, IL-6, and IL-18 serves as the initial triggering mechanism 
to start a thrombotic response. The investigators demonstrated the critical role of IL-6 in 
this process and demonstrated that GLS-1027 was able to effectively block the initiating 
inflammatory cytokine IL-1B and IL-6 activation pathways.  
It is of interest that there have been a large number of recent reports of relatively healthy, 
young patients presenting with SARS-CoV-2 infection complicated by intracerebral and 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-20- 
 
 
peripheral arterial thromboses resulting in stroke (including fatal strokes) and vascular 
compromise leading to amputation of legs and myocardial infarction.  
Whether the thrombotic complications associated with SARS-CoV-2 infection are related 
to an inflammatory priming event is, as yet, unknown. However, should such a 
mechanism ultimately be proven, it provides yet another inflammatory complication of 
SARS-CoV-2 infection that may be benefitted by GLS-1027. Thus, this study as an 
exploratory goal will additionally determine whether thrombotic complications differ 
relative to treatment group.   
1.1.1.5. GLS-1027 inhibits IL-6 mediated neuroinflammation in TBI and autism 
models  
Additional studies documented the ability of GLS-1027 to inhibit IL-6, IL-1β, and TNFα in 
neuroinflammatory models.  
The study by Laird et al. investigated the role of GLS-1027 to reduce cerebral edema and 
neuroinflammation following traumatic brain injury (TBI) [9]. In this study, the investigators 
found that high mobility group box protein-1 (HMGB1) is released from damaged neurons 
following traumatic brain injury in mice. HMGB1 in turn activates TLR4 on microglial cells 
and induces release of aquaporin-4, a water channel, that results in cerebral edema. This 
pathway is IL-6 mediated and was blocked by pharmacologic treatment of mice with GLS-
1027. Thus, a common secondary complication of increased cerebral edema that can 
occur following cerebral thrombosis and stroke may additionally be benefitted by 
treatment with GLS-1027. Since vascular complications are considered to be seen in a 
minority of study subjects, with stroke representing only a subset of patients, any potential 
treatment effects of GLS-1027 in preventing or ameliorating cerebral edema will be 
observed and catalogued but will not be included as an exploratory aim of the study. 
Should such complications be observed then they will be catalogued as part of the Clinical 
Study Report (CSR) and published with clinical trial results.  
Ahmad et al. studied the effect of GLS-1027 on neuroinflammation in BTPR Itpr3tf/J mice, 
a model of human autism [10]. As with other studies, GLS-1027 was observed to down-
regulate inflammatory cytokines IL-1β, IL-6, and TNFα in peripheral mononuclear cells. 
Of note, GLS-1027 was also able to down regulate the same inflammatory response in 
neural tissue, confirming that the drug was able to penetrate the blood brain barrier and 
limit neuroinflammation.  
1.1.2 Human experience with GLS-1027 
GLS-1027 has completed two Phase I safety and pharmacodynamic studies: CAT-001 
(NCT00627120) and CAT-002 (NCT00760396). The compound was then called VGX-
1027. Both human clinical studies, as well as pre-clinical pharmacokinetic (PK) studies, 
were published together in 2016 by Lee et al. [11]. More detailed information regarding 
these clinical trials is presented in the GLS-1027 Investigator’s Brochure.  
CAT-001 was a single-ascending dose study of GLS-1027. Six subjects each received 
single doses of drug at 0, 1, 10, 100, 200, 400, and 800 mg in a fasted state with 72-96 
hours between administration of successive doses. An additional sub-study was 
conducted to determine PK of a 100 mg dose given in a fasted or fed state. CAT-002 was 
a multiple-ascending dose study of GLS-1027 administered at doses of either 0, 40, 100, 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-21- 
 
 
200 mg daily, or 200 mg twice daily over a 5-day period. Adverse events and PK were 
assessed during the trial.  
Overall, in the multiple ascending dose study, 15 of the 40 subjects experienced one or 
more adverse events. Among those receiving study drug, grade 1 hypertension was 
observed in 4 subjects at each of the three highest doses of 100, 200, and 200 mg BID. 
Each of these subjects had borderline elevations in systolic blood pressure (>145). 
Additionally, two subjects in the single ascending dose study (100, 200 mg) experienced 
neutropenia. Both subjects were of African American ethnicity and had low baseline 
neutrophil counts. Headache was observed in two individuals in the multiple dose study 
(200, 200 mg BID). Hypersomnia was observed in two individuals in the single dose study 
who received 10 mg of GLS-1027, however, it was also observed in two placebo subjects 
in the single dose study.  
The pharmacokinetic profile of GLS-1027 showed proportionate increases in peak serum 
concentration and AUC relative to dose with normalized Cmax of approximately 60 μg/L/mg 
and normalized AUC of 450-500 μg-hr/L/mg. Serum Cmax and AUC was increased by a 
factor of approximately 1.4-1.5 in the fed state. The serum half-life was approximately 7 
hours with no drug accumulation observed over the 5-day period at any dose level. Drug 
was highly bioavailable with 90% excreted unchanged in the urine. Separate pre-clinical 
toxicology studies showed no evidence of hepatic metabolism or interaction with the 
cytochrome P450 enzymes.   
GLS-1027 was safe and well-tolerated in these two Phase I studies with a PK profile that 
demonstrated high bioavailability, renal excretion, and pharmacodynamics that support 
daily dosing.  
1.2 
Investigational Agent 
GLS-1027, the therapeutic agent in this study, is an isoxazole compound. The structure 
of GLS-1027, [S,R]-3-phenyl-4,5-dihydro-isoxazoleacetic acid, is shown below (Figure 
1.2-1). 
Microcrystalline cellulose will be used as the placebo in this study. The structure of 
microcrystalline cellulose is shown below (Figure 1.2-2). 
                                          
 
   
 
Figure 1.2-1: Structure of GLS-1027 
 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-22- 
 
 
 
Figure 1.2-2: Structure of microcrystalline cellulose 
 
1.3 
Dose and Regimen Rationale  
The doses of GLS-1027 used in this clinical trial are 120 mg or 360 mg given orally once 
daily. Pre-clinical studies have found that the effective dose in mice of 20 mg/kg would 
correlate to a human dose of 1.626 mg/kg, or 113 mg for a 70 kg person. This study will 
assess doses of 120 mg and 360 mg given in the fasting state to determine whether there 
is a dose effect. Treatment will commence on the day of enrollment (or the following day 
if drug administration would be after 10 pm) and then once daily, given with daily AM 
medications through the period of hospitalization to a maximum treatment period of 28 
days.  
1.4 
Risk/Benefit Assessment 
In accordance with the International Conference on Harmonization (ICH), this study has 
been designed to minimize the risk to study participants. The potential benefit of treatment 
is to reduce the incidence of progression to severe disease is consistent with the known 
risks and adverse events known to occur with GLS-1027. Since patients will be monitored 
in an in-patient setting, daily changes in clinical status can be assessed and changes to 
drug regimens made as clinically indicated.  
GLS-1027 has been well tolerated in Phase I clinical studies. The doses chosen conform 
to those already studied and known to be tolerated. The maximal dose level is below the 
800 mg/day maximal dose in the single ascending dose study (CAT-001) or the 400 
mg/day maximal dose in the multiple ascending dose study (CAT-002).  
An initial PK assessment of GLS-1027 will be conducted for the initial 15 enrollees. For 
all subjects, trough dosing will be assessed throughout the study. Modifications to drug 
dosing will be made based on changes in renal function as warranted, as described in 
Section 5.4.  
 
 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-23- 
 
 
 
2. 
HYPOTHESIS AND STUDY OBJECTIVES 
2.1 
Hypothesis 
GLS-1027 will be safe, well tolerated and, for those admitted to hospital with PCR 
confirmed SARS-CoV-2 infection at WHO COVID-19 classification level of 3 or 4, will 
reduce likelihood for progression to WHO COVID-19 classification level of 6 or greater 
(defined as severe pneumonitis characterized by the need for intubation with mechanical 
ventilation, initiation of ECMO, or death) or need for salvage treatment started 72 hours 
after study entry with either an IL-6 monoclonal antibody or dexamethasone at a dose of 
≥ 6 mg/day. 
2.2 
Primary Objectives and Outcome Variables 
 Incidence of serious adverse events relative to treatment group 
 Incidence of treatment failure within 28 days from enrollment 
2.3 
Exploratory Objectives 
 Assess the number of days requiring ICU care relative to treatment group 
 Assess the number of days of mechanical ventilation relative to treatment group 
 Assess incidence of WHO COVID-19 Classification levels relative to baseline 
serum IL-6 level 
 Assess incidence of WHO COVID-19 Classification levels relative to baseline 
serum ferritin level 
 Assess incidence of WHO COVID-19 Classification levels relative to baseline 
CRP  
 Assess trough level of GLS-1027 relative to serum creatinine 
 Assess the maximal level of Positive End-Expiratory Pressure (PEEP) for 
subjects who are intubated relative to treatment group.  
 Assess the number of days of PEEP > 5 cm H2O for subjects who are intubated 
relative to treatment group 
 Incidence of progression to  WHO COVID-19 Classification level 6, or 7, or 8 
(individually) 
 
Assess SARS-CoV-2 IgM antibody responses relative to treatment group 
3. 
STUDY DESIGN 
This is a Phase II, randomized, double-blind, placebo-controlled study to assess 2 dose 
levels of GLS-1027 for the prevention of treatment failure among participants admitted to 
hospital with PCR confirmed infection with SARS-CoV-2 (WHO classification 3 or 4). The 
enrollment period will extend to 72 hours from hospital admission. 
 
Participants will be randomized to placebo or GLS-1027 at either 120 mg or 360 mg daily 
in a 1:1:1 ratio as adjunctive to standard of care based on the hospital COVID-19 
treatment algorithm and/or local COVID-19 treatment practices. Participants will be 
administered study drug for a maximum treatment period of 28 days or until discharge or 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-24- 
 
 
death, whichever comes first. Follow-up will continue through to Day 56 to document AEs 
and outcome as to discharge, death, or WHO COVID-19 classification level if subject 
remains hospitalized.  
3.1 
Safety Monitoring 
Participants will be monitored by hospital personnel as per protocol. Clinical adverse 
events (AEs) will be reviewed daily through to discharge or the end of the treatment 
period. Safety monitoring will also include laboratory assessment of hematology, 
chemistry and ECG as per the Schedule of Events. Serum trough levels of GLS-1027 will 
be assessed at select times throughout the trial as per the Schedule of Events. 
Participants will also be followed for up to 56 days post-enrollments for health status and 
adverse events. 
3.2 
Data and Safety Monitoring Board (DSMB) 
In addition to internal monitoring of safety data by the site PI and medical monitor, an 
independent data and safety monitoring board (DSMB), consisting of expert members not 
related to the clinical trial or sponsor staff will provide safety oversight. The DSMB will 
include at a minimum three members: a physician specializing in either Infectious Disease 
or Pulmonary / Critical Care, a second health-care practitioner who may be a physician, 
and someone with statistical experience (physician or non-physician).  
The DSMB will meet at the start of the clinical trial to review and finalize the DSMB charter. 
At a minimum, the DSMB will meet to review interim data when 50% of the target enrollees 
(66 subjects) have completed the primary observation period to discharge, death, 
discontinuation or 28 days of treatment. The DSMB will review safety data and outcomes 
for enrolled subjects in a blinded manner. Unless a safety signal has been encountered, 
enrollment will continue through to at least 44 per group (total N=132).  
A summary of all AEs and SAEs will be provided to the DSMB as masked treatment 
groups by an independent statistician together with a summary rates of retention in the 
study, and other relevant events. Reports will include a summary of participants’ baseline 
characteristics, early study discontinuations, and a summary of participants who reach 
primary endpoint and/or end of study follow-up. The DSMB may recommend corrective 
measures, up to termination of the study for safety concerns. Study termination can be 
implemented by the Project PI, FDA, Sponsor, or site-specific or other supervising IRBs. 
Conference call or video conference meetings are allowed as necessary.  
Additional details can be found in the DSMB Charter. 
4. 
SELECTION AND ENROLLMENT OF PARTICIPANTS 
4.1 
Recruitment of Participants 
4.2 
Inclusion Criteria for enrollment 
1. Age 18 years or older 
2. Able to provide informed consent  
3. Able and willing to comply with study procedures 
4. Enrollment within 72 hrs of hospitalization with a diagnosis of PCR confirmed SARS-
CoV-2 infection 
5. WHO COVID-19 classification level of 3 or 4  


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-25- 
 
 
4.3 
Exclusion Criteria for enrollment 
1. Pregnant or lactating 
2. SpO2 less than 90% on room air or less than 95% on supplemental oxygen 
3. Calculated GFR < 60 (Cockcroft-Gault)  
4. Meets hospital treatment algorithm for treatment with dexamethasone at a dose of 6 
mg/day for a 10 day course. A single bolus dose of 6 mg of dexamethasone given in the 
Emergency Department and continued at a dose of ≤ 3.5 mg/day or less is allowed. 
5. Meets treatment algorithm criteria for treatment with toclizumab or other anti-IL-6 agent 
6. Treatment with an anti-IL-6 inhibitor, anti-IL-1 inhibitor, anti-TNF monoclonal antibody, or 
anti-JAK inhibitor (see Appendix A for exclusionary period for individual drugs)  
7. Participation in a COVID-19 clinical trial that includes prescription of a drug with anti-
cytokine activity 
8. Treatment within the past 60 days with a chemotherapeutic agent 
9. Current outpatient treatment with systemic corticosteroids at a dose equivalent of 20 
mg/day or greater of prednisone or prednisolone, 16 mg/day or greater of 
methylprednisolone 
10. Diagnosis of leukemia or lymphoma  
11. WHO COVID-19 classification level of 5 or greater (use of high-flow oxygen, non-
mechanical ventilation such as CPAP, mechanical ventilation)  
4.4 
Discontinuation/Withdrawal of Study Participants 
The Informed Consent will require that subjects allow follow-up for the primary outcome 
and safety through to 56 days post-enrollment or death. A subject may withdraw from the 
study by withdrawing consent to continue participation.  If a subject withdraws consent 
from participating in the study at any time after enrollment, but prior to the final scheduled 
study visit, the investigator will make every effort to have the participant complete all 
assessments at the time of withdrawal. All data collected up to the time of withdrawal will 
be used for data analyses. The request to withdraw consent must be documented.   
 
Discontinuing treatment is not a reason for withdrawing from participating in the study.  
Subjects who discontinue treatment for any reason should be followed until 56 days post-
enrollment or death, whichever comes first. 
 
Reasons for treatment discontinuation are defined below.  
 The PI or Medical Monitor consider that continuation of treatment may pose a 
safety risk to the subject.  Treatment discontinuation will be considered a treatment 
failure, unless the subject discontinues treatment due to pregnancy or renal 
insufficiency. The subject should however continue to be monitored as per protocol 
for outcome measures through to study end (Day 56). 
 Adverse event (Adverse Reaction): clinical or laboratory events that in the medical 
judgement of the investigator are grounds for discontinuation of treatment. This will 
be considered as a treatment failure. Subjects should however continue to be 
monitored as per protocol for outcome measures through to study end (Day 56).  
 Lost to follow-up: for subjects who are discharged from the hospital within 28 days 
of treatment initiation who cannot be contacted after multiple attempts, will be 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-26- 
 
 
considered as Lost to Follow-up for purposes of Long-term outcomes (56 days). 
Otherwise, without relapse of COVID-19 symptoms, discharge within 28 days of 
enrollment is considered a treatment success. For subjects who are discharged 
from the hospital, every effort should be made to contact the subject to determine 
clinical status and adverse events post-discharge. 
 
Transfer of subject to another hospital.  All transfers will be considered treatment 
failures. 
 
 
4.5 
Treatment with dexamethasone post-enrollment  
Treatment with dexamethasone at a dose of 6 mg/day for 10 days is currently considered 
as part of the standard of care for COVID-19 at many institutions, however, the specifics 
of treatment and whether such treatment is formally algorithm based varies between 
institutions. Moreover, it is recognized that dexamethasone treatment may be ordered as 
part of clinical care for some subjects after enrollment into the study.    
Enrollment into the study is allowed for individuals who have not been treated with 
dexamethasone since hospital admission. Enrollment into the study is also allowed for 
those have received a single bolus dose of 6 mg of dexamethasone at presentation to the 
hospital with or without continuation of dexamethasone at a dose of 3.5 mg/day or less.  
Enrolled subjects for whom dexamethasone is initiated within 72 hours of the time of 1st 
dose of study drug will be considered to have required dexamethasone at the time of 
presentation to hospital and will be treated the same as those who received a single bolus 
dose of 6 mg at presentation to the hospital. Unless dexamethasone is prescribed for 10 
days at 6 mg, sSuch subjects will not be considered to have met the definition of the need 
for salvage therapy, and will not be considered as meeting a study endpoint for failure.  
Enrolled subjects for whom dexamethasone is ordered at a dose of ≥ 6 mg per day and 
is initiated 72 hours or later after the 1st dose of study drug will be considered to have met 
the definition of need for salvage therapy and thus have met a study endpoint for failure. 
Initiation of treatment with dexamethasone at a dose of less than 6 mg/day after 
enrollment in the study will not be considered as treatment failure.  
 
Subjects will be subgrouped for summary by concomitant bolus dexamethasone within 
72 hours of enrollment versus no concomitant dexamethasone with 72 hours of 
enrollment.  
5. 
STUDY PRODUCT 
5.1 
Investigational Product 
GLS-1027 is a small molecule with a chemical structure as shown in Figure 1.2-1 and has 
a molecular weight of 205.21 g/mol. GLS-1027 will be formulated in capsules at a dose 
of 120 mg per capsule. 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-27- 
 
 
Microcrystalline cellulose, the placebo used in this study, has a chemical structure as 
shown in Figure 1.2-2 and has a molecular weight of 658.7 g/mol. Microcrystalline 
cellulose will be formulated in capsules at a dose of 105 mg per capsule. 
5.2 
Packaging and Labeling  
GLS-1027 will be supplied to the investigational pharmacy in bottles of 50 capsules, while 
the placebo will be supplied in bottles of 100 capsules. Drug will be dispensed by 
pharmacy personnel to study participants as part of daily medication dispensing to 
maintain blinding of other study personnel.  
Drug product vial label is shown below in Table 5.2-1.  
 
Table 5.2-1. GLS-1027 and Placebo drug product vial labels 
GLS-1027 
PLACEBO 
GLS-1027 Capsules, 120 mg   
Protocol No. GLS27-005 
Lot No. xxxx 
Quantity: 50 capsules 
(Caution New Drug Limited by Federal (United States) 
Law to Investigational Use 
Keep out of reach from children: Take as directed 
Store at 25ºC (77°F) excursion permitted to 15°-30°C 
(56° - 86°F) 
Sponsor: GeneOne Life Science 
Mfd by CoreRx Inc., 14205 Myerlake Circle, 
Clearwater FL 33760 
 
 
Placebo Capsules, 105 mg   
Protocol No. GLS27-005 
Lot No. xxxx 
Quantity: 100 capsules 
(Caution New Drug Limited by Federal (United States) 
Law to Investigational Use 
Keep out of reach from children: Take as directed 
Store at 25ºC (77°F) excursion permitted to 15°-30°C 
(56° - 86°F) 
Sponsor: GeneOne Life Science 
Mfd by CoreRx Inc., 14205 Myerlake Circle, 
Clearwater FL 33760 
 
 
5.3 
Handling of Study Drug 
Study drug will be stored at 25°C (ambient temperature, range  15°C to 30°C) in the 
hospital Investigational Drug Service. Investigational product must be stored in a secure 
area according to local regulations.  
5.4 
Dispensing of Study Drug 
Pharmacy service will provide 3 capsules per day (GLS-1027 or matching placebo) based 
on randomization assignment. The randomization treatment code will be provided to the 
site pharmacists from a web-based system. How to access the randomization system is 
covered in a separate Pharmacy Manual. It is the responsibility of the Investigators that 
study drug is dispensed only to study participants by hospital nursing personnel. 
Authorized personnel are the only ones to dispense product according to local regulation 
and study specific Delegation Log. Study drug administration is to be discontinued for 
periods when subject either has an eGFR < 60 mL/min/1.73 m2, is unable to take 
medications orally, or reaches a study endpoint (WHO COVID-19 classification of 6 or 
greater).  
5.5 
Precautions with Investigational Medicinal Product 
Medication should not be taken by children or anyone outside of the current clinical trial.  
5.6 
Preparation of Investigational Product 
No preparation of Investigational Product is required.   


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-28- 
 
 
5.7 
Record of Investigational Product Disposition at Site 
It is the responsibility of the Investigator to ensure that a current record of investigational 
product disposition is maintained at each study site where investigational product is 
inventoried and disposed. Investigational Pharmacy and/or Hospital Pharmacy records or 
logs must comply with applicable regulations and guidelines. 
5.8 
Return and Destruction of Investigational Product 
Remaining study drug at the hospital investigational drug service will be returned to 
GeneOne Life Science accompanied with relevant return log(s).  
6. 
STUDY PROCEDURES AND TREATMENTS 
6.1 
Procedures by Visit (also see Table S2) 
6.1.1 Day 1: Review Study and Eligibility Criteria; Obtain Informed Consent, Enrollment  
Subjects will be recruited and Study staff will review the protocol with the prospective 
participant and obtain written informed consent. One copy of the informed consent form 
(ICF) will be maintained with the investigative team, and the other given to the participant. 
Study procedures that will be completed include:  
 Document review of ICF process and that copy was provided to participant 
 Review and record medical history, demographics  
 Review concomitant medications 
 Record physical exam, height, weight, vital signs from medical record 
 Record baseline ECG 
 Record COVID-19 PCR result 
 Record baseline CBC and Basic Metabolic Profile (BMP), liver function tests 
(LFTs), CRP, IL-6, troponin, D-dimer, procalcitonin, admission CXR  
 Determine and record baseline WHO COVID-19 Classification (Appendix B)  
 Record whether participant is prescribed supplemental nasal O2 and flow rate or 
O2 via facemask and Fi O2 
 Perform urine pregnancy test if person is of child-bearing potential 
 Collect blood for CPK and GGT 
 Alert Pharmacy to enrollment to direct administration of study drug per 
randomization (if drug administration would occur after 10 pm, then start study drug 
on Day 2) 
 Collect serum and PBMCs as indicated in the Schedule of Events 
6.1.2 Day 2 (PK sub-study participants ONLY) 
 For the 15 persons enrolled, additional blood samples (5 ml) will be collected as 
follows  
o Pre-Dose 
o Post-Dose 1, 2, 4, 8 hr 
6.1.3 Day 2 through 29 (or until discharge or death) 
 
Administer study drug with AM medications if calculated creatinine clearance is ≥ 60.  
 
Determine and record WHO COVID-19 classification level (Appendix B) 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-29- 
 
 
 
Review new concomitant medications 
 
Record past 24 hour maximal and minimal temperature (°C), respiratory rate, heart rate, 
systolic and diastolic BP  
 
Record potential co-morbid complications of SARS-CoV-2 infection to include shortness 
of breath, arterial thrombosis (myocardial infarction, stroke, peripheral blood clot), mental 
confusion, death 
 
Record adverse effects 
 
Collect and Record labs as indicated in the Schedule of Events: CBC, BMP, LFTs, CRP, 
ferritin, D-dimer, CPK, IL-6 
 
Record if care given in ICU setting 
 
Record ventilatory status: O2 use, CPAP use, ventilator, ECMO 
 
Record O2 flow rate, FiO2 % (if intubated), CPAP pressure (as relevant), PEEP setting (as 
relevant) 
 
Perform ECG (12 lead) on day 2 at 75-90 minutes post dose, and on day 15 ± 2 days 
 
Collect serum for CPK and GGT (Day 7) and, if abnormal, then weekly until values 
normalize  
 
Collect blood for plasma for GLS-1027 trough measurement as indicated in the Schedule 
of Events 
 
Collect blood for serum and PBMCs as indicated in the Schedule of Events 
 
Pharmacy to review patient creatinine and calculated creatinine clearance daily.  
6.1.4 Day 56  
 
Review medical record to document date of discharge or death, as relevant 
 
Determine and record WHO COVID-19 classification level (Day 56) 
 
If hospitalized, review chart to document intercurrent AEs 
 
If not hospitalized, query participant to document intercurrent AE’s from the end of the 
primary study period 
6.2 
Timing and Evaluations 
6.2.1 Informed Consent (Day 1) 
Study personnel will meet with prospective study participants, explain the study, and 
provide them with an informed consent form (ICF) that describes the eligibility criteria for 
entering the study, study treatments, randomization, and follow-up procedures. An 
informed consent must be signed prior to any study related procedures being performed. 
A copy of the signed and dated consent form will be given to the participant.  
6.2.2 Enrollment (Day 1) 
Participants who consent to be in the study will be assigned a unique participant 
identification designation number (PID#). PID#’s consist of a 3 digit site code followed by 
a 3-digit subject number. Subject numbers are assigned in numerical order of enrollment 
(i.e., 1st subject is assigned XXX-001, 2nd subject is assigned XXX-002 with XXX a 
placeholder for the site number). Once assigned, PID numbers cannot be reused for any 
reason. Information regarding participant’s PID# will also be documented on a screening 
log. Study personnel will alert pharmacy to enrollment for drug administration and review 
medical record for study related procedures.  
Medical History 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-30- 
 
 
Investigators should document all significant illnesses that the participant has 
experienced as Medical History in the last 6 months. Illnesses’ first occurring or detected 
during the study and/or worsening of an existing illness that occurs after the first 
administration of study drug are documented as AEs on the electronic case report form 
(eCRF).  
Prior and Concomitant medications 
Prior treatments, defined as administered up to 4 months prior to the time of enrollment 
with designation as to whether the drug was prescribed as an outpatient or only since 
admission, will be recorded in the eCRF as prior medications. Concomitant treatments, 
defined as continuing or new treatments taken at or after the signing of the informed 
consent, will be recorded in the eCRF as concomitant medications. 
Review and record baseline labs 
The medical record will be reviewed and labs from the day of enrollment recorded. Labs 
and evaluations such as procalcitonin, CXR, D-dimer, troponin will be recorded from the 
1st recorded instance in the medical record if not repeated through to the time of or on the 
day of enrollment.  
Determine and record WHO COVID-19 classification level 
Determine from the clinical record the WHO COVID-19 classification level (Appendix B) 
and record. This will be determined and recorded on a daily basis. 
Review and record oxygenation status 
Document that participant is prescribed nasal O2 and the flow rate.  
If mechanically ventilated, record level of PEEP and %FiO2 
Record if CPAP prescribed and expiratory pressure 
Record if given ECMO treatment 
Contact pharmacy for study drug administration 
Contact the investigational pharmacy regarding study recruitment for assignment of 
randomization code and to dispense study drug to inpatient ward.  
6.2.3 Safety Assessments 
6.2.3.1  
SARS-CoV-2 associated events 
The medical record will be reviewed daily for the occurrence of SARS-CoV-2 associated 
events, which include shortness of breath and arterial thrombosis (myocardial infarction, 
stroke, peripheral blood clot).  
6.2.3.2  
Adverse events 
The medical record will be reviewed daily for the occurrence of any adverse events, 
change in clinical status, or death. These will be graded as per the NCI Common 
Terminology Criteria for Adverse Events (CTCAE) v5.0. 
6.2.3.3  
Vital Signs 
Vital signs will be recorded from the medical record daily to include maximal and minimal 
temperature (°C), respiratory rate, heart rate, and systolic and diastolic blood pressure.  
6.2.3.4  
Weight and Height 
Height and as listed in the medical record at the time of admission will be recorded at the 
time of enrollment.  


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-31- 
 
 
6.2.3.5  
12-lead ECG 
The results of the participant’s baseline or first 12-lead ECG from the admission will be 
recorded. A repeat ECG will be performed on Day 2 at 75-90 minutes post-dose and Day 
15 of the study (± 2 days). 
6.2.3.6  
Laboratory Evaluations 
Laboratory evaluations to include CXR, CBC, biochemistries, CPK; and ferritin, CRP, IL-
6 (if ordered at site), D-dimer, and procalcitonin as available; are recorded as per the 
Schedule of Events.   
6.3 
Assessment of Laboratory Abnormalities 
Serum chemistries (complete metabolic panel) and complete blood count with differential 
blood count will be graded as noted in Section 7.1.  
6.4 
Assessment of Clinical Adverse Events 
The Investigator will grade clinical AEs (based on discussions with study participants) 
using the CTCAE v5.0.  
6.5 
Plasma for PK sub-study and/or trough level determination of GLS-1027  
Blood will be collected for plasma as per the Schedule of Events for measurement of 
trough concentrations of GLS-1027. The first 15 subjects are to be enrolled into a sub-
study to determine drug elimination of GLS-1027 in SARS-CoV-2 infected patients. 
6.6 
Serum and PBMCs for immunology assessments 
Serum and PBMCs are collected per the Schedule of Events to assess the effect of 
treatment on cytokine expression and serum levels, and STAT3 activation in PBMCs 
relative to treatment group.  
7. 
EVALUATION OF SAFTY AND MANAGEMENT OF TOXICITY 
7.1 
Safety Parameters 
7.1.1 Adverse Events (AEs) 
An AE (also referred to as an adverse experience) is defined as any unfavorable and 
unintended sign, symptom, or laboratory abnormality that is temporarily associated with 
the use of a drug or treatment and does not imply any judgement about causality. An 
adverse event can arise with any use of a drug or treatment regardless of route of 
administration, dose, and may be delayed after a drug or treatment has been 
discontinued. An adverse event is not the same as an “overdose”; an overdose is a dose-
related event specifically caused by exposure to an increased amount of drug.  
An unexpected AE is:  
• 
Not identified in the Investigator’s Brochure (IB) or otherwise not expected from the 
characteristics of the clinical material 
• 
Not listed at the specificity or severity that has been previously observed 
• 
Not specifically mentioned in the IB as known to occur with the particular drug under 
investigation, even though the adverse event may be known to occur with other drugs 
in the same pharmacologic class or with drugs that share pharmacologic properties 
with the study drug. 
Treatment emergent AEs (TEAE) include the following: 
• 
Post-treatment complications that occur as a result of protocol mandated procedure  


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-32- 
 
 
• 
Any pre-existing condition that increases in severity, or changes in nature during or as 
a consequence of the study drug phase of a human clinical trial, will also be 
considered an AE 
• 
Complications and termination of pregnancy; see Section 7.1.8 for additional 
information.  
• 
Non-elective medical or surgical procedures  
Study related AEs do not include the following: 
• 
Expected complications or clinical consequences due to elective medical or surgical 
procedures 
• 
Pre-existing diseases or conditions or laboratory abnormalities present or detected 
before study enrollment or prior to the first administration of study drug that do not 
worsen 
• 
Overdose of non-study drug  
• 
Incorrect or increased dose administration of study drug without adverse clinical 
sequelae 
• 
Any laboratory abnormality that is considered as non-significant  
• 
Uncomplicated pregnancy 
• 
An induced elective abortion to terminate a pregnancy without medical reason 
7.1.2 Serious Adverse Events (SAEs) 
A SAE is any AE that meets one of the following conditions: 
 
Is immediately life-threatening (e.g., participant was, in the view of the Investigator, 
at immediate risk of death from the event as it occurred).  
 
Requires or prolongs hospitalization; 
 
Results in congenital anomaly or birth defect; 
 
Results in persistent or significant disability/incapacity; 
 
Is an important medical event that may not result in death or be life threatening, but 
based upon appropriate medical judgment, may jeopardize the participant and may 
require medical or surgical intervention to prevent one of the outcomes listed above.  
 
Results in death 
Important medical events that do not result in death, are life-threatening, or require 
hospitalization may be considered as an SAE when, in the judgement of the Investigator, 
potentially jeopardize the study participant and may require medical or surgical 
intervention. 
SAE’s occurring up to and including the final study visit will be collected regardless of the 
Investigator’s opinion of causation.  
If an Investigator becomes aware of an SAE that has occurred after a participant has 
completed the study, the Investigator should report the SAE to the sponsor regardless of 
the Investigator’s opinion of causation. 
SAEs should be followed until resolution. The reporting period for SAEs is described in 
Section 9.6.2. 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-33- 
 
 
7.1.3 Suspected Unexpected Serious Adverse Drug Reactions (SUSARs) 
A SUSAR is a serious adverse event not listed in the IB and that the PI identifies as 
related to study drug or procedure. 
7.1.4 Assessing Severity (Intensity) 
The Investigator will grade laboratory AEs and clinical AEs (based on discussions with 
study participants) using the NCI Common Terminology Criteria for Adverse Events v5.0: 
 Mild (Grade 1) 
 Moderate (Grade 2) 
 Severe (Grade 3) 
 Life-threatening consequences (Grade 4) 
 Death related to AE (Grade 5) 
Adverse events will be recorded on the eCRF at the severity reported by the investigator. 
If an ongoing AE worsens or increases in its severity or its relationship to the study drug 
changes, a new AE entry for the event should be entered on the eCRF. 
The following is a link to the grading scale: 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_R
eference_5x7.pdf 
7.1.5 Causal Relationship of Investigational Product to Adverse Events 
A causally related AE is one judged to have a suspected relationship to the administration 
of the investigational agent. Conversely, an AE may also be assessed as not related to 
the investigational product. The Investigator is responsible for reporting adverse events 
and judging the relationship between the administration of the investigational product and 
an AE because the investigator is knowledgeable about the participant (e.g., medical 
history, concomitant medications), administers the investigational product, and monitors 
the participant’s response to the investigational product. The Sponsor will assess the 
overall safety of the investigational product and determine whether expedited reporting to 
regulatory agencies is indicated. 
Investigators should use their knowledge of the Study Participant, the circumstances 
surrounding the event, and an evaluation of any potential alternative causes to determine 
whether or not an adverse event is considered to be related to the study drug by the 
following criteria: 
• 
Related – the investigator considers that there is a causal relationship between the 
event and study drug; 
o Probably related – the Investigator considers that there is a probability of a causal 
relationship of the event to the study drug. Such events should be entered as 
“related” in the database  
o Possibly related – the investigator considers that there is a possible causal 
relationship of the event to the study drug. Such events should be entered as 
“related” in the database 
• 
Not related – the investigator considers that the event has no relationship to 
administration of the study drug  


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-34- 
 
 
The following guidance should also be taken into consideration: 
• 
Temporal relationship of event to initiation of study drug; 
• 
Course of the event, discontinuation of study drug, or reintroduction of study drug 
(when applicable); 
• 
Known association of the event with the study drug or with similar treatments; 
• 
Known association of the event with the disease under study; 
• 
Presence of risk factors in the Study Participant or use of concomitant medications 
known to increase the occurrence of the event 
7.1.6 Abnormal Laboratory Values 
Laboratory abnormalities will be classified according to the CTCAE v5: 
7.1.7 Pregnancy During Study 
Pregnancy is an exclusion criterium for the study. If a participant is found to be pregnant 
at any time during the study after enrollment, then study medication will be immediately 
discontinued. Such participants are requested to remain in the study for continued 
observation and will be analyzed with regard to assigned study treatment.  Data on fetal 
outcome will be collected for regulatory reporting. Pregnant subjects will be assessed for 
efficacy endpoints in the same manner as all other subjects. 
7.1.8 Decreases in renal function during study 
Pharmacy will monitor patient’s renal function during the study. Study drug will be 
administered as per the assigned group for a calculated creatinine clearance ≥ 60. If the 
calculated creatinine clearance decreases below 60 then study drug will be discontinued 
until the eGFR is ≥ 60. Should study drug administration be interrupted due to a change 
in renal function, the total length of treatment is determined by the day of enrollment. The 
primary treatment period is still up to 28 days from enrollment and is not extended for 
days of interrupted therapy. Subjects with interrupted or discontinued treatment due to 
renal function, will be assessed for efficacy endpoints in the same manner as all other 
subjects. 
7.1.9 Post-study Reporting Requirements 
SAEs, including deaths, regardless of cause or relationship, must be reported to Sponsor 
at the time that such events become known to the Investigator. 
Investigators are not obligated to actively seek AEs or SAEs beyond the follow up period 
for participants. However, if the Investigator learns of an SAE that occurs within 30 days 
from completion or termination visit, the Investigator should promptly document and report 
the event to the study team and medical monitor. 
7.2 
Methods and Timing for Collection and Recording of Safety Data 
Participants will be queried daily as to adverse events that have occurred since the 
previous day and the current status of any AE that was reported at a prior visit that has 
not yet resolved. Additionally, labs and ECGs will be reviewed for safety.   


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-35- 
 
 
All AEs, regardless of severity, seriousness, or presumed relationship to study treatment, 
must be recorded using medical terminology in source documents and on the eCRF. 
Whenever possible, a diagnosis will be documented, in lieu of symptoms. The source 
document and the eCRF must contain the Investigator’s opinion concerning the 
relationship of the AE to study treatment. 
AEs should be described with the following attributes: 
• 
Duration (start and end dates) 
• 
Seriousness 
• 
Severity 
• 
Causality 
• 
Action(s) taken 
• 
Outcome 
7.3 
Safety and Toxicity Management 
The Medical Monitor will be responsible for the overall safety monitoring of the study. The 
site Investigator will be responsible locally for safety.  
Safety assessments include the following: 
• 
Incidence of all adverse events classified by system organ class, preferred term, 
severity, and relationship to study treatment 
• 
Changes in safety laboratory parameters  
• 
Changes in ECGs 
• 
Other clinically significant changes in safety evaluations 
7.3.1 Events Requiring Expedited Reporting 
Events requiring expedited reporting (ERER) are defined as Adverse Events including: 
 Suspected or confirmed anaphylaxis or drug-related allergic reaction 
Sites will inform the Sponsor of any ERER within 24 hours to discuss whether dosing to 
the participant should continue. 
7.3.2 Reasons to Discontinue Treatment 
Discontinuation or interruption of study drug 
Study drug will be discontinued with any of the following:  
1. Diagnosis of pregnancy.  
2. Anaphylaxis or allergic reaction possibly related to study drug 
Study drug will be temporarily halted with any of the following:  
3. If the eGFR falls below 60 mL/min/1.73 m2 
4. If the patient is intubated and/or ECMO is initiated 
5. If oral administration is not possible 
6. For those with baseline serum bilirubin in the normal range: a serum bilirubin ≥ 5 times 
the upper limit of normal (ULN)  
7. For those with baseline serum bilirubin above the normal range: a serum bilirubin ≥ 10 
times the ULN 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-36- 
 
 
8. Transaminase (ALT or AST) elevation of ≥ 20 times the ULN 
9. An absolute neutrophil count of < 1000 (Grade 4) 
10. Electrocardiographic findings of any of the following: Torsades de Pointes, polymorphic 
ventricular tachycardia 
11. Malignant hypertension characterized by a systolic BP of ≥ 220 mm Hg or a diastolic BP 
≥ 110 mm Hg with concomitant neurologic deficit or need for urgent medical intervention 
12. Headache with neurologic deficit in a patient without history of migraine or similar 
syndrome or condition 
13. Gastric hemorrhage requiring transfusion or other emergent intervention 
14. Uncontrolled emesis for greater than 24 hours, or incident emesis considered to be 
definitely or probably caused by study drug 
15. Occurrence of any opportunistic infection 
Study drug should be reinstituted when the event that resulted in temporary interruption 
of study drug administration has resolved or has improved to a Grade 2 event or lower. 
In the case that the subject has been intubated or started on ECMO, study drug should 
be restarted once extubated and/or ECMO discontinued and oral administration of 
medications is possible. Exceptions are any diagnosis of pregnancy or an opportunistic 
infection. If a second episode of the same adverse event occurs, study drug will be 
stopped and not restarted.  
If two or more episodes of anaphylaxis possibly related to study drug occur, then the 
unblinded clinical research coordinator will request that pharmacy provide a report 
regarding study drug assignments of these participants to the DSMB to determine 
potential causality. The DSMB will review and determine appropriateness of study 
continuation.   
All episodes of study drug interruption or stoppage should be reported to the Medical 
Monitor.  
Any permanent stoppage of study drug in response to meeting any of the individual 
stopping rules will be considered as meeting study endpoint for failure except for a 
diagnosis of pregnancy, or stoppage related to decreased renal function.  
Pause in Treatment or Termination of clinical trial 
The Medical Monitor or DSMB may recommend global pause of study drug administration 
to all enrolled subjects if a safety signal is encountered that requires investigation and in 
the opinion of either the Medical Monitor or DSMB that continuation during the 
investigation period would present a safety risk to enrolled subjects. The decision to 
reinstitute study medication may be made at the conclusion of the investigation. The IRB 
will be informed of all such treatment interruptions and will be provided a report of the 
investigation.  
Except for detection of a safety signal, the study will continue to the target enrollment 
unless enrollment has been increased to gain additional statistical power for assessing 
dose dependent response.    


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-37- 
 
 
7.3.3 Unblinding 
This is a double-blind study. Treatment assignments should be maintained as blinded 
unless such unblinding is considered as critical to the care and well-being of the subject. 
Unblinding should occur following discussion with the Sponsor Medical Monitor, however, 
emergency unblinding can occur if the Investigator deems that such a delay would unduly 
harm the subject and knowledge of the treatment assignment is a critical factor in medical 
decision making versus a discontinuation of study drug until discussion with the Medical 
Monitor. In the case of unblinding, the Investigator must record the date, time and reason 
for unblinding, however, the Investigator is not required to inform the Sponsor of treatment 
assignment. Unblinded treatment assignment will only be accessible to those who require 
such information as part of medical decision making and for those involved in Safety 
reporting to Health Authorities and/or the relevant IRB. 
 
The Investigational Pharmacy will maintain a listing of subject treatment assignments 
and will provide a mechanism for unblinding in emergency situations. 
 
 
8. 
STATISTICAL METHODS and CONSIDERATIONS 
Prior to unblinding and analysis of the final study data, a detailed Statistical Analysis Plan 
(SAP) will be written describing all analyses that will be performed for reporting of results 
from this clinical trial.  
8.1 
Data Sets to be Analyzed 
 The intention to treat population (ITT) includes all participants who are randomized to 
a treatment allocation. The ITT population will be used for the summary of all 
demographic and baseline characteristics and for analysis of the primary outcome of 
treatment failure. Subjects will be grouped in analyses and summaries based on their 
randomization allocation.  
 The modified intention to treatment (mITT) population includes all participants who are 
randomized to a treatment allocation, and who have received at least one dose of 
study drug. The mITT population will be used for the summary and analysis of the 
primary outcome of treatment failure. Participants will be grouped based on the 
treatment allocation.  
 The safety analysis set includes all mITT participants. Participants will be grouped 
based on the treatment actually received.  
 
Per-protocol (PP) analysis set includes all Safety subjects who complete the trial by 
meeting the endpoint or being discharged within 28-days without meeting the endpoint. 
Participants in this set will be grouped to treatment arms they actually received. This 
set will be used as a sensitivity analysis to summarize the primary endpoint and for 
summary of all other efficacy outcomes. 
8.2 
Sample Size  
Based on the initial data obtained to date and data in the literature [1], it is anticipated that 
approximately 50% of subjects hospitalized with PCR-positive SARS-CoV-2 infections 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-38- 
 
 
(WHO COVID-19 Classification level 3 or 4) will progress to WHO COVID-19 
classification level of 6 or greater as defined by one or more of the following: the need for 
intubation or mechanical ventilation (level 6), the need for ECMO (level 7), or any cause 
death (level 8). The sample size estimate for this proof of concept is based on Fisher’s 
Exact two-sided test for 2 proportions using NQuery 8 (www.statsols.com). Estimates of 
admitted patients requiring salvage therapy is unknown, however, the clinical data set 
who require intubation is a likely subset of those whose condition worsens but do not 
progress to respiratory compromise.  
 
Although the interim analysis will utilize masked treatment assignments, the O’Brien 
Fleming group sequential sample size estimation confirms that a single interim look would 
retain a cumulative exit probability of 70% with a cumulative alpha =0.05 after the final 
analysis using the target enrollment of 132 (44 per group) to detect a reduction of those 
reaching the endpoint of treatment failure, which includes advancing to WHO COVID-19 
Classification level ≥6 from 50% (SOC treated) to 25% in either treatment group of SOC 
plus GLS-1027. Other conditions also qualify a subject as treatment failure include: need 
for salvage therapy with IL-6 monoclonal antibody; or institution of salvage therapy with 
dexamethasone (≥ 6 mg/day), withdrawing consent from the study, becoming lost to 
follow-up, or discontinuation of treatment for any reason other than renal function or 
pregnancy.  This study is not powered to assess statistically significant differences 
between GLS-1027 doses.  
8.3 
Randomization 
Randomization to treatments will occurred using a centralized randomization system.  
Randomization will be stratified by site to ensure equal distribution of treatments within each site. 
Subjects within each site will be randomly assigned in a 1:1:1 ratio to receive placebo, 120 mg 
GLS1027 or 360 mg GLS1027 daily for their duration of hospitalization or until intubation or 
mechanical ventilation constrains oral medication. 
8.4 
Demographic and Other Baseline Characteristics 
Demographic and baseline data, vital signs, medical history, concomitant illnesses, and 
current medications/treatments will be summarized by means of descriptive statistics: 
continuous variables as mean, median, standard deviation, minimum and maximum 
values and categorical variables as frequencies and percentages, grouped by treatment 
arm based on the ITT population and overall. 
8.5 
Safety Analysis 
All safety and tolerability summaries will be performed on the safety analysis population. 
8.5.1 Adverse events 
Treatment emergent AEs will be summarized by frequencies and will be presented by 
system organ class and preferred term with the number and percentage of participants 
affected. Frequencies will be presented with respect to maximum severity. Multiple 
occurrences of the same AE will be counted only once following a worst-case approach 
with respect to severity and relationship to Study Treatment.  
8.5.2 Laboratory Data 
Continuous response variables per time point will be summarized with mean, median, 
minimum, and maximum values. Categorical response variables will be summarized per 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-39- 
 
 
time point with percentages. In addition, each laboratory parameter will be summarized 
as a shift from baseline based to the last lab assessments prior to meeting the primary 
endpoint or 28 days, whichever comes last. 
8.6 
Efficacy Analysis 
The primary endpoint is treatment failure which is defined as any subject who achieved 
WHO level ≥ 6 (intubation and mechanical ventilation, requirement for ECMO, or death) 
within 28 days of initiating treatment or who meet the following reasons for treatment 
failure: 
 Receiving salvage therapy with either an IL-6 monoclonal antibody or for those 
who are prescribed daily dexamethasone starting 72 hours or later after the 1st 
dose of study drug within the 28-day primary treatment period.  
 Lost to follow-up through hospital transfer, within the 28-day primary treatment 
period.  
 Discontinuation of  study drug for any cause prior to discharge will be considered 
as a treatment failure, except for those for whom study drug was suspended due 
to a decrease in renal function (creatinine clearance of < 60 mL/min), and those 
become pregnant during treatment. These subjects will be followed for the primary 
endpoint for up to 28 days post enrollment, and for up to 56 days for safety. 
 
Subjects who complete 28 days of treatment  but remain hospitalized without increase in 
WHO COVID-19 Classification level to ≥6, will not considered be as treatment failures 
with respect to the primary endpoint. 
 
The proportion of subjects in each treatment group who reach the study endpoint of 
treatment failure by 28 days will be compared to placebo using Fisher’s Exact 2-sided 
test of proportions. Additionally, the frequency for each outcome (intubation, ECMO, 
death) will be determined within each group. The ITT, mITT and PP analysis populations 
will be used to analyze the primary endpoint.  
8.7 
Other Analysis 
Exploratory endpoints include the following which will be summarized using the PP 
populations by treatment group received: 
 Assess the number of days requiring ICU care relative to treatment group. If a 
subject does not require ICU care, the number of days will be set to zero for the 
group summary.  The number of ICU days will be summarized for all subjects in 
each group and for the proportion of those who are actually in ICU. 
 Assess the number of days of mechanical ventilation relative to treatment group. 
If a subject does not require mechanical ventilation, the number of days will be 
set to zero for the group summary.  The number of mechanical ventilation days 
will be summarized for all subjects in each group and for the proportion of those 
who are actually on mechanical ventilation. 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-40- 
 
 
 Assess incidence of WHO COVID-19 Classification levels relative to baseline 
serum IL-6 level 
 Assess incidence of WHO COVID-19 Classification levels relative to baseline 
serum ferritin level 
 Assess incidence of WHO COVID-19 Classification levels relative to baseline 
CRP  
 Assess trough level of GLS-1027 relative to serum creatinine 
 Assess the maximal level of Positive End-Expiratory Pressure (PEEP) for 
subjects who are intubated relative to treatment group.  
 Assess the number of days of PEEP > 5 cm H2O for subjects who are intubated 
relative to treatment group 
 Incidence of progression to  WHO COVID-19 Classification level 6, or 7, or 8 
(individually) 
 
Assess SARS-CoV-2 IgM antibody responses relative to treatment group  
No adjustments or imputations will be made for deaths or other forms of missingness 
except those already described above.  
  
8.8 
Interim Analysis 
A masked interim analysis will be performed when 22 subjects in each group have been 
assessed for the primary endpoint of treatment failure.  Unless safety is of concern, the 
study will not be stopped for futility and enrollment will continue to at least the targeted 
sample size of 132. 
8.9 
Missing Values 
Subjects may have a missing endpoint for the following reasons: 
 Lost to follow up due to transfer to another hospital 
 Remains in the hospital for >28 days without ever achieving WHO COVID-19 
Classification level ≥ 6. 
 
Withdrawal of consent prior to meeting endpoint 
If a subject is lost to follow-up due to transfer to another hospital, the subject will be 
considered a treatment failure per the ITT and mITT populations and will be excluded 
from the analysis per the PP population. Missing primary endpoint assessment because 
of continued hospitalization beyond 28 days will be counted as treatment success if the 
subject has not met the criteria for WHO COVID-19 Classification level ≥ 6 at any time up 
to 28 days.   Subject who withdraw consent without being assessed for the primary 
endpoint will be considered treatment failure. To minimize missing values, enrolled 
participants will be followed through to the end of the primary study period (through to 
hospital discharge, death, or 28 days from treatment initiation) for safety and efficacy 
assessment. Additionally, safety and clinical status will be monitored through to Day 56 
as per the schedule of events.  


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-41- 
 
 
9. 
DATA COLLECTION, MONITORING, AND AE REPORTING 
9.1 
Confidentiality 
Information about study participants will be kept confidential to the best of the study site’s 
ability. 
In the event that a participant revokes authorization to collect or use personal health 
information (PHI), the sponsor retains the ability to use all information collected prior to 
the revocation of participant authorization. For participants that have revoked 
authorization to collect or use PHI, attempts should be made to obtain permission to 
collect at least vital status (i.e., that the participant is alive) at the end of their scheduled 
study period. 
9.2 
Source Documents 
Source data is all information, original records or clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial. 
Source data are contained in original source documents. Examples of these original 
documents and data records include (as applicable): hospital records, clinical and office 
charts, laboratory notes, memoranda, participant’s diaries or evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copies or 
transcriptions certified after verification as being accurate and complete, microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, participant files, pharmacy 
records, laboratory records, medical records (including electronic records) relative to the 
clinical trial.  
9.3 
Data Collection 
Data will be collected using Electronic Data Capture (EDC). Participants will be identified 
by PID#. Initial data collection may utilize a paper form of the EDC. Any such records will 
be maintained as source data.  
9.4 
Record Retention 
It is the Investigator’s responsibility to retain study essential documents as per country 
regulations: in the US for at least 2 years after the last approval of a marketing application 
in their country and until there are no pending or contemplated marketing applications in 
their country or at least 2 years have elapsed since the formal discontinuation of clinical 
development 
of 
the 
investigational 
product. 
The 
sponsor 
will 
inform 
the 
investigator/institution as to when these documents are no longer needed to be retained. 
9.5 
Safety and Quality Monitoring and Record Availability 
Monitoring 
Monitoring of the clinical trial will be performed by experienced monitors, who will report 
to the Sponsor as outlined in the Monitoring Plan. 
Record availability and auditing 
The investigator will make study documents (e.g., ICFs, drug accountability forms) and 
pertinent hospital or clinic records readily available for inspection by the local IRB, the site 
monitors, regulatory agencies, GeneOne Life Science, Inc. or its designee for 
confirmation of the study data. 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-42- 
 
 
Participation as an investigator in this study implies acceptance of potential inspection by 
regulatory authorities and applicable compliance and quality assurance offices. 
9.6 
Adverse event (AE) Reporting 
AEs will be recorded and forwarded to regulatory agencies as required. 
9.6.1 Study Reporting Period of Adverse Events 
All AEs will be recorded throughout the study and the 28 day follow-up period.  
9.6.2 Study Reporting Period for Serious Adverse Events  
SAE’s will be recorded throughout the study and the 28-day follow-up period. 
Expedited reporting of SAEs will be determined by GeneOne Life Science using reference 
safety information specified in the Investigator’s Brochure. An event may qualify for 
expedited reporting to regulatory authorities if it is an SAE, SUSAR in line with relevant 
regulatory requirements.  
At any time after completion of the SAE reporting period, if an Investigator becomes aware 
of an SAE that is suspected by the Investigator to be related to the study drug, the event 
will be reported to the Sponsor. 
SAE TELEPHONE AND CONTACT INFORMATION: 
SAE REPORTING 
 
MEDICAL MONITOR: 
Catalyst Pharmacovigilance 
 
Joel Maslow, MD PhD MBA 
 
safety@catalystcr.com 
 
MAILING ADDRESS: 
PHONE: 
(484) 965-9147p; (610) 331-7844 c 
 
GeneOne Life Science, Inc. 
MEDICAL LIAISON: 
Celine Remigio, RN DPT 
 
1040 DeKalb Pike 
CELL: 
(914) 606-1199 
 
Suite 200 
EMAIL: 
cremigio@geneonels-us.com 
 
Blue Bell, PA 19422 
24 hr Answering Service 
(215) 703-5843 
 
 
GeneOne FACSIMILE: 
(484) 965-9146 
 
 
GeneOne Safety Email 
GeneOneSafety@geneonels-us.com 
 
 
 
The report should contain as much clinical safety information as possible, but at minimum, 
the initial report must include the following information: 
• 
Participant number and Study name 
• 
Date of Onset and Date of Resolution (if applicable) 
• 
Detailed description of event 
• 
Investigational product (if known) 
 
Causal relationship of event to investigational product 
• 
Reporter name and contact information 
Follow-up reports will be sent as soon as more information becomes available. Events for 
which the study participant seeks medical care, the study site will attempt to obtain 
relevant medical records to include as source documents. These include but are not 
limited to discharge summary, results of relevant laboratory tests, and reports of relevant 
radiographic studies. In the case of death, the investigator will attempt to procure relevant 
reports (such as autopsy reports, medical examiner report, discharge summary).  


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-43- 
 
 
Each SAE must be followed by the investigator until resolution, stabilization, or return to 
baseline, even if this extends beyond the end of the study, with follow-up report filed to 
provide a summary of the event through resolution.  
The electronic data capture (EDC) system is integrated to the safety database (Veeva) 
vault and all SAE information will be collected electronically. A paper SAE form will be 
available as a back-up. Copies (or electronic copy) will be provided to GeneOne Life 
Science or its representative, who will be responsible for reporting to regulatory 
authorities as indicated, and copy will be forwarded to the study sites IRB/REC.  
9.6.3 Notification of Serious Adverse Events 
In accordance with local regulations, the Sponsor shall notify the appropriate regulatory 
authorities, and all participating investigators in a written safety report of any adverse 
experience associated with the use of the product that is both serious and unexpected 
(e.g., FDA Form 3500A in the US). SUSARs reports shall be made as soon as possible 
and in no event later than 15 calendar days after the Sponsor’s initial receipt of the 
information. Written notification may be submitted on the form described above or 
equivalent or in a narrative format and shall bear prominent identification of its contents. 
Each written notification to regulatory agencies shall be transmitted to the division that 
has responsibility for review. In each written safety report, the Sponsor shall identify all 
safety reports previously filed concerning a similar adverse experience, and shall analyze 
the significance of the adverse experience in light of the previous, similar reports. The 
Sponsor shall also notify the relevant regulatory authorities by telephone, facsimile, or 
email transmission of all deaths and any unexpected fatal or life-threatening experience, 
regardless of causality, as soon as possible but in no event later than 7 calendar days 
after the Sponsor’s initial receipt of the information. Each telephone call or facsimile 
transmission to regulatory agencies shall be transmitted to the division that has 
responsibility for review.  
Follow up information to a safety report shall be submitted as soon as the relevant 
information is available. If the results of a Sponsor’s event investigation show that an 
adverse drug experience not initially determined to be reportable is, in fact, reportable, 
the Sponsor shall report such experience in a written safety report as soon as possible, 
but in no event later than 15 calendar days after the determination is made. Results of 
investigations of other safety information shall be submitted, as appropriate, in an 
information amendment or annual report. In the event of death, if an autopsy is performed, 
a copy of the report, redacted for PHI but labeled with the PID#, should be sent to 
GeneOne Life Science, Inc. 
9.7 
Study Termination 
GeneOne Life Science reserves the right to terminate the study for safety or 
administrative reasons, including lack of enrollment, at any time. Investigational product 
must be returned to GeneOne, unless instructed otherwise. Document retention will follow 
local regulation.   


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-44- 
 
 
10. 
PUBLICATION OF RESEARCH FINDINGS 
Publication of the results of this trial will be allowed. Any proposed presentation, abstract and/or 
manuscript must be made available to GeneOne at least 60 days prior to submission. GeneOne 
shall have fifteen (15) days for review. If GeneOne considers that material would reveal 
protectable intellectual property, GeneOne may request a delay in submission for a maximum of 
three (3) months from the date of receipt in order for patent application(s) to be filed with the 
United States Patent and Trademark Office and/or foreign patent office(s). 
11. 
LIST OF ABBREVIATIONS 
AE 
Adverse event 
Alk Phos 
Alkaline phosphatase 
ALT 
Alanine transaminase 
AST 
Aspartate transaminase 
BUN 
Blood urea nitrogen 
CBC 
Complete blood count 
CI 
Confidence interval 
CMP 
Complete Metabolic Profile 
CPAP 
Continuous positive airway pressure 
CPK 
Creatinine phosphokinase 
COPD 
Chronic obstructive pulmonary disease 
CRP 
C-reactive protein 
CTCAE 
National Cancer Institute Common terminology criteria for adverse events 
CXR 
Chest X-ray (chest radiograph) 
CRS 
Cytokine release syndrome 
DSMB 
Data and Safety Monitoring Board 
ECG 
Electrocardiogram (synonymous with EKG) 
eCRF 
Electronic case report form 
EDC 
Electronic data capture 
eGFR 
Estimated glomerular filtration rate (Cockroft-Gault formula) 
ERER 
Event requiring expedited reporting 
GFR 
Glomerular filtration rate 
GGT 
Gamma-glutamyl transferase 
HMGB1 
High mobility group box protein-1  
IB 
Investigator’s brochure 
ICF 
Informed consent form 
ICU 
Intensive Care Unit 
IL 
Interleukin 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-45- 
 
 
IRB 
Investigation review board 
ITT 
Intention-to-treat 
LDH 
Lactate dehydrogenase 
LPS 
Lipopolysaccharide 
mAb 
Monoclonal antibody 
MERS-CoV Middle East respiratory syndrome coronavirus  
NS 
Not stated 
PBMC 
Peripheral blood mononuclear cell 
PEEP 
Positive end-expiratory pressure 
PHI 
Personal health information 
PID# 
Participant identification designation number 
PK 
Pharmacokinetic 
PM 
Particulate matter 
PM2.5 
Particulate matter of a size < 2.5 μm 
PP 
Per-protocol 
SARS-CoV Severe acute respiratory syndrome coronavirus 
SARS-CoV-2 Severe acute respiratory syndrome coronavirus, type 2 
SAE  
Serious adverse event 
SAP 
Statistical analysis plan 
SOC  
Standard of care 
SUSAR 
Suspected unexpected serious adverse reaction 
TBI 
Traumatic brain injury 
ULN 
Upper limit of normal 
 
12. 
REFERENCES 
 
1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult 
inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 
395(10229):1054-1062. 
2. Karki R, Sharma BR, Tuladhar S, WIlliams EP, Zalduondo L, Samir P, et al. Synergism of TNF-alpha and 
IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection 
and cytokine shock syndromes. Cell 2020; S0092-8674(20)31542-7. Online ahead of print. PMID: . 
3. Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D, Wang M, et al. In vitro, ex vivo and in 
vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of 
cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in 
murine models. Clin Immunol 2007 123(3):311-323. 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-46- 
 
 
4. Mangano K, Sardesai NY, Quattrocchi C, Mazzon E, Cuzzocrea S, Bendtzen K, et al. Effects of the 
immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. Br J Pharmacol 2008 
155(5):722-730. 
5. Zhang JL, Huang WM, Zeng QY. Atractylenolide I protects mice from lipopolysaccharide-induced 
acute lung injury. Eur J Pharmacol 2015 765:94-99. . 
6. Xu M, Li F, Wang M, Zhang H, Xu L, Adcock IM, et al. Protective effects of VGX-1027 in PM2.5-induced 
airway inflammation and bronchial hyperresponsiveness. Eur J Pharmacol 2019; 842:373-383. 
7. Cui Y, Zhang ZF, Froines J, Zhao J, Wang H, Yu SZ, et al. Air pollution and case fatality of SARS in the 
People's Republic of China: an ecologic study. Environ Health; 2(1):15. 
8. Lagadec P, Balaguer T, Boukhechba F, Michel G, Bouvet-Gerbettaz S, Bouler JM, et al. Calcium 
supplementation decreases BCP-induced inflammatory processes in blood cells through the NLRP3 
inflammasome down-regulation. Acta Biomaterialia 2017; 57:462-471. 
9. Laird MD, Shields JS, Sukumari-Ramesh S, Kimbler DE, Fessler RD, Shakir B, et al. High mobility group 
box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 
4. Glia 2014 62(1):26-38. 
10. Ahmad SF, Nadeem A, Ansari MA, Bakheet SA, Alasmari F, Alasmari AF, et al. The potent 
immunomodulatory compound VGX-1027 regulates inflammatory mediators in CD4+ T cells, which are 
concomitant with the prevention of neuroimmune dysregulation in BTBR T+ Itpr3tf/J mice. Life Sci 
2019 Oct 11:116930. 
11. Lee JC, Menacherry S, Diehl MC, Giffear MD, White CJ, Juba R, et al. Safety, bioavailability, and 
pharmacokinetics of VGX-1027-A novel oral anti-inflammatory drug in healthy human subjects. Clin 
Pharmacol Drug Dev 2016 5(2):91-101. 
 
 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-47- 
 
 
13. 
APPENDICES 
APPENDIX A: Exclusionary period for anti-cytokine agents 
CATEGORY 
Generic name 
Brand name 
Exclusionary 
period  
IL-1 inhibitors 
Rilonacept 
Arcalyst 
35 days 
 
Canakinumab 
Ilaris 
30 days 
 
Anakinra 
Kineret 
30 days 
IL-6 inhibitors 
Toclizumab 
Actemra 
50 days 
 
SIltuximab 
Sylvant 
100 days 
 
Sarilumab 
Kevzara 
105 days 
 
Atezolizumab 
Tencentriq 
135 days 
 
Clazakizumab 
 
120 days 
 
Olokizumab 
 
120 days 
 
Sirukumab 
 
120 days 
JAK inhibitors 
Ruxolitinib 
Jakafi 
30 days 
 
Tofacitinib 
Xeljanz 
30 days 
 
Oclacitinib 
Apoquel 
30 days 
 
Baricitinib 
Olumiant 
30 days 
 
Peficitinib 
Smyraf 
30 days 
 
Fedratinib 
Inrebic 
30 days 
 
Upadacitinib 
Rinvoq 
30 days 
 
Filgotinib 
 
30 days 
 
Cerdulatinib 
 
30 days 
 
Gandotinib 
 
30 days 
 
Lestaurtinib 
 
30 days 
 
Momelotinib 
 
30 days 
 
Pacritinib 
 
30 days 
 
Abrocitinib 
 
30 days 
TNFα inhibitors 
Infliximab 
Remicade 
50 days 
 
Etanercept 
Enbrel 
30 days 
 
Adalimumab 
Humira 
75 days 
 
Certolizumab 
Cimzia 
55 days 
 
Golimumab 
Simponi 
60 days 
 
Note 1: This appendix may be updated through the clinical trial as new agents are either 
approved or brought into clinical practice. The time prior to enrollment that each drug is 
to be excluded is listed, but may be updated if new information is published regarding 
modifications to drug half-life.  
Note 2: The decision to initiate treatment with any of the agents listed below is 
determined either according to the hospital specific SARS-CoV-2 Treatment Algorithm 
or per individual physician decision. If any agent is started post-enrollment, use should 
be documented as a concomitant medication. Other study procedures should continue 
as per the schedule of events.  
 
 


 
 
GLS27-005 
GeneOne Life Science, Inc. 
 
Clinical Protocol 
 
 
 
-48- 
 
 
APPENDIX B: WHO COVID-19 Classification  
PATIENT STATE 
DESCRIPTOR 
SCORE  
Uninfected 
No clinical or virologic evidence of 
infection 
0 
Ambulatory 
Infected, with no limitation of activities  
 
1 
 
Infected, with limitation of activities 
 
2 
Hospitalized 
No oxygen therapy 
 
3 
     Mild disease 
Oxygen by mask or nasal canula 
 
4 
Hospitalized 
Non-invasive ventilation or high-flow 
oxygen  
5 
     Severe disease 
Intubation with mechanical ventilation 
 
6 
 
Ventilation plus any of vasopressor Rx, 
RRT, ECMO 
7 
Death 
Death 
 
8 
 
 

SAP_001.pdf: 
  
 
 
STATISTICAL ANALYSIS PLAN 
 
 
 
 
Study Title: 
Safety, Tolerability, Efficacy and Dose Response of GLS-
1027 in the Prevention of Severe Pneumonitis caused by 
SARS-CoV-2 Infection 
Name of Test Drug: 
GLS-1027 
 
Study Number: 
 
GLS27-005 
 
 
Protocol Version: 
5.0 
 
 
Protocol Date: 
11 Aug 2021 
 
 
Analysis Plan Version: 
1.0 
 
 
Analysis Plan Date: 
03 Dec 2021 
 
 
Analysis Plan Author: 
Catalyst Clinical Research, LLC 
 
 
 
CONFIDENTIAL AND PROPRIETARY INFORMATION 
 
 
 


	
	


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                  Version 1.0  
 
 
CONFIDENTIAL 
Page 2 
03DEC2021 
LIST OF ABBREVIATIONS ................................................................................................................................. 4 
1. 
INTRODUCTION ......................................................................................................................................... 5 
2. 
STUDY OBJECTIVES .................................................................................................................................. 5 
2.1. 
Primary Objectives ............................................................................................................................ 5 
2.2. 
Exploratory Objectives ...................................................................................................................... 5 
3. 
STUDY DESIGN AND PLAN ...................................................................................................................... 6 
4. 
DETERMINATION OF SAMPLE SIZE ...................................................................................................... 8 
5. 
GENERAL ANALYSIS CONSIDERATIONS ............................................................................................. 8 
6. 
ANALYSIS POPULATIONS ........................................................................................................................ 9 
6.1. 
Intent-to-treat (ITT) Population ........................................................................................................ 9 
6.2. 
Modified Intent-to-treat (mITT) Population ...................................................................................... 9 
6.3. 
Safety Population .............................................................................................................................. 9 
6.4. 
Per-protocol (PP) Population ............................................................................................................ 9 
7. 
STUDY POPULATION ................................................................................................................................ 9 
7.1. 
Subject Disposition ........................................................................................................................... 9 
7.2. 
Protocol Deviations ......................................................................................................................... 10 
7.3. 
Demographics and Baseline Characteristics ................................................................................... 10 
7.4. 
Medical History ............................................................................................................................... 10 
7.5. 
Prior and Concomitant Medications ................................................................................................ 10 
7.6. 
Study Drug Exposure ...................................................................................................................... 10 
7.7. 
Blood Collection for Pharmacokinetic and PBMC Results ............................................................. 10 
8. 
EFFICACY ANALYSES ............................................................................................................................ 11 
8.1. 
Definition of the Primary Efficacy Endpoint .................................................................................. 11 
8.2. 
Analysis of the Primary Efficacy Endpoint ..................................................................................... 11 
8.3. 
Definition of the Exploratory Efficacy Endpoints ........................................................................... 11 
8.4. 
Analysis of the Exploratory Efficacy Endpoints ............................................................................. 12 
9. 
SAFETY ANALYSES ................................................................................................................................. 13 
9.1. 
Adverse Events................................................................................................................................ 13 
9.1.1. 
Severity ......................................................................................................................... 13 
9.1.2. 
Relationship ................................................................................................................... 13 
9.1.3. 
Serious Adverse Events ................................................................................................. 13 
9.1.4. 
Treatment-Emergent Adverse Events (TEAEs) ............................................................ 14 
9.1.4.1. 
Definition of Treatment-Emergent ........................................................... 14 
9.1.4.2. 
Incomplete Dates...................................................................................... 14 
9.1.5. 
Summaries of Adverse Events....................................................................................... 14 
9.2. 
Clinical Laboratory Evaluations ...................................................................................................... 15 
9.3. 
Vital Signs ....................................................................................................................................... 15 
9.4. 
ECG Results .................................................................................................................................... 15 
9.5. 
Physical Exam ................................................................................................................................. 16 
9.6. 
Urine Pregnancy Test ...................................................................................................................... 16 
9.7. 
Other Data ....................................................................................................................................... 16 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                  Version 1.0  
 
 
CONFIDENTIAL 
Page 3 
03DEC2021 
APPENDIX A: PRESENTATION OF DATA AND PROGRAMMING SPECIFICATIONS ........................... 17 
APPENDIX B: TABLE OF CONTENTS FOR STATISTICAL TABLES AND LISTINGS ............................. 20 
APPENDIX C: TABLE LAYOUTS .................................................................................................................... 26 
APPENDIX D: FIGURE LAYOUTS................................................................................................................... 63 
APPENDIX E:  LISTING LAYOUTS ................................................................................................................. 66 
 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                  Version 1.0  
 
 
CONFIDENTIAL 
Page 4 
03DEC2021 
LIST OF ABBREVIATIONS 
 
 
AE  
adverse event  
ATC 
Anatomical Therapeutic Chemical 
BMI 
body mass index 
bpm 
beats per minute  
CRF  
case report form  
CSR  
Clinical Study Report 
DBP  
diastolic blood pressure  
ECG  
electrocardiogram  
ET 
early termination 
FDA 
Food and Drug Administration 
GI 
gastrointestinal 
HBsAg  
hepatitis B surface antigen  
HCV  
hepatitis C virus  
ICH  
International Conference on Harmonisation  
IP 
Investigational Product 
ITT 
Intent-to-Treat 
MedDRA Medical Dictionary for Regulatory Activities 
OTC 
over-the-counter 
PEEP 
Positive End-Expiratory Pressure 
PT 
preferred term 
SAE  
serious adverse event  
SBP  
systolic blood pressure  
SD  
standard deviation  
SOC  
system organ class 
TLFs 
tables, listings, and figures 
ULN 
upper limit of normal 
WHO 
World Health Organization 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                  Version 1.0  
 
 
CONFIDENTIAL 
Page 5 
03DEC2021 
1. 
INTRODUCTION 
This document outlines the statistical methods to be implemented during the analyses of data 
collected within the scope of GeneOne Life Science Inc.’s Protocol GLS27-005 [Safety, 
Tolerability, Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis 
caused by SARS-CoV-2 Infection]. The purpose of this plan is to provide specific guidelines 
from which the statistical analyses will proceed. Any deviations from this plan will be 
documented in the clinical study report (CSR). 
The reader is referred to the following complementary documents: 
• Protocol GLS27-005, version 5.0, dated 11 Aug 2021 
• Case Report Form (CRF), version 1.05, dated 08 Feb 2021 
• Data Management Plan, version 1.0, dated 04 Feb 2021 
2. 
STUDY OBJECTIVES 
2.1. 
Primary Objectives 
The primary objectives of the study are to evaluate the following: 
• Incidence of serious adverse events relative to treatment group 
• Incidence of treatment failure within 28 days from enrollment 
2.2. 
Exploratory Objectives 
The exploratory objectives are: 
• Assess the number of days requiring ICU care relative to treatment group. 
• Assess the number of days of NIV, high-flow O2 or mechanical ventilation relative to 
treatment group. 
• Assess incidence of WHO COVID-19 Classification levels relative to baseline serum IL-
6 level. 
• Assess incidence of WHO COVID-19 Classification levels relative to baseline serum 
ferritin level. 
• Assess incidence of WHO COVID-19 Classification levels relative to baseline CRP 
• Assess trough level of GLS-1027 relative to serum creatinine. 
• Assess the maximal level of Positive End-Expiratory Pressure (PEEP) for subjects who 
are intubated relative to treatment group. 
• Assess the number of days of PEEP > 5 cm H2O for subjects who are intubated relative 
to treatment group. 
• Assess change in WHO COVID-19 Classification level at Day 28 from enrollment, 
relative to group. 
• Assess SARS-CoV-2 IgM antibody responses relative to treatment group. 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                  Version 1.0  
 
 
CONFIDENTIAL 
Page 6 
03DEC2021 
3. 
STUDY DESIGN AND PLAN 
This is a Phase II, randomized, double-blind, placebo-controlled study to assess 2 dose levels of 
GLS-1027 for the prevention of treatment failure among participants admitted to the hospital 
with PCR confirmed infection with SARS-CoV-2 (WHO classification 3 or 4). Subjects can be 
enrolled up to 72 hours from the time of hospital admission. 
Participants will be randomized to placebo or GLS-1027 at either 120 mg or 360 mg daily in a 
1:1:1 ratio as adjunctive to standard of care based on the hospital COVID-19 treatment algorithm 
and/or local COVID-19 treatment practices. Participants will be administered study drug for a 
maximum treatment period of 14 days or until discharge or death, whichever comes first. 
Primary outcome will be assessment at day 28, with follow-up to continue to Day 56 to 
document AEs and outcome as to discharge, death, or WHO COVID-19 classification level if 
subject remains hospitalized.  
All subjects will be considered to have completed the study except for the following 
circumstances: 
• Withdrawal of consent from study 
• Loss to follow-up 
• Stopped study treatment for any reason other than discharge, pregnancy, or decreased 
renal function


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 7 
03DEC2021 
 
Table 1: Schedule of Assessments 
 
a Vital signs to be recorded daily to include: temperature, respiratory rate, heart rate, systolic and diastolic blood 
pressure 
b Hematology labs to be recorded (as collected as part of clinical care) and recorded: Hemoglobin, hematocrit, 
platelets, neutrophils, band forms, lymphocytes, eosinophils 
c Basic metabolic panel labs: Sodium, potassium, creatinine, BUN, glucose, liver function tests; LFTs include AST, 
ALT, bilirubin (direct), alkaline phosphatase, LDH, albumin. . 
d Other labs to be recorded if performed: Ferritin, CRP, IL-6, troponin, D-dimer 
e Procalcitonin: record only initial measurement or within 48 hours of admission and/or SARS-CoV-2 diagnosis 
(may be performed prior to date of enrollment) 
f Record maximal daily level of O2 by nasal cannula prescribed, if participant is receiving O2 by nasal cannula 
g Record maximal daily level of end expiratory pressure delivered by CPAP prescribed, if participant is receiving 
CPAP 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 8 
03DEC2021 
 
h Record maximal daily level of PEEP and delivered FiO2 by mechanical ventilation, if participant is receiving 
mechanical ventilation 
i Study drug administration will commence on the day of enrollment if treatment can be administered before 10 pm 
and then with AM medications thereafter, If, study drug cannot be administered prior to 10 pm on the day of 
enrollment, then the 1st day of treatment will occur on the day after enrollment. 
j Perform a 12-lead ECG on the 2nd day of treatment with study drug between 75 and 90 minutes post-
administration on day 2; and on day 15 (± 2 days) 
k Serum is collected for CPK and GGT on day 1 and day 7, and weekly thereafter, if values on day 7 are abnormal 
until return to normal 
l PK assessment will be performed for the initial 15 subjects enrolled. Blood (5 ml) will be collected for plasma 
collection at baseline (pre-treatment), and then at 1, 2, 4, and 8 hr. Trough measurements will be obtained as 
indicated for all study participants 
m The clinical record should be reviewed at Day 28 and Day 56 as relevant to denote date of discharge, date of 
death, or clinical status (WHO COVID-19 Classification Level); if discharged, subjects should be contacted by 
telephone to ascertain clinical status. 
n PBMCs will be collected at specified sites only 
 
4. 
DETERMINATION OF SAMPLE SIZE 
Based on the initial data obtained to date and data in the literature, it is anticipated that 
approximately 50% of subjects hospitalized with PCR-positive SARS-CoV-2 infections (WHO 
COVID-19 Classification level 3 or 4) will experience treatment failure at day 28 from 
enrollment. Treatment failure is defined as progression to WHO COVID-19 classification level 
of 6 or greater as defined by one or more of the following: the need for high-flow oxygen or non-
invasive ventilation, the need for intubation or mechanical ventilation (level 6), the need for 
ECMO (level 7), or any cause death (level 8); the initiation of a non-study immune modulator; 
withdrawing consent from the study; becoming lost to follow-up; or discontinuation of treatment 
for any reason other than renal function or pregnancy. The sample size estimate for this proof of 
concept is based on Fisher’s Exact two-sided test for 2 proportions using NQuery 8 
(www.statsols.com). Estimates of admitted patients requiring salvage therapy is unknown, 
however, the clinical data set who require intubation is a likely subset of those whose condition 
worsens but do not progress to respiratory compromise.  
Although the interim analysis will utilize masked treatment assignments, the O’Brien Fleming 
group sequential sample size estimation confirms that a single interim look would retain a 
cumulative exit probability of 70% with a cumulative alpha =0.05 after the final analysis using 
the target enrollment of 132 (44 per group) to detect a reduction of those reaching the endpoint 
of treatment failure. This study is not powered to assess statistically significant differences 
between GLS-1027 doses. A gate-keeping method will be used to compare the highest dose to 
placebo first and then compare the lower dose if the higher dose shows significant benefit. 
 
5. 
GENERAL ANALYSIS CONSIDERATIONS 
The statistical analysis results will be reported using tables, listings, and figures (TLFs). 
Summaries of continuous variables will display means, standard deviations (SDs), medians, 
minimums, maximums, and the number of observations. Summaries of categorical variables will 
display frequency counts and percentages. 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 9 
03DEC2021 
 
All analyses will be performed using SAS Version 9.4 or higher. 
A masked interim analysis will be performed when 22 subjects in each group have been assessed 
for the primary endpoint of treatment failure. The primary goals of this analysis are to review 
blinded safety to ensure that GLS-1027 has no concerns or causes worsening conditions. Unless 
safety is of concern, the study will not be stopped for futility and enrollment will continue to the 
targeted sample size of 132.  
6. 
ANALYSIS POPULATIONS 
6.1. 
Intent-to-treat (ITT) Population 
The ITT Population will include all subjects randomized to a treatment allocation. The ITT 
population will be used for the summary of all demographic and baseline characteristics and for 
analysis of the primary outcome of treatment failure. Subjects will be grouped in analyses and 
summaries based on their randomization allocation. 
6.2. 
Modified Intent-to-treat (mITT) Population 
The modified intention to treatment (mITT) population includes all participants who are 
randomized to a treatment allocation, and who have received at least one dose of study drug. The 
mITT population will be used for the summary and analysis of the primary outcome of treatment 
failure. Participants will be grouped based on the treatment allocation. 
6.3. 
Safety Population 
The Safety Population will include all participants in the mITT population. Subjects will be 
grouped in analyses and summaries based on their actual treatment. 
6.4. 
Per-protocol (PP) Population 
The PP Population includes all safety subjects who complete the trial by meeting the endpoint of 
treatment failure or being discharged within 14 days without meeting the endpoint. Subjects will 
be grouped in analyses and summaries based on their actual treatment. This set will be used as a 
sensitivity analysis to summarize the primary and other efficacy outcomes. 
7. 
STUDY POPULATION 
7.1. 
Subject Disposition 
The number and percentage of subjects who were screened and failed screening, who were in 
each analysis population, who completed the study and who discontinued prior to study 
completion will be presented by treatment group (GLS-1027 120 mg, GLS-1027 360 mg, and 
placebo) and overall. Subjects who discontinued prior to completing the study will also be 
summarized by reason for discontinuation.  
Subject disposition will also be listed.  


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 10 
03DEC2021 
 
7.2. 
Protocol Deviations 
Protocol deviations with significance will be listed. 
7.3. 
Demographics and Baseline Characteristics 
Demographics and baseline data, vital signs, medical history, prior and concomitant medications, 
and treatments will be summarized by means of descriptive statistics: continuous variables as 
mean, median, SD, minimum/maximum ranges and categorical variables as frequencies and 
percentages, grouped by treatment arms and overall, based on ITT population. Demographic and 
baseline characteristics will also be listed.  
7.4. 
Medical History 
Medical history verbatim terms collected from the CRF will be mapped to system organ classes 
(SOCs) and preferred terms (PTs) using the Medical Dictionary for Regulatory Activities 
(MedDRA) (version 23.0).  
Summaries (number and percentage of subjects) of medical history by SOC and PT will be 
provided by treatment and overall.  
A listing of medical history will also be provided. 
7.5. 
Prior and Concomitant Medications 
A prior medication is defined as a medication that was administered up to 4 months prior to time 
of enrollment. All other medications will be considered concomitant. 
Medication verbatim names collected from the CRF will be mapped to Anatomical Therapeutic 
Chemical (ATC) Classes and Preferred Names using the World Health Organization's 
WHODrug Global March 2020 version. Preferred Names will consist of only the base 
compounds and not the salts (e.g., Naproxen Sodium will be listed only as Naproxen). 
Concomitant medications will be summarized for each treatment by ATC class and preferred 
name. Prior and concomitant medications will be listed. 
7.6. 
Study Drug Exposure 
Exposure summaries of duration of exposure, total number of doses taken, and total number of 
doses missed will be provided by treatment. Duration of exposure is defined as the date of last 
dose minus the date of first dose + 1, regardless of if any doses were missed in between. 
Exposure data will be listed. 
7.7. 
Blood Collection for Pharmacokinetic and PBMC Results 
Blood collection information (date/time and volume of blood) for PK assessments, trough drug 
measurements, serum, and PBMCs will be listed. 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 11 
03DEC2021 
 
8. 
EFFICACY ANALYSES  
8.1. 
Definition of the Primary Efficacy Endpoint 
The primary endpoint is treatment failure within 28 days of enrollment. Treatment failure is 
defined as: 
• Progression to WHO classification level 6 or greater including the need for high-flow 
oxygen or non-invasive ventilation 
• Receiving salvage therapy with a non-study immune-modulator (Appendix A). 
• Lost to follow-up through hospital transfer, within the 14-day primary treatment period. 
• Discontinuation of study drug for any cause prior to day 14 or hospital discharge will be 
considered as a treatment failure, except for those for whom study drug was temporarily 
suspended due to a decrease in renal function (creatinine clearance of < 60 mL/min), 
other reasons for temporary cessation of treatment listed in Section 7.3.2 of the protocol, 
or for discontinuation in the case of pregnancy. These subjects will be followed for the 
primary endpoint at 28 days with long-term follow-up at day 56. 
Subjects who complete 14 days of treatment but remain hospitalized but do not meet the criteria 
for treatment failure, will not considered be as treatment failures with respect to the primary 
endpoint. 
8.2. Analysis of the Primary Efficacy Endpoint 
The proportion of subjects in each treatment group who reach the study endpoint of treatment 
failure by 28 days will be compared to placebo using Fisher’s Exact 2-sided test of proportions. 
Additionally, the frequency for each outcome (intubation, ECMO, death) will be determined 
within each group. The ITT, mITT and PP analysis populations will be used to analyze the 
primary endpoint. 
8.3. 
Definition of the Exploratory Efficacy Endpoints 
Exploratory endpoints include the following which will be summarized using the PP populations 
by treatment group received: 
• Assess the number of days of hospitalization relative to treatment group 
• Assess the number of days requiring ICU care relative to treatment group. If a subject 
does not require ICU care, the number of days will be set to zero for the group summary. 
The number of ICU days will be summarized for all subjects in each group and for the 
proportion of those who are actually in ICU. 
• Assess the number of days of non-invasive or mechanical ventilation relative to treatment 
group. If a subject does not require non-invasive or mechanical ventilation, the number of 
days will be set to zero for the group summary. The number of mechanical ventilation 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 12 
03DEC2021 
 
days will be summarized for all subjects in each group and for the proportion of those 
who are actually on mechanical ventilation. 
• Assess incidence of WHO COVID-19 Classification levels relative to baseline serum IL-
6 level 
• Assess incidence of WHO COVID-19 Classification levels relative to baseline serum 
ferritin level 
• Assess incidence of WHO COVID-19 Classification levels relative to baseline CRP 
• Assess trough level of GLS-1027 relative to serum creatinine 
• Assess the maximal level of Positive End-Expiratory Pressure (PEEP) for subjects who 
are intubated relative to treatment group. 
• Assess the number of days of PEEP > 5 cm H2O for subjects who are intubated relative 
to treatment group 
• Assessment of WHO COVID-19 Classification at 28 day relative to treatment group 
• Assess SARS-CoV-2 IgM antibody responses relative to treatment group 
No adjustments or imputations will be made for deaths or other forms of missingness except 
those already described above. 
Corticosteroids will be recorded as a prior or concomitant medication. Subgroup analysis will be 
performed to compare outcomes relative to treatment group and relative to use or non-use of 
corticosteroids. Primary treatment outcomes will be determined from the time of enrollment 
through to Day 28. 
8.4. 
Analysis of the Exploratory Efficacy Endpoints 
PEEP values during intubation will be plotted separately by treatment over time. Assessment of 
WHO COVID-19 Classification at 28 day relative to treatment group is discussed in Sections 8.1 
and 8.2. Shift tables for worst (most extreme) values of serum IL-6 level, serum ferritin level, 
and CRP relative to baseline will be presented for each WHO COVID-19 Classification level. 
The number of days in ICU, requiring mechanical ventilation and of PEEP > 5 cm H2O will be 
summarized by treatment using descriptive statistics (sample size, mean, median, SD, minimum, 
maximum). 
The number and percentage of subjects will be summarized by treatment according to their 
SARS-CoV-2 IgM antibody response. The above exploratory endpoint analyses will be 
presented for the PP population and individual results will be listed by treatment and study day. 
No formal statistical analysis is planned. 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 13 
03DEC2021 
 
The relationship of trough level of GLS-1027 to serum creatinine relative to treatment group will 
be examined on an adhoc basis and is outside the scope of this document. 
9. 
SAFETY ANALYSES 
All safety analyses will be based on the Safety Population. 
9.1. 
Adverse Events 
An adverse event (AE) is defined as any unfavorable and unintended change in the structure, 
function, or chemistry of the body, or worsening of a pre-existing condition, temporally 
associated with the use of a product whether or not considered related to the use of the product. 
In this study, such changes will be monitored, classified, and summarized, as Clinical or 
Laboratory AEs. Medical conditions/diseases present before starting the investigational drug will 
be considered adverse events only if they worsen after starting study treatment. Verbatim terms 
on CRFs will be mapped to preferred terms (PTs) and system organ classes (SOCs) using the 
Medical Dictionary for Regulatory Activities (MedDRA) (version 23.0).  
 
9.1.1. 
 Severity 
AEs are graded by the investigator as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), 
Grade 4 (potentially life threatening) or Grade 5 (death) according to the NCI Common 
Terminology Criteria for Adverse Events version 5.0.  
9.1.2. 
Relationship  
Based on the criteria described below, AEs will be classified according to one of the following 
categories:  
•     Related – the investigator considers that there is a causal relationship between the event 
and study drug  
•     Probably related – the investigator considers that there is a probability of a causal 
relationship of the event to the study drug  
•     Possibly related – the investigator considers that there is a possible causal relationship of 
the event to the study drug 
•     Unlikely related – the investigator considers that there is an unlikely causal relationship 
of the event to the study drug 
•     Not related – the investigator considers that the event has no relationship to 
administration of the study drug  
 
For the purpose of analysis, related AEs are those reported as “Related,” “Probably related,” 
“Possibly related” and unrelated AEs are those reported as "Unlikely related" or “Not related.” 
Events for which the investigator did not record relationship will be considered related for 
analysis. Data listings will show relationship as missing. 
 
9.1.3. 
Serious Adverse Events 
An SAE is any AE that meets one of the following conditions: 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 14 
03DEC2021 
 
 
• 
Is immediately life-threatening (e.g., participant was, in the view of the Investigator, at 
immediate risk of death from the event as it occurred); 
• 
Requires or prolongs hospitalization; 
• 
Results in congenital anomaly or birth defect; 
• 
Results in persistent or significant disability/incapacity; 
• 
Is an important medical event that may not result in death or be life threatening, but based 
upon appropriate medical judgment, may jeopardize the participant and may require 
medical or surgical intervention to prevent one of the outcomes listed above; 
• 
Results in death. 
 
 
9.1.4. 
Treatment-Emergent Adverse Events (TEAEs) 
9.1.4.1. Definition of Treatment-Emergent 
TEAEs include the following: 
a) Post-treatment complications that occur as a result of protocol mandated procedure. 
b) Any pre-existing condition that increases in severity, or changes in nature during or as a 
consequence of the study drug phase of a human clinical trial, will also be considered an 
AE. 
c) Complications and termination of pregnancy; see protocol v5.0 section 7.1.7 for additional 
information. 
d) Non-elective medical or surgical procedures. 
 
9.1.4.2. Incomplete Dates 
If the date of onset is incomplete, then the month and year (or year alone if month is not 
recorded) of onset determine treatment emergence as follows. The event is treatment emergent if 
the month and year of onset (or year of onset) of the event is the same as or after the month and 
year (or year) of date of first dose. 
9.1.5. 
Summaries of Adverse Events 
An overall summary of AEs will display, by treatment, the number and percentage of subjects 
who had any TEAE, whose strongest TEAE relationship to study drug is related or not related, 
whose maximum TEAE severity is mild, moderate, or severe, who had any SAE, any Serious 
TEAE, any TEAE leading to study discontinuation, and any TEAE leading to death.  
The following summaries (number and percentage of subjects) of AEs (by SOC and PT) will be 
provided by treatment: 
• 
All TEAEs 
• 
All TEAEs by strongest relationship 
• 
All TEAEs by maximum severity grade 
• 
All Related TEAEs by maximum severity grade 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 15 
03DEC2021 
 
• 
All Serious AEs 
• 
All Serious TEAEs 
• 
All TEAEs leading to study discontinuation 
• 
All TEAEs leading to death 
 
These summaries will present the number and percentage of subjects with at least one qualifying 
AE. Subjects may have more than one AE per SOC and PT. Each summary will be ordered by 
descending order of incidence of SOC and PT within each SOC.  
In addition to the by-treatment summaries, data listings will be provided for the following: 
• 
All AEs (with a flag indicating whether the event is treatment emergent) 
• 
SAEs 
• 
AEs leading to study discontinuation 
• 
Deaths 
 
9.2. 
Clinical Laboratory Evaluations 
Continuous response variables per time point will be summarized with mean, median, minimum, 
and maximum values. Categorical response variables will be summarized per time point with 
percentages. Shift from baseline in laboratory parameter results (indicated as Low, Normal, or 
High) will be summarized for the worse (most extreme) post-baseline assessment. Mean (+/- SD) 
laboratory parameter values of interest will be graphically presented over time by treatment. All 
laboratory parameters will be listed and include indicators for low/high and clinical significance 
as determined by the investigator. 
 
9.3. 
Vital Signs  
Vital signs (temperature, heart rate, systolic blood pressure (SBP), diastolic blood pressure 
(DBP)) will be summarized using descriptive statistics (sample size, mean, SD, median, 
minimum, and maximum) at baseline and at each post-baseline time point by treatment. Change 
from baseline will also be summarized at each post-baseline time point. Mean (+/- SD) vital sign 
values will be graphically presented over time by treatment. All vital signs results will be listed. 
9.4. 
ECG Results 
Shift from baseline in 12-Lead ECG overall interpretation (results are Normal, Abnormal Not 
Clinically Significant (NCS), or Abnormal Clinically Significant (CS)) will be summarized at 
each post-baseline study day by treatment. Mean (+/- SD) continuous ECG parameter values will 
be graphically presented over time by treatment. 
 
Additionally, the number and percentage of subjects will be summarized for the following QTcF 
Interval result categories at baseline and study day 15 by treatment: 
 
• <=450 msec (males) or <=470 msec (females) 
• >450 msec (males) or >470 msec (females) 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 16 
03DEC2021 
 
• Change from baseline <=60 msec (only applies to post-baseline visits) 
• Change from baseline >60 msec (only applies to post-baseline visits) 
 
A listing of ECG results will present the interpretations of abnormalities and whether these are 
considered clinically significant by the investigator.  
 
9.5. 
Physical Exam 
Physical exam findings will be listed. 
 
9.6. 
Urine Pregnancy Test 
Pregnancy test results will be listed. 
 
9.7. 
Other Data 
Chest x-ray scores, nasal oxygen (O2) administration and flow rate, and CPAP usage and PEEP, 
% FiO2 if mechanically ventilated, ECMO treatment will be presented in listings. The number of 
days of nasal oxygen (O2) administration and flow rate, level of PEEP, % of FiO2 if 
mechanically ventilated, ECMO treatment and CPAP usage, will be summarized by treatment 
using descriptive statistics (sample size, mean, median, SD, minimum, maximum).


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 17 
03DEC2021 
 
APPENDIX A: PRESENTATION OF DATA AND PROGRAMMING SPECIFICATIONS 
 
Tables 
• 
Formal organization of tabulations may be changed during programming if appropriate, 
e.g., tables for the different variables may be combined into a single table, or tables with 
more than one variable may be split into several tables. 
• 
Means and medians will be presented to one more decimal place than the raw data. SDs 
will be presented to two more decimal places than the raw data. Minimums and 
maximums will be reported with the same number of decimal places as the raw data.  
• 
Percentages will be presented to the tenths place. 
• 
For frequency counts of categorical variables, categories whose counts are zero will be 
displayed for the sake of completeness. For example, if none of the subjects discontinue 
due to “lost to follow-up,” this reason will be included in the table with a count of 0. 
Categories with zero counts will not have zero percentages displayed. 
• 
The last footnote will be “Reference: xxx”, where xxx indicates the source listing 
number(s).   
 
Listings 
• 
Formal organization of the listing may be changed during programming if appropriate, 
e.g., additional variables may be included, change in the column order, or the listing may 
be split into multiple parts due to space constraints, etc. 
• 
If not otherwise specified, all data listings will be sorted by treatment, subject number, 
visit, and date/time as appropriate.   
• 
All date values will be presented in an ISO 8601 date (e.g., 2001-08-29) format.  
• 
All observed time values will be presented using a 24-hour clock HH:MM:SS format 
(e.g., 01:35:45 or 11:26). Seconds will only be reported if they were measured as part of 
the study. 
 
Missing or incomplete dates, i.e., AEs and concomitant medications 
The most conservative approach will be systematically considered. If the AE onset date is 
missing or incomplete, it is assumed to have occurred during the study treatment phase (i.e., 
considered a TEAE) except if the partial onset date or other data such as the stop date, indicates 
differently. Similarly, a medication with partial start and stop dates could be considered as a 
concomitant treatment. 
 
The following algorithms will be applied to missing and incomplete start and stop dates: 
 
Start Dates 
• 
If the day portion of the start date is missing, then the start date will be estimated to be 
equal to the date of IP administration, provided the start month and year are the same as 
IP administration and the stop date is either after IP administration or completely missing. 
Otherwise, the missing day portion will be estimated as ‘01’. 
• 
If both the day and month portions of the start date are missing, then the start date will be 
estimated to be equal to the date of IP administration, provided the start year is the same 
as IP administration and the stop date is either after IP administration or completely 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 18 
03DEC2021 
 
missing. Otherwise, the event will be assumed to start on the first day of the given year, 
e.g., 2013-??-?? is estimated as 2013-01-01. 
• 
If the start date is completely missing and the stop date is either after IP administration or 
completely missing, the start date will be estimated to be the day of IP administration. 
Otherwise, the start date will be estimated to be the first day of the same year as the stop 
date. All other non-AE and non-concomitant medication day calculations where only 
partial dates are available will be handled as follows: the first day of the month will be 
used in the calculations if the day part of a start date is missing while January 1 will be 
employed if both the month and day parts of a start date are missing. 
 
Stop Dates 
• 
If only the day of resolution is unknown, the day will be assumed to be the last of the 
month, e.g., 2013-01-?? will be treated as 2013-01-31.  
• 
If both the day and month of resolution are unknown, the event will be assumed to have 
ceased on the last day of the year, e.g., 2013-??-?? will be treated as 2013-12-31.  
• 
If the stop date is completely missing or the event is continuing, the event will be 
assumed to be after IP administration and will be left as missing. 
 
Standard Calculations 
Variables requiring calculation will be derived using the following formulas: 
 
• 
Days – A duration expressed in days between two dates (start date and end date)  is 
calculated using the formulas noted below: 
• 
duration in days = end date  – start date + 1, where end date ≥ treatment start date 
• 
duration in days = end date  – start date, where end date < treatment start date 
• 
Months – A duration expressed in months is calculated as the number days divided by 
365.25/12 (~30.4).  
• 
Years – A duration expressed in years between one date (date1) and another later date 
(date2) is calculated using the formula: duration in years = (date2-date1+1)/365.25  
• 
Height – Height entries made in inches (in) are converted to centimeters (cm) using the 
following formula: height (cm) = height (in) × 2.54 
• 
Weight – Weight entries made in pounds (lb.) are converted to kilograms (kg) using the 
following formula: weight (kg) = weight (lb.) / 2.2046 
• 
Temperature – Temperature entries in degrees Fahrenheit are converted to degrees 
centigrade using the following formula: temp (degrees centigrade) = 5/9 × [temp (degrees 
Fahrenheit) - 32] 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 19 
03DEC2021 
 
• 
Change from baseline – Change from baseline will be calculated as: Change = post 
baseline value – baseline value 
• 
Percent change from baseline – Change from baseline will be calculated as: percent 
change from baseline = post baseline value – baseline value / baseline value  
× 100 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 20 
03DEC2021 
 
APPENDIX B: TABLE OF CONTENTS FOR STATISTICAL TABLES AND LISTINGS 
 
The following TFL numbering is completed according to ICH guidelines.  The ICH heading 
number and description are in bold. Minor changes from this planned index do not need to be 
amended in the SAP. Formal organization of tabulations may be changed during programming if 
appropriate, e.g., tables for the different variables may be combined into a single table, or tables 
with more than one variable may be split into several tables. 
 
List of Tables 
 
ICH 
Heading 
Table 
Number 
 
Table Description 
14.1 
 
DEMOGRAPHIC/BASELINE DATA 
 
14.1.1.1 
Subject Disposition (All Subjects) 
 
14.1.1.2 
Reason for Screen Failure (All Screen Failure Subjects) 
 
14.1.2 
Demographic and Baseline Characteristics (ITT Population) 
 
14.1.3 
Medical History (ITT Population) 
 
14.1.4 
Prior and Concomitant Medications (ITT Population) 
 
14.1.5 
Treatment Exposure (Safety Population) 
14.2 
 
EFFICACY DATA 
 
14.2.1.1 
Analysis of Overall Treatment Failure (ITT Population) 
 
14.2.1.2 
Analysis of Overall Treatment Failure (mITT Population) 
 
14.2.1.2 
Analysis of Overall Treatment Failure (PP Population) 
 
14.2.2.1.1 
Summary of the Number of Days Requiring ICU Care (ITT 
Population) 
 
14.2.2.1.2 
Summary of the Number of Days Requiring ICU Care (PP 
Population) 
 
14.2.2.2.1 
Summary of the Number of Days on Mechanical Ventilation (ITT 
Population) 
 
14.2.2.2.2 
Summary of the Number of Days on Mechanical Ventilation (PP 
Population) 
 
14.2.2.3.1 
Summary of Number of Days Requiring Nasal Oxygen (O2) 
Administration (ITT Population) 
 
14.2.2.3.2 
Summary of Number of Days Requiring Nasal Oxygen (O2) 
Administration (PP Population) 
 
14.2.2.4.1 
Summary of Number of Days Requiring CPAP Usage (ITT 
Population) 
 
14.2.2.4.2 
Summary of Number of Days Requiring CPAP Usage (PP 
Population) 
 
14.2.2.5.1 
Summary of Number of Days Requiring ECMO Administration 
(ITT Population) 
 
14.2.2.5.2 
Summary of Number of Days Requiring ECMO Administration 
(PP Population) 
 
14.2.2.6.1 
Summary of Number of Days with PEEP > 5cm H2O (ITT 
Population) 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 21 
03DEC2021 
 
ICH 
Heading 
Table 
Number 
 
Table Description 
 
14.2.2.6.2 
Summary of Number of Days with PEEP > 5cm H2O (PP 
Population) 
 
14.2.2.7.1 
Summary of Maximal Levels of PEEP values (ITT Population) 
 
14.2.2.7.2 
Summary of Maximal Levels of PEEP values (PP Population) 
 
14.2.2.8.1 
Summary of the Number of Days in Hospital (ITT Population) 
 
14.2.2.8.2 
Summary of the Number of Days in Hospital (PP Population) 
 
14.2.3.1 
Cumulative Incidence of SARS-CoV-2 IgM Antibody Response by 
Study Day (PP Population) 
 
14.2.4.1 
WHO COVID-19 Classification Levels Relative to Baseline Serum 
Ferritin Level 
 
14.2.4.2 
WHO COVID-19 Classification Levels Relative to Baseline Serum 
IL-6 Level 
 
14.2.4.3 
WHO COVID-19 Classification Levels Relative to Baseline CRP 
14.3 
 
SAFETY DATA 
14.3.1 
 
Displays of Adverse Events 
 
14.3.1.1 
Overall Summary of Treatment-Emergent Adverse Events (Safety 
Population) 
 
14.3.1.2 
Treatment-Emergent Adverse Events by System Organ Class and 
Preferred Term (Safety Population) 
 
14.3.1.3 
Treatment-Emergent Adverse Events by System Organ Class, 
Preferred Term, and Strongest Relationship to Study Drug (Safety 
Population) 
 
14.3.1.4 
Treatment-Emergent Adverse Events by System Organ Class, 
Preferred Term, and Maximum Severity Grade (Safety Population) 
 
14.3.1.5 
Related Treatment-Emergent Adverse Events by System Organ 
Class, Preferred Term, and Maximum Severity Grade (Safety 
Population) 
14.3.2 
 
Serious and Significant Adverse Events 
 
14.3.2.1 
Serious Adverse Events by System Organ Class and Preferred 
Term (Safety Population) 
 
14.3.2.2 
Serious Treatment-Emergent Adverse Events by System Organ 
Class and Preferred Term (Safety Population) 
 
14.3.2.3 
Treatment-Emergent Adverse Events Leading to Study 
Discontinuation by System Organ Class and Preferred Term 
(Safety Population) 
 
14.3.2.4 
Treatment-Emergent Adverse Events Leading to Death by System 
Organ Class and Preferred Term (Safety Population) 
14.3.4 
 
Laboratory 
 
14.3.4.1 
Hematology (Safety Population) 
 
14.3.4.2 
Chemistry (Safety Population) 
 
14.3.4.3 
Shift from Baseline in Hematology Results by Test (Safety 
Population) 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 22 
03DEC2021 
 
ICH 
Heading 
Table 
Number 
 
Table Description 
 
14.3.4.4 
Shift from Baseline in Chemistry Results by Test (Safety 
Population) 
 
14.3.4.5 
Observed and Change from Baseline in Vital Sign Results by Test 
and Study Day (Safety Population) 
 
14.3.4.6.1 
Shift from Baseline in 12-Lead ECG Overall Interpretation by 
Study Day (Safety Population) 
 
14.3.4.6.2 
Summary of QTcF Interval (msec) by Study Day and Result 
Category (Safety Population) 
 
 
 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 23 
03DEC2021 
 
List of Figures 
 
ICH 
Heading 
Figure 
Number 
 
Figure Description 
14.2 
 
Efficacy Data 
 
14.2.2.1 
Line Plots of Mean (+/- SD) PEEP Results During Intubation by 
Study Day (ITT Population) 
 
14.2.2.2 
Line Plots of Mean (+/- SD) PEEP Results During Intubation by 
Study Day (PP Population) 
 
 
 
14.3.4 
 
Laboratory 
 
14.3.4.1 
Line Plots of Mean (+/- SD) Vital Sign Results by Test and Study 
Day (Safety Population) 
 
14.3.4.2 
Line Plots of Mean (+/- SD) 12-Lead ECG Results by Test and 
Study Day (Safety Population) 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 24 
03DEC2021 
 
List of Data Listings 
ICH Heading Listing 
Number 
 
Listing Description 
16.2 
 
SUBJECT DATA LISTINGS 
16.2.1 
 
Discontinued Subjects 
 
16.2.1 
Subject Disposition 
16.2.2 
 
Protocol Deviations 
 
16.2.2 
Protocol Deviations  
16.2.3 
 
Subjects Excluded from the Safety Analysis 
 
16.2.3 
Inclusion/Exclusion Criteria 
16.2.4 
 
Demographic and Baseline Data 
 
16.2.4.1 
Demographic and Baseline Characteristics 
 
16.2.4.2 
Medical History 
 
16.2.4.3 
Prior and Concomitant Medications 
16.2.5 
 
Exposure and/or Drug Concentration Data  
 
16.2.5.1 
Treatment Exposure  
 
16.2.5.2 
Study Drug Administration 
 
16.2.5.3 
Pharmacokinetic Assessment 
 
16.2.5.4 
Blood Draw 
16.2.6 
 
Individual Efficacy Response Data  
 
16.2.6.1 
WHO Clinical Classification 
 
16.2.6.2 
Mechanical Ventilation 
 
16.2.6.3 
Nasal Oxygen (O2) Administration 
 
16.2.6.4 
CPAP Use, ECMO Prescription, ICU Admission 
 
16.2.6.5 
SARS-CoV-2 IgM Antibody Titer and Response 
16.2.7 
 
Adverse Events listings 
 
16.2.7.1 
Adverse Events 
 
16.2.7.2 
Serious Adverse Events 
 
16.2.7.3 
Adverse Events Leading to Study Discontinuation 
 
16.2.7.4 
Deaths 
16.2.8 
 
Laboratory and Other Data 
 
16.2.8.1 
Hematology 
 
16.2.8.2 
Chemistry 
 
16.2.8.3 
Vital Signs 
 
16.2.8.4 
12-Lead Electrocardiogram 
 
16.2.8.5 
Physical Examination 
 
16.2.8.6 
Urine Pregnancy Test 
 
16.2.8.7 
Chest X-Ray Score 
 
 
 
 
 
 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 25 
03DEC2021 
 


GeneOne Life Science Inc. 
Statistical Analysis Plan 
GLS27-005 
                   Version 1.0 
CONFIDENTIAL 
Page 26 
03DEC2021 
 
APPENDIX C: TABLE LAYOUTS 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
 
Table 14.1.1.1 
Subject Disposition 
(All Subjects) 
 
Subject Status 
 
GLS-1027 
120 mg 
GLS-1027 
360 mg 
Placebo 
 
Overall 
 
 
 
 
 
 
Screened  
 
 
 
 
 
xx 
Screen Failure  
 
 
 
 
 
xx 
ITT Population [1] 
 
xx 
xx 
xx 
 
xx 
mITT Population [2] 
 
xx 
xx 
xx 
 
xx 
Safety Population [3] 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
PP Population [4] 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
 
 
 
 
 
 
Completed the study 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
Discontinued the study 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
Reason for discontinuation 
 
 
 
 
 
 
<Reason #1> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
<Reason #2> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
<Reason #3> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
 
 
 
 
 
 
Percentages are based on the ITT Population, unless otherwise noted.  
[1] The Intent-to-treat (ITT) Population includes all randomized to treatment allocation. 
[2] The modified intention to treatment (mITT) population includes all participants who are randomized to a treatment allocation, and who have 
received at least one dose of study drug. 
[3] The Safety Population includes all subjects in the ITT population who received at least one dose of study drug. 
[4] The PP Population includes all safety subjects who complete the trial by meeting the endpoint or being discharged within 14 days without 
meeting the endpoint. 
Reference: Listing 16.2.1 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
 
Table 14.1.1.2 
Reason for Screen Failure 
(All Screen Failure Subjects) 
                    
Reason 
 
 
Overall 
(xx) 
 
 
 
<Reason #1>   
 
 
x (xx.x%) 
<Reason #2>   
 
 
x (xx.x%) 
<Reason #3>   
 
 
x (xx.x%) 
 
 
 
Reference: Listing 16.2.3 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas 
 
date 
 time 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
 
Table 14.1.2 
Demographic and Baseline Characteristics 
(ITT Population) 
 
Characteristic 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
Placebo 
(N=XX) 
 
Overall 
(N=XX) 
 
 
 
 
 
Age (years) 
 
 
 
 
 
n 
xx 
xx 
xx 
 
xx 
Mean (SD) 
xx.x (xx.xx) 
xx.x (xx.xx) 
xx.x (xx.xx) 
 
xx.x (xx.xx) 
Median 
xx.x 
xx.x 
xx.x 
 
xx.x 
Min, Max 
xx, xx 
xx, xx 
xx, xx 
 
xx, xx 
 
 
 
 
 
 
<65 years  
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
>=65 years 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
 
 
 
 
 
Sex 
 
 
 
 
 
Male 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
Female 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
 
 
 
 
 
Race 
 
 
 
 
 
American Indian or Alaskan Native 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
Asian  
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
Black or African American 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
Native Hawaiian or Other Pacific Islander 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
White 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
Other 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
 
 
 
 
 
 
Ethnicity 
 
 
 
 
 
Hispanic or Latino 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
Not Hispanic or Latino 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
Not Reported 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
Unknown 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
 
 
 
 
 
Baseline is the last non-missing value prior to first dose of study treatment. 
Reference: Listing 16.2.4.1 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 


 
 
GeneOne Life Science Inc. 
Page 2 of 2 
Protocol: GLS27-005 
 
 
Table 14.1.2 
Demographic and Baseline Characteristics 
(ITT Population) 
 
Characteristic 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
Placebo 
(N=XX) 
 
Overall 
(N=XX) 
 
 
 
 
 
Height (cm) 
 
 
 
 
 
n 
xx 
xx 
xx 
 
xx 
Mean (SD) 
xx.x (x.xx) 
xx.x (x.xx) 
xx.x (x.xx) 
 
xx.x (x.xx) 
Median 
xx.x 
xx.x 
xx.x 
 
xx.x 
Min, Max 
xx, xx 
xx, xx 
xx, xx 
 
xx, xx 
 
 
 
 
 
Weight (kg) 
 
 
 
 
 
n 
xx 
xx 
xx 
 
xx 
Mean (SD) 
xx.x (x.xx) 
xx.x (x.xx) 
xx.x (x.xx) 
 
xx.x (x.xx) 
Median 
xx.x 
xx.x 
xx.x 
 
xx.x 
Min, Max 
xx, xx 
xx, xx 
xx, xx 
 
xx, xx 
 
 
 
 
 
BMI (kg/m^2) 
 
 
 
 
 
n 
xx 
xx 
xx 
 
xx 
Mean (SD) 
xx.x (x.xx) 
xx.x (x.xx) 
xx.x (x.xx) 
 
xx.x (x.xx) 
Median 
xx.x 
xx.x 
xx.x 
 
xx.x 
Min, Max 
xx, xx 
xx, xx 
xx, xx 
 
xx, xx 
 
 
 
 
 
BMI = Body Mass Index 
Baseline is the last non-missing value prior to first dose of study treatment. 
Note: Body mass index (BMI) calculated as weight (kg) / [[height (cm)/100]2].  
Reference: Listing 16.2.4.1 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
 
Table 14.1.3 
Medical History 
(ITT Population) 
 
System Organ Class  
   Preferred Term 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
 
 
Overall 
(N=XX) 
 
 
 
 
 
 
Subjects with at least one medical history event  
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
 
 
 
 
 
 
 
<System Organ Class #1> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
<Preferred Term #1> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
<Preferred Term #2> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
 
 
 
 
 
 
 
<System Organ Class #2> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
<Preferred Term #1> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
<Preferred Term #2> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
 . 
 
 
 
 
 
 
 . 
 
 
 
 
 
 
 
 
 
 
 
 
MedDRA = Medical Dictionary for Regulatory Activities. 
Medical history terms are coded using MedDRA version 23.0 and ordered by descending order of overall incidence of SOC and overall incidence of PT 
within each SOC. At each level of summation (overall, SOC, PT), subjects reporting more than one medical history term are counted only once. 
Reference: Listing 16.2.4.2 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
 
Table 14.1.4 
Prior and Concomitant Medications 
(ITT Population) 
 
ATC Class 
 Preferred Name 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
Placebo 
(N=XX) 
 
 
 
 
 
 
Subjects who received any prior or concomitant  
medications 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
Subjects who received any prior or concomitant corticosteroids 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
 
<ATC Class # 1> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
<Preferred Name #1> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
<Preferred Name #2> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
<Preferred Name #3> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
 
<ATC Class # 2> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
<Preferred Name #1> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
<Preferred Name #2> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
<Preferred Name #3> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
 . 
 
 
 
 
 
 . 
 
 
 
 
 
 
 
 
 
 
A concomitant medication is any medication that was ongoing or started on or after the date of first dose. A prior medication is defined as a 
medication that was administered up to 4 months prior to time of enrollment. 
Medications are coded using WHODrug Global (March 2020) and ordered by descending order of overall incidence of ATC class and overall incidence 
of preferred name within each class. At each level of summation (overall, ATC class, preferred name), subjects reporting more than one medication 
are counted only once. 
Reference: Listing 16.2.4.3 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Sort table by descending overall count of ATC class and descending overall count of preferred name within each class. 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
Table 14.1.5 
Treatment Exposure  
(Safety Population) 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
 
 
 
Duration of exposure (days) [1] 
 
 
 
n 
xx 
xx 
xx 
Mean (SD) 
xx.x (xx.xx) 
xx.x (xx.xx) 
xx.x (xx.xx) 
Median 
xx.x 
xx.x 
xx.x 
Min, Max 
xx, xx 
xx, xx 
xx, xx 
 
 
 
 
Total number of doses taken 
 
 
 
n 
xx 
xx 
xx 
Mean (SD) 
xx.x (xx.xx) 
xx.x (xx.xx) 
xx.x (xx.xx) 
Median 
xx.x 
xx.x 
xx.x 
Min, Max 
xx, xx 
xx, xx 
xx, xx 
 
 
 
 
Total number of doses missed 
 
 
 
n 
xx 
xx 
xx 
Mean (SD) 
xx.x (xx.xx) 
xx.x (xx.xx) 
xx.x (xx.xx) 
Median 
xx.x 
xx.x 
xx.x 
Min, Max 
xx, xx 
xx, xx 
xx, xx 
 
 
 
 
 
 
 
[1] Duration of exposure is defined as the date of last dose minus the date of first dose + 1. 
Reference: Listing 16.2.5.1. 
 
 


 
 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
Table 14.2.1.1 
Analysis of Overall Treatment Failure 
(ITT Population) 
 
Overall/Subjects with prior or concomitant corticosteroids/Subjects without prior or concomitant corticosteroids 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
Placebo 
(N=XX) 
 
 
 
Treatment Failure [1] 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Achieved WHO level >=6 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Lost to follow-up 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Withdrawal of informed consent 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Required salvage therapy 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Discontinued study drug prior to discharge 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Had missing assessment of WHO level classification 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
p-value [2] 
0.xxxx 
0.xxxx 
 
 
 
 
Maximum WHO Level = 6 (Intubation or Mechanical Ventilation) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Maximum WHO Level = 7 (Requirement for ECMO) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Maximum WHO Level = 8 (Death) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
 
 
[1] Subjects who met any of the reasons listed are considered treatment failures. Subjects who failed treatment for multiple reasons are counted 
once for each reason. 
[2] P-value is calculated using a Fisher’s exact test and compares the active treatment to placebo. Will only be provided for the 120 mg group if 
the 360 mg group is significant. 
Reference: Listing 16.2.6.1 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming note: Repeat for Table 14.2.1.2 Analysis of Overall Treatment Failure (mITT Population). 
Programming note: Repeat for Table 14.2.1.3 Analysis of Overall Treatment Failure (PP Population). 
Programming note: P-values will not be provided for corticosteroid use/non-use subset pages. 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
Table 14.2.2.1.1 
Summary of the Number of Days Requiring ICU Care 
(ITT Population) 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
 
 
 
 
Number of Days Requiring ICU Care 
 
 
 
 
 n 
x 
x 
 
x 
 Mean (SD) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
 
xx.xx (xx.xxx) 
 Median 
x.xx 
x.xx 
 
x.xx 
 Min, Max 
xx.x, xx.x 
xx.x, xx.x 
 
xx.x, xx.x 
 
 
 
 
 
Reference: Listing xxxxx 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming note: Repeat for Table 14.2.2.1.2 Summary of the Number of Days Requiring ICU Care (PP Population). 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
Table 14.2.2.2.1 
Summary of the Number of Days on Mechanical Ventilation 
(ITT Population) 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
 
 
 
 
Number of Days on Mechanical Ventilation 
 
 
 
 
 n 
x 
x 
 
x 
 Mean (SD) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
 
xx.xx (xx.xxx) 
 Median 
x.xx 
x.xx 
 
x.xx 
 Min, Max 
xx.x, xx.x 
xx.x, xx.x 
 
xx.x, xx.x 
 
 
 
 
 
Reference: Listing 16.2.6.2 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming note: Repeat for Table 14.2.2.2.2 Summary of the Number of Days on Mechanical Ventilation (PP Population). 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
Table 14.2.2.3.1 
Summary of the Number of Days Requiring Nasal Oxygen (O2) Administration 
(ITT Population) 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
 
 
 
 
Number of Days Requiring Nasal Oxygen (O2) 
 
 
 
 
 n 
x 
x 
 
x 
 Mean (SD) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
 
xx.xx (xx.xxx) 
 Median 
x.xx 
x.xx 
 
x.xx 
 Min, Max 
xx.x, xx.x 
xx.x, xx.x 
 
xx.x, xx.x 
 
 
 
 
 
Reference: Listing 16.2.6.3 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming note: Repeat for Table 14.2.2.3.2 Summary of the Number of Days Requiring Nasal Oxygen (O2) Administration (PP Population). 
 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
Table 14.2.2.4.1 
Summary of the Number of Days Requiring CPAP Usage 
(ITT Population) 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
 
 
 
 
Number of Days Requiring CPAP Usage 
 
 
 
 
 n 
x 
x 
 
x 
 Mean (SD) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
 
xx.xx (xx.xxx) 
 Median 
x.xx 
x.xx 
 
x.xx 
 Min, Max 
xx.x, xx.x 
xx.x, xx.x 
 
xx.x, xx.x 
 
 
 
 
 
Reference: Listing 16.2.6.4 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming note: Repeat for Table 14.2.2.4.2 Summary of the Number of Days Requiring CPAP Usage (PP Population). 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
Table 14.2.2.5.1 
Summary of the Number of Days Requiring ECMO Administration 
(ITT Population) 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
 
 
 
 
Number of Days Requiring ECMO Administration 
 
 
 
 
 n 
x 
x 
 
x 
 Mean (SD) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
 
xx.xx (xx.xxx) 
 Median 
x.xx 
x.xx 
 
x.xx 
 Min, Max 
xx.x, xx.x 
xx.x, xx.x 
 
xx.x, xx.x 
 
 
 
 
 
Reference: Listing 16.2.6.5 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming note: Repeat for Table 14.2.2.5.2 Summary of the Number of Days Requiring ECMO Administration (PP Population). 
 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
Table 14.2.2.6.1 
Summary of the Number of Days with PEEP > 5 cm H2O 
(ITT Population) 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
 
 
 
 
Number of Days with PEEP > 5 cm H2O 
 
 
 
 
 n 
x 
x 
 
x 
 Mean (SD) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
 
xx.xx (xx.xxx) 
 Median 
x.xx 
x.xx 
 
x.xx 
 Min, Max 
xx.x, xx.x 
xx.x, xx.x 
 
xx.x, xx.x 
 
 
 
 
 
Note: Only subjects who were intubated are included in this endpoint analysis. 
Reference: Listing 16.2.6.2 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming note: Repeat for Table 14.2.2.6.2 Summary of the Number of Days with PEEP > 5 cm H2O (PP Population). 
 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
Table 14.2.2.7.1 
Summary of Maximal Levels of PEEP Values 
(ITT Population) 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
 
 
 
 
Maximal Level of PEEP 
 
 
 
 
 n 
x 
x 
 
x 
 Mean (SD) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
 
xx.xx (xx.xxx) 
 Median 
x.xx 
x.xx 
 
x.xx 
 Min, Max 
xx.x, xx.x 
xx.x, xx.x 
 
xx.x, xx.x 
 
 
 
 
 
Note: Only subjects who were intubated are included in this endpoint analysis. 
Reference: Listing 16.2.6.2 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming note: Repeat for Table 14.2.2.7.2 Summary of Maximal Levels of PEEP Values (PP Population). 
 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
Table 14.2.2.8.1 
Summary of the Number of Days in Hospital 
(ITT Population) 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
 
 
 
 
Number of Days in Hospital 
 
 
 
 
 n 
x 
x 
 
x 
 Mean (SD) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
 
xx.xx (xx.xxx) 
 Median 
x.xx 
x.xx 
 
x.xx 
 Min, Max 
xx.x, xx.x 
xx.x, xx.x 
 
xx.x, xx.x 
 
 
 
 
 
Reference: Listing xxxxx 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming note: Repeat for Table 14.2.2.8.2 Summary of the Number of Days in Hospital (PP Population). 
 
 
 


 
 
 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
Table 14.2.3.1 
Cumulative Incidence of SARS-CoV-2 IgM Antibody Response by Study Day 
(PP Population) 
 
Study Day 
Responded 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
120 mg 
(N=XX) 
Placebo 
(N=XX) 
n(%) 
 
 
 
Day 1 
 
 
 
n 
x 
x 
x 
Yes 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
No 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
 
 
Day 2 
 
 
 
n 
x 
x 
x 
Yes 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
No 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
 
 
Day 3 
 
 
 
n 
x 
x 
x 
Yes 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
No 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
 
 
Day 4 
 
 
 
n 
x 
x 
x 
Yes 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
No 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
 
 
... 
 
 
 
 
 
 
The incidence of antibody response is summarized based on results obtained at or prior to the study day. 
Reference: Listing 16.2.6.3 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Table 14.2.4.1 
WHO COVID-19 Classification Levels Relative to Baseline Serum Ferritin Level 
(PP Population) 
 
WHO Classification 
Level 
Serum Ferritin [1] 
GLS-1027 
120 mg 
(N=XX) 
Post-Baseline 
GLS-1027 
360 mg 
(N=XX) 
Post-Baseline 
 
Placebo 
(N=XX) 
Post-Baseline 
Overall 
(N=XX) 
Post-Baseline 
 
Baseline 
Low 
Normal 
High 
Low 
Normal 
High 
Low  
Normal 
High 
Low  
Normal 
High 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
n 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
Low 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
Normal 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
High 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
n 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Low 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
Normal 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
High 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
n 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
Low 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
Normal 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
High 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
n 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
Low 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
Normal 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
High 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[1] Worst (most extreme) values presented for serum ferritin. 
Reference: Listing xx.x.x.x 
 


 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Table 14.2.4.2 
WHO COVID-19 Classification Levels Relative to Baseline Serum IL-6 Level 
(PP Population) 
 
WHO Classification 
Level 
Serum IL-6 [1] 
GLS-1027 
120 mg 
(N=XX) 
Post-Baseline 
GLS-1027 
360 mg 
(N=XX) 
Post-Baseline 
 
Placebo 
(N=XX) 
Post-Baseline 
Overall 
(N=XX) 
Post-Baseline 
 
Baseline 
Low 
Normal 
High 
Low 
Normal 
High 
Low  
Normal 
High 
Low  
Normal 
High 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
n 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
Low 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
Normal 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
High 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
n 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Low 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
Normal 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
High 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
n 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
Low 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
Normal 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
High 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
n 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
Low 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
Normal 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
High 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[1] Worst (most extreme) values presented for serum IL-6. 
Reference: Listing xx.x.x.x 
 


 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Table 14.2.4.3 
WHO COVID-19 Classification Levels Relative to Baseline CRP 
(PP Population) 
 
WHO Classification 
Level 
CRP [1] 
GLS-1027 
120 mg 
(N=XX) 
Post-Baseline 
GLS-1027 
360 mg 
(N=XX) 
Post-Baseline 
 
Placebo 
(N=XX) 
Post-Baseline 
Overall 
(N=XX) 
Post-Baseline 
 
Baseline 
Low 
Normal 
High 
Low 
Normal 
High 
Low  
Normal 
High 
Low  
Normal 
High 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
n 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
Low 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
Normal 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
High 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
n 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Low 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
Normal 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
High 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
n 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
Low 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
Normal 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
High 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
n 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
Low 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
Normal 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
High 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
xx 
(xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[1] Worst (most extreme) values presented for CRP. 
Reference: Listing xx.x.x.x 
 


 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of 1 
Protocol: GLS27-005 
 
 
Table 14.3.1.1 
Overall Summary of Treatment-Emergent Adverse Events 
(Safety Population) 
 
 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
Placebo 
(N=XX) 
Overall 
(N=XX) 
 
 
 
 
 
Subjects with any TEAE  
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Subjects whose strongest TEAE relationship to study drug is 
related [1] 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Subjects whose strongest TEAE relationship to study drug is 
not related [2] 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Subjects whose maximum TEAE severity grade is grade 1 [3] 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Subjects whose maximum TEAE severity grade is grade 2 [3] 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Subjects whose maximum TEAE severity grade is grade 3 [3] 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Subjects whose maximum TEAE severity grade is grade 4 [3] 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Subjects with any SAE 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Subjects with any Serious TEAE 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Subjects with any TEAE leading to study discontinuation 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
Subjects with any TEAE leading to death 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
AE = Adverse Event; SAE = Serious Adverse Event; TEAE = Treatment-Emergent Adverse Event;  
[1] Related TEAEs are those with a relationship of related, possibly related, or probably related. If the relationship is missing, it is 
considered related. 
[2] Not related TEAEs are those with a relationship of unlikely related or not related. 
[3] Severity grades are determined according to the NCI Common Terminology Criteria for Adverse Events version 5.0. 
Reference: Listing 16.2.7.1 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
 
Table 14.3.1.2 
Treatment-Emergent Adverse Events by System Organ Class and Preferred Term 
(Safety Population) 
 
System Organ Class  
   Preferred Term 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
Placebo 
(N=XX) 
Overall 
(N=XX) 
 
 
 
 
 
 
 
Subjects with at least 
one TEAE 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
 
 
 
<System Organ Class #1> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
<Preferred Term #1> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
<Preferred Term #2> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
 
 
 
<System Organ Class #2> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
<Preferred Term #1> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
<Preferred Term #2> 
 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 
 . 
 
 
 
 
 
 
 . 
 
 
 
 
 
 
 
 
 
 
 
 
AE=Adverse Event; TEAE = Treatment-Emergent Adverse Event; MedDRA = Medical Dictionary for Regulatory Activities. 
AEs are coded using MedDRA version 23.0 and ordered by descending order of overall incidence of SOC and overall incidence of PT within each SOC. 
At each level of summation (overall, SOC, PT), subjects reporting more than one TEAE are counted only once. 
Reference: Listing 16.2.7.1 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
 
Table 14.3.1.3 
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term, and Strongest Relationship to Study Drug 
(Safety Population) 
 
System Organ Class  
   Preferred Term 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
Placebo 
 (N=XX) 
Overall 
(N=XX) 
 
Related 
Not Related 
Related 
Not Related 
Related 
Not Related 
Related 
Not Related  
 
 
 
 
 
 
 
 
 
 
Subjects with at least one related TEAE  x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%)  
 
 
 
 
 
 
 
 
 
 
 
<System Organ Class #1> 
 x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%)  
<Preferred Term #1> 
 x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%)  
<Preferred Term #2> 
 x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%)  
 
 
 
 
 
 
 
 
 
 
 
<System Organ Class #2> 
 x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%)  
<Preferred Term #1> 
 x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%)  
<Preferred Term #2> 
 x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%)  
 . 
 
 
 
 
 
 
 
 
 
 
 . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AE=Adverse Event; TEAE = Treatment-Emergent Adverse Event; MedDRA = Medical Dictionary for Regulatory Activities. 
AEs are coded using MedDRA version 23.0 and ordered by descending order of overall incidence of SOC and overall incidence of PT within each SOC. 
At each level of summation (overall, SOC, PT), subjects reporting more than one TEAE are counted only once using the strongest relationship. 
Related TEAEs are those with a relationship of related, possibly related, or probably related. If the relationship is missing, it is considered 
related. Not Related TEAEs are those with a relationship of unlikely related or not related. 
Reference: Listing 16.2.7.1 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
 
Table 14.3.1.4 
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term, and Maximum Severity Grade 
(Safety Population) 
Treatment Group: xxxx 
System Organ Class  
   Preferred Term 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Subjects with at least one TEAE 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
<System Organ Class #1> 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #1> 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #2> 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
<System Organ Class #2> 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #1> 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #2> 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
x (xx.x%) 
 . 
 . 
AE=Adverse Event; TEAE = Treatment-Emergent Adverse Event; MedDRA = Medical Dictionary for Regulatory Activities 
AEs are coded using MedDRA version 23.0 and ordered by descending order of overall incidence of SOC and overall incidence of PT within each SOC. 
At each level of summation (overall, SOC, PT), subjects reporting more than one TEAE are counted only once using the highest grade. 
Severity grades are determined according to the NCI Common Terminology Criteria for Adverse Events version 5.0. 
Reference: Listing 16.2.7.1 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Repeat Table layout for: 
Table 14.3.1.5 
Related Treatment-Emergent Adverse Events by System Organ Class, Preferred Term, and Maximum Severity Grade 
(Safety Population) 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
 
Table 14.3.2.1 
Serious Adverse Events by System Organ Class and Preferred Term 
(Safety Population) 
 
System Organ Class  
   Preferred Term 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
Overall 
(N=XX) 
 
 
 
 
 
 
Subjects with at least one serious AE 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
 
 
<System Organ Class #1> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #1> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #2> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
 
 
<System Organ Class #2> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #1> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #2> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
 . 
 
 
 
 
 
 
 . 
 
 
 
 
 
 
 
 
 
 
 
 
AE=Adverse Event; Adverse Event; MedDRA = Medical Dictionary for Regulatory Activities. 
AEs are coded using MedDRA v23.0 and ordered by descending order of overall incidence of SOC and overall incidence of PT within each SOC. At each 
level of summation (overall, SOC, PT), subjects reporting more than one AE are counted only once. 
Reference: Listing 16.2.7.2 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
 
Table 14.3.2.2 
Serious Treatment-Emergent Adverse Events by System Organ Class and Preferred Term 
(Safety Population) 
 
System Organ Class  
   Preferred Term 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
Overall 
(N=XX) 
 
 
 
 
 
 
Subjects with at least one serious TEAE 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
 
 
<System Organ Class #1> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #1> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #2> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
 
 
<System Organ Class #2> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #1> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #2> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
 . 
 
 
 
 
 
 
 . 
 
 
 
 
 
 
 
 
 
 
 
 
AE=Adverse Event; TEAE = Treatment-Emergent Adverse Event; MedDRA = Medical Dictionary for Regulatory Activities. 
AEs are coded using MedDRA v23.0 and ordered by descending order of overall incidence of SOC and overall incidence of PT within each SOC. At each 
level of summation (overall, SOC, PT), subjects reporting more than one TEAE are counted only once. 
Reference: Listing 16.2.7.2 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
 
Table 14.3.2.3 
Treatment-Emergent Adverse Events Leading to Study Discontinuation by System Organ Class and Preferred Term 
(Safety Population) 
 
System Organ Class  
   Preferred Term 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
Overall 
(N=XX) 
 
 
 
 
 
 
Subjects with at least one TEAE leading to study 
discontinuation 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
 
 
<System Organ Class #1> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #1> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #2> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
 
 
<System Organ Class #2> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #1> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #2> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
 . 
 
 
 
 
 
 
 . 
 
 
 
 
 
 
 
 
 
 
 
 
AE=Adverse Event; TEAE = Treatment-Emergent Adverse Event; MedDRA = Medical Dictionary for Regulatory Activities 
AEs are coded using MedDRA v23.0 and ordered by descending order of overall incidence of SOC and overall incidence of PT within each SOC. At each 
level of summation (overall, SOC, PT), subjects reporting more than one TEAE are counted only once. 
Reference: Listing 16.2.7.4 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
 
Table 14.3.2.4 
Treatment-Emergent Adverse Events Leading to Death by System Organ Class and Preferred Term 
(Safety Population) 
 
System Organ Class  
   Preferred Term 
 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
Overall 
(N=XX) 
 
 
 
 
 
 
Subjects with at least one TEAE leading to death 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
 
 
<System Organ Class #1> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #1> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #2> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
 
 
 
 
 
 
 
<System Organ Class #2> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #1> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
<Preferred Term #2> 
 
x (xx.x%) 
x (xx.x%) 
 
x (xx.x%) 
x (xx.x%) 
 . 
 
 
 
 
 
 
 . 
 
 
 
 
 
 
 
 
 
 
 
 
AE = Adverse Event; TEAE = Treatment-Emergent Adverse Event; MedDRA = Medical Dictionary for Regulatory Activities 
AEs are coded using MedDRA v23.0 and ordered by descending order of overall incidence of SOC and overall incidence of PT within each SOC. At each 
level of summation (overall, SOC, PT), subjects reporting more than one TEAE are counted only once. 
Reference: Listing 16.2.7.1 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
 
 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Table 14.3.4.1 
Hematology 
(Safety Population) 
Test 
Time Point 
GLS-1027 
120 mg 
(N=xx) 
GLS-1027 
360 mg 
(N=xx) 
Placebo 
(N=xx) 
Total 
(N = xx) 
Result 
Change from 
Baseline 
Result 
Change from 
Baseline 
Result 
Change from 
Baseline 
Result 
Change from 
Baseline 
 
 
 
 
 
 
 
 
<Test #1> 
(<unit>) Baseline 
 
 
 
 
 
 
 
 
 
n 
xx 
 
xx 
 
xx 
 
xx 
 
 
Mean (SD) 
xx.x (xx.xx) 
 
xx.x (xx.xx) 
 
xx.x (xx.xx) 
 
xx.x (xx.xx) 
 
 
Median 
xx.x 
 
xx.x 
 
xx.x 
 
xx.x 
 
 
Min, Max 
xx, xx 
 
xx, xx 
 
xx, xx 
 
xx, xx 
 
 
 
 
 
 
 
 
 
Day 2  
 
 
 
 
 
 
 
 
 
n 
xx 
xx 
xx 
xx 
xx 
xx 
xx 
xx 
 
Mean (SD) 
xx.x (xx.xx) xx.x (xx.xx) xx.x (xx.xx) xx.x (xx.xx) xx.x (xx.xx) xx.x (xx.xx) xx.x (xx.xx) xx.x (xx.xx) 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
 
Min, Max 
xx, xx 
xx, xx 
xx, xx 
xx, xx 
xx, xx 
xx, xx 
xx, xx 
xx, xx 
 
 
 
 
 
 
 
 
Etc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline is the last non-missing value prior to first dose of study treatment. 
 
Reference: Listing 16.2.8.1 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Continue for all hematology tests. 
 
Repeat Table 14.3.4.1 Layout for: 
Table 14.3.4.2 
Chemistry 
(Safety Population)


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Table 14.3.4.3 
Shift from Baseline in Hematology Results by Test 
(Safety Population) 
 
Test [1] 
 
GLS-1027 
120 mg 
(N=XX) 
Baseline 
GLS-1027 
360 mg 
(N=XX) 
Baseline 
 
Placebo 
(N=XX) 
Baseline 
Overall 
(N=XX) 
Baseline 
Low 
Normal 
High 
Low 
Normal 
High 
Low  
Normal 
High 
Low  
Normal 
High 
 
 
 
 
 
 
 
 
 
 
 
 
<Test #1> (units) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n 
 
x 
 
 
x 
 
 
x 
 
 
x 
 
  Low 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
  Normal 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
  High 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
... 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[1] Worst (most extreme) values presented for each test. 
Baseline is the last non-missing value prior to first dose of study treatment. 
Percentages are based on n, the number of subjects with both a baseline and post-baseline result at the study day. 
Shifts are based on local labs from each site. 
Reference: Listing 16.2.8.1 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Continue for all hematology tests. 
 
Repeat Table 14.3.4.1 Layout for: 
Table 14.3.4.4 
Shift from Baseline in Chemistry Results by Test and Study Day 
(Safety Population) 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Table 14.3.4.5 
Observed and Change from Baseline in Vital Sign Results by Test and Study Day 
(Safety Population) 
 
Test 
Study Day 
GLS-1027 
120 mg 
(N=XX) 
GLS-1027 
360 mg 
(N=XX) 
Placebo 
(N=XX) 
Overall 
(N=XX) 
Observed 
Change from Baseline 
Observed 
Change from Baseline 
Change from Baseline 
Change from Baseline 
 
 
 
 
 
 
 
 
<Test #1> (units) 
 
 
 
 
 
 
 
 
Baseline 
 
 
 
 
 
 
 
 
  n 
x 
 
x 
 
x 
 
x 
 
  Mean (SD) 
xx.xx (xx.xxx) 
 
xx.xx (xx.xxx) 
 
xx.xx (xx.xxx) 
 
xx.xx (xx.xxx) 
 
  Median 
x.xx 
 
x.xx 
 
x.xx 
 
x.xx 
 
  Min, Max 
xx.x, xx.x 
 
xx.x, xx.x 
 
xx.x, xx.x 
 
xx.x, xx.x 
 
 
 
 
 
 
 
 
 
 
Day 2 
 
 
 
 
 
 
 
 
  n 
x 
x 
x 
x 
x 
x 
x 
x 
  Mean (SD) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) xx.xx (xx.xxx) xx.xx (xx.xxx) xx.xx (xx.xxx) 
  Median 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
  Min, Max 
xx.x, xx.x 
xx.x, xx.x 
xx.x, xx.x 
xx.x, xx.x 
xx.x, xx.x 
xx.x, xx.x 
xx.x, xx.x 
xx.x, xx.x 
 
 
 
 
 
 
 
 
 
Day 3 
 
 
 
 
 
 
 
 
  n 
x 
x 
x 
x 
x 
x 
x 
x 
  Mean (SD) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) 
xx.xx (xx.xxx) xx.xx (xx.xxx) xx.xx (xx.xxx) xx.xx (xx.xxx) 
  Median 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
  Min, Max 
xx.x, xx.x 
xx.x, xx.x 
xx.x, xx.x 
xx.x, xx.x 
xx.x, xx.x 
xx.x, xx.x 
xx.x, xx.x 
xx.x, xx.x 
 
 
 
 
 
 
 
 
 
... 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline is the last non-missing value prior to first dose of study treatment. 
Reference: Listing 16.2.8.3 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
Programming Note: Continue for all vital sign tests. 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Table 14.3.4.6.1 
Shift from Baseline in 12-Lead ECG Overall Interpretation by Study Day 
(Safety Population) 
 
Study Day 
GLS-1027 
120 mg 
(N=XX) 
Baseline 
GLS-1027 
360 mg 
(N=XX) 
Baseline 
Placebo 
(N=XX) 
Baseline 
Overall 
(N=XX) 
Baseline 
Normal Abnormal NCS Abnormal CS Normal Abnormal NCS Abnormal CS Normal Abnormal NCS Abnormal CS 
Normal 
Abnormal 
NCS 
Abnormal 
CS 
 
 
 
 
 
 
 
 
 
 
 
 
Day 2 
 
 
 
 
 
 
 
 
 
 
 
 
n 
 
x 
 
 
x 
 
 
x 
 
 
x 
 
  Normal 
xx 
(xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
  Abnormal 
NCS 
xx 
(xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
  Abnormal 
CS 
xx 
(xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
Day 15 
 
 
 
 
 
 
 
 
 
 
 
 
n 
 
x 
 
 
x 
 
 
x 
 
 
x 
 
  Normal 
xx 
(xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
  Abnormal 
NCS 
xx 
(xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
  Abnormal 
CS 
xx 
(xx.x) 
xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) 
xx (xx.x) xx (xx.x) xx (xx.x) xx (xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(N)CS = (Not) Clinically Significant. 
Baseline is the last non-missing value prior to first dose of study treatment. 
Percentages are based on n, the number of subjects with both a baseline and post-baseline result at the study day. 
Reference: Listing 16.2.8.4 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Table 14.3.4.6.2 
Summary of QTcF Interval (msec) by Study Day and Result Category 
(Safety Population) 
 
Study Day 
Result Category 
 
GLS-1027 
120 mg 
(N=XX) 
 
GLS-1027 
360 mg 
(N=XX) 
 
Placebo 
(N=XX) 
 
Overall 
(N=XX) 
 
 
 
 
Baseline 
 
 
 
 
n 
x 
x 
x 
x 
<=450 msec (males) or <=470 msec (females) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
>450 msec (males) or >470 msec (females) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Day 2 
 
 
 
 
n 
x 
x 
x 
x 
<=450 msec (males) or <=470 msec (females) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
>450 msec (males) or >470 msec (females) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
Change from baseline <=60 msec 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
Change from baseline >60 msec 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Day 15 
 
 
 
 
n 
x 
x 
x 
x 
<=450 msec (males) or <=470 msec (females) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
>450 msec (males) or >470 msec (females) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
Change from baseline <=60 msec 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
Change from baseline >60 msec 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
xx (xx.x) 
 
 
 
 
 
Baseline is the last non-missing value prior to first dose of study treatment. 
Percentages are based on n, the number of subjects with a baseline and post-baseline (for Week 4) result at the study day. 
Reference: Listing 16.2.8.4 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 


 
 
APPENDIX D: FIGURE LAYOUTS 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
 
 
 
Figure 14.2.2.1 
Line Plot of Mean (+/- SD) PEEP Results During Intubation by Study Day 
(ITT Population) 
 
Figure 14.2.2.2 
Line Plot of Mean (+/- SD) PEEP Results During Intubation by Study Day 
(PP Population) 
 
 
 


 
 
 
 
Figure 14.3.4.1 
Line Plots of Mean (+/-SD) Vital Sign Results by Test and Study Day 
(Safety Population) 
 
Figure 14.3.4.2 
Line Plots of Mean (+/-SD) 12-Lead ECG Results by Test and Study Day 
(Safety Population) 
 


 
 
APPENDIX E:  LISTING LAYOUTS 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.1 
Subject Disposition 
 
Treatment: GLS-1027 120 mg 
 
Subject 
ID 
Informed 
Consent 
Date 
Randomization 
Date 
ITT 
Population 
[1] 
mITT 
Population 
[2] 
Safety 
Population 
[3] 
PP 
Population 
[4] 
First Dose 
Date/Time 
Study 
Completion 
Status 
Study Completion 
or 
Discontinuation 
Date 
(Study Day) 
xxxxx 
yyyy-mm-dd  
yyyy-mm-dd  Yes/No 
Yes/No 
Yes/No 
Yes/No 
yyyy-mm-dd 
hh:mm  
xxxxxxxxxx 
yyyy-mm-dd (xx) 
xxxxx 
yyyy-mm-dd  
yyyy-mm-dd  Yes/No 
Yes/No 
Yes/No 
Yes/No 
yyyy-mm-dd 
hh:mm   
xxxxxxxxxx 
yyyy-mm-dd (xx) 
xxxxx 
yyyy-mm-dd  
yyyy-mm-dd  Yes/No 
Yes/No 
Yes/No 
Yes/No 
yyyy-mm-dd 
hh:mm  
xxxxxxxxxx 
yyyy-mm-dd (xx) 
xxxxx 
yyyy-mm-dd  
yyyy-mm-dd  Yes/No 
Yes/No 
Yes/No 
Yes/No 
yyyy-mm-dd 
hh:mm   
xxxxxxxxxx 
yyyy-mm-dd (xx) 
xxxxx 
yyyy-mm-dd  
yyyy-mm-dd  Yes/No 
Yes/No 
Yes/No 
Yes/No 
yyyy-mm-dd 
hh:mm  
xxxxxxxxxx 
yyyy-mm-dd (xx) 
xxxxx 
yyyy-mm-dd  
yyyy-mm-dd  Yes/No 
Yes/No 
Yes/No 
Yes/No 
yyyy-mm-dd 
hh:mm   
xxxxxxxxxx 
yyyy-mm-dd (xx) 
xxxxx 
yyyy-mm-dd  
yyyy-mm-dd  Yes/No 
Yes/No 
Yes/No 
Yes/No 
yyyy-mm-dd 
hh:mm  
xxxxxxxxxx 
yyyy-mm-dd (xx) 
xxxxx 
yyyy-mm-dd  
yyyy-mm-dd  Yes/No 
Yes/No 
Yes/No 
Yes/No 
yyyy-mm-dd 
hh:mm   
xxxxxxxxxx 
yyyy-mm-dd (xx) 
[1] The Intent-to-treat (ITT) Population includes all randomized to treatment allocation. 
[2] The modified intention to treatment (mITT) population includes all participants who are randomized to a treatment allocation, and who have 
received at least one dose of study drug. 
[3] The Safety Population includes all subjects who received at least one dose of study drug. 
[4] The PP Population includes all safety subjects who complete the trial by meeting the endpoint or being discharged within 14 days without 
meeting the endpoint. 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.2 
Protocol Deviations 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Deviation Date 
(Study Day) 
Deviation Category 
Description 
xxxxxx 
yyyy-mm-dd (xx) 
Major/Minor 
xxxxxx 
xxxxxx 
yyyy-mm-dd (xx) 
Major/Minor 
xxxxxx 
xxxxxx 
yyyy-mm-dd (xx) 
Major/Minor 
xxxxxx 
xxxxxx 
yyyy-mm-dd (xx) 
Major/Minor 
xxxxxx 
xxxxxx 
yyyy-mm-dd (xx) 
Major/Minor 
xxxxxx 
xxxxxx 
yyyy-mm-dd (xx) 
Major/Minor 
xxxxxx 
xxxxxx 
yyyy-mm-dd (xx) 
Major/Minor 
xxxxxx 
xxxxxx 
yyyy-mm-dd (xx) 
Major/Minor 
xxxxxx 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.3 
Inclusion/Exclusion Criteria 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
All eligibility criteria met 
Criterion not met 
Criterion Description 
xxxxxx 
Yes/No 
Inclusion xx/Exclusion xx 
xxxxxxxx 
xxxxxx 
Yes/No 
Inclusion xx/Exclusion xx 
xxxxxxxx 
xxxxxx 
Yes/No 
Inclusion xx/Exclusion xx 
xxxxxxxx 
xxxxxx 
Yes/No 
Inclusion xx/Exclusion xx 
xxxxxxxx 
xxxxxx 
Yes/No 
Inclusion xx/Exclusion xx 
xxxxxxxx 
xxxxxx 
Yes/No 
Inclusion xx/Exclusion xx 
xxxxxxxx 
xxxxxx 
Yes/No 
Inclusion xx/Exclusion xx 
xxxxxxxx 
xxxxxx 
Yes/No 
Inclusion xx/Exclusion xx 
xxxxxxxx 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. If more than one criterion IDs are selected for a subject, list each one on a separate line. 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.4.1 
Demographic and Baseline Characteristics 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Age 
(years) 
Gender at Birth/ 
Current Gender 
Taking Approved 
Form of Birth Control 
Race 
Ethnicity 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kg/m^2) 
xxxxxx 
xx 
Male/Female 
Yes 
xxxxxxxxxxxx 
xxxxxxxxxxxx 
xx.x 
xx.x 
xx.x 
xxxxxx 
xx 
Male/Female 
No: Reason 
xxxxxxxxxxxx 
xxxxxxxxxxxx 
xx.x 
xx.x 
xx.x 
xxxxxx 
xx 
Male/Female 
N/A 
xxxxxxxxxxxx 
xxxxxxxxxxxx 
xx.x 
xx.x 
xx.x 
xxxxxx 
xx 
Male/Female 
Yes/No 
xxxxxxxxxxxx 
xxxxxxxxxxxx 
xx.x 
xx.x 
xx.x 
xxxxxx 
xx 
Male/Female 
Yes/No 
xxxxxxxxxxxx 
xxxxxxxxxxxx 
xx.x 
xx.x 
xx.x 
xxxxxx 
xx 
Male/Female 
Yes/No 
xxxxxxxxxxxx 
xxxxxxxxxxxx 
xx.x 
xx.x 
xx.x 
xxxxxx 
xx 
Male/Female 
Yes/No 
xxxxxxxxxxxx 
xxxxxxxxxxxx 
xx.x 
xx.x 
xx.x 
xxxxxx 
xx 
Male/Female 
Yes/No 
xxxxxxxxxxxx 
xxxxxxxxxxxx 
xx.x 
xx.x 
xx.x 
Baseline is the last non-missing value prior to first dose of study treatment. 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.4.2 
Medical History 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Any medical history 
System Organ Class/ 
Preferred Term/ 
Verbatim Term 
Start Date 
Ongoing 
Stop Date 
xxxxxx 
Yes/No 
xxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxxx 
yyyy-mm-dd 
Yes/No 
yyyy-mm-dd 
xxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxx 
yyyy-mm-dd 
Yes/No 
yyyy-mm-dd 
xxxxxx 
Yes/No 
xxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxxx 
yyyy-mm-dd 
Yes/No 
yyyy-mm-dd 
xxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxx 
yyyy-mm-dd 
Yes/No 
yyyy-mm-dd 
xxxxxx 
Yes/No 
xxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxxx 
yyyy-mm-dd 
Yes/No 
yyyy-mm-dd 
xxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxx 
yyyy-mm-dd 
Yes/No 
yyyy-mm-dd 
MedDRA = Medical Dictionary for Regulatory Activities. 
Medical history terms are coded using MedDRA version 23.0. 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.4.3 
Prior and Concomitant Medications 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
ATC Class/ 
Preferred Name/ 
Verbatim Term 
Start Date 
(Study Day) 
End Date 
(Study Day) 
Dose 
Units 
Route 
Frequency 
Indication 
 
xxxxxx 
xxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxxx 
yyyy-mm-dd (xx) yyyy-mm-dd (xx) xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxx 
yyyy-mm-dd (xx) yyyy-mm-dd (xx) xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxx 
xxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxxx* 
yyyy-mm-dd (xx) yyyy-mm-dd (xx) xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx/ 
xxxxxxxxx/ 
xxxxxxxx+ 
yyyy-mm-dd (xx) yyyy-mm-dd (xx) xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
... 
 
 
 
 
Medications are coded using WHODrug Global (March 2020). 
Prior medications are denoted by *. Prior corticosteroids are denoted by +. 
A prior medication is defined as a medication that started and stopped prior to first dose of study treatment. A concomitant medication is any 
medication that is ongoing or started on or after the date of first dose. 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
Programming Note: Repeat for each treatment group. 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.5.1 
Treatment Exposure  
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Date/time of first dose 
Date/time of last dose 
Duration of Exposure 
(days) [1] 
Number of Days 
with At Least 
One Dose Taken 
Total Doses Taken 
Total Doses Missed 
xxxxxx 
yyyy-mm-dd hh:mm 
yyyy-mm-dd hh:mm 
xx 
xx 
xx 
xx 
xxxxxx 
yyyy-mm-dd hh:mm 
yyyy-mm-dd hh:mm 
xx 
xx 
xx 
xx 
xxxxxx 
yyyy-mm-dd hh:mm 
yyyy-mm-dd hh:mm 
xx 
xx 
xx 
xx 
xxxxxx 
yyyy-mm-dd hh:mm 
yyyy-mm-dd hh:mm 
xx 
xx 
xx 
xx 
xxxxxx 
yyyy-mm-dd hh:mm 
yyyy-mm-dd hh:mm 
xx 
xx 
xx 
xx 
xxxxxx 
yyyy-mm-dd hh:mm 
yyyy-mm-dd hh:mm 
xx 
xx 
xx 
xx 
xxxxxx 
yyyy-mm-dd hh:mm 
yyyy-mm-dd hh:mm 
xx 
xx 
xx 
xx 
xxxxxx 
yyyy-mm-dd hh:mm 
yyyy-mm-dd hh:mm 
xx 
xx 
xx 
xx 
 
 
[1] Duration of exposure is defined as the date of last dose minus the date of first dose + 1. 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 
 
 


 
 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.5.2 
Study Drug Administration 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Study Day 
Study drug 
administered 
Date/time of 
administration 
Full dose given 
If partial dose, 
amount given 
Number of pills 
administered 
xxxxxx 
xxxxxx 
Yes/No: Reason 
yyyy-mm-dd hh:mm 
Yes/No 
xx 
xx 
xxxxxx 
Yes/No: Reason 
yyyy-mm-dd hh:mm 
Yes/No 
xx 
xx 
xxxxxx 
xxxxxx 
Yes/No: Reason 
yyyy-mm-dd hh:mm 
Yes/No 
xx 
xx 
xxxxxx 
Yes/No: Reason 
yyyy-mm-dd hh:mm 
Yes/No 
xx 
xx 
xxxxxx 
xxxxxx 
Yes/No: Reason 
yyyy-mm-dd hh:mm 
Yes/No 
xx 
xx 
xxxxxx 
Yes/No: Reason 
yyyy-mm-dd hh:mm 
Yes/No 
xx 
xx 
xxxxxx 
xxxxxx 
Yes/No: Reason 
yyyy-mm-dd hh:mm 
Yes/No 
xx 
xx 
xxxxxx 
Yes/No: Reason 
yyyy-mm-dd hh:mm 
Yes/No 
xx 
xx 
 
 
 
 
 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.5.3 
Pharmacokinetic Assessment 
Treatment: GLS-1027 120 mg 
 
Subject ID Study Day 
Blood for PK Assessment 
Collected 
PK Timepoint 
Date/Time of PK Collection 
Result 
(unit) 
xxxxxx 
Day 2 
Yes/No 
Pre-Treatment 
yyyy-mm-dd hh:mm 
xx.x 
1 Hour Post-Dose 
NOT DONE 
2 Hours Post-Dose 
yyyy-mm-dd hh:mm 
xx.x 
4 Hours Post-Dose 
yyyy-mm-dd hh:mm 
xx.x 
8 Hours Post-Dose 
yyyy-mm-dd hh:mm 
xx.x 
xxxxxx 
Day 2 
Yes/No 
Pre-Treatment 
yyyy-mm-dd hh:mm 
xx.x 
1 Hour Post-Dose 
NOT DONE 
2 Hours Post-Dose 
yyyy-mm-dd hh:mm 
xx.x 
4 Hours Post-Dose 
yyyy-mm-dd hh:mm 
xx.x 
8 Hours Post-Dose 
yyyy-mm-dd hh:mm 
xx.x 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each active treatment group. 
 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.5.4 
Blood Draw 
 
Treatment: GLS-1027 120 mg 
 
Subject 
ID 
Study 
Day 
Blood for Trough Drug 
Measurement Collected/ 
Volume Collected 
Date/Time of Trough Drug 
Measurement Collection 
Blood for Serum 
Collected/ 
Volume Collected 
Date/Time of Serum 
Collection 
Blood for PBMCs 
Collected/ 
Volume Collected 
Date/Time of PBMCs 
Collection 
xxxxxx 
Day 1 N/A 
Yes/No/xx 
yyyy-mm-dd hh:mm 
Yes/No/xx 
yyyy-mm-dd hh:mm 
Day 2 Yes/No/xx 
yyyy-mm-dd hh:mm 
N/A 
N/A 
N/A 
Day 3 Yes/No/xx 
yyyy-mm-dd hh:mm 
N/A 
N/A 
N/A 
Day 4 Yes/No/xx 
yyyy-mm-dd hh:mm 
Yes/No/xx 
yyyy-mm-dd hh:mm 
Yes/No/xx 
yyyy-mm-dd hh:mm 
Day 9 Yes/No/xx 
yyyy-mm-dd hh:mm 
Yes/No/xx 
yyyy-mm-dd hh:mm 
Yes/No/xx 
yyyy-mm-dd hh:mm 
Day 16 Yes/No/xx 
yyyy-mm-dd hh:mm 
Yes/No/xx 
yyyy-mm-dd hh:mm 
Yes/No/xx 
yyyy-mm-dd hh:mm 
Day 23 Yes/No/xx 
yyyy-mm-dd hh:mm 
Yes/No/xx 
yyyy-mm-dd hh:mm 
Yes/No/xx 
yyyy-mm-dd hh:mm 
Day 28 Yes/No/xx 
yyyy-mm-dd hh:mm 
Yes/No/xx 
yyyy-mm-dd hh:mm 
Yes/No/xx 
yyyy-mm-dd hh:mm 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.6.1 
WHO Clinical Classification 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Study Day 
Date of Assessment 
Score 
xxxxxx 
Day 1 
yyyy-mm-dd 
x 
Day 2 
yyyy-mm-dd 
x 
... 
xxxxxx 
Day 1 
yyyy-mm-dd 
x 
Day 2 
yyyy-mm-dd 
x 
... 
xxxxxx 
Day 1 
yyyy-mm-dd 
x 
Day 2 
yyyy-mm-dd 
x 
... 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.6.2 
Mechanical Ventilation 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Study Day 
Mechanical Ventilation Used Date of Mechanical 
Ventilation 
Maximal Daily 
Level of PEEP 
(cm) 
Maximal Daily 
Level of Delivered 
FiO2 
(%) 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
xxx.x 
xxx.x 
Day 2 
Yes/No 
yyyy-mm-dd 
xxx.x 
xxx.x 
... 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
xxx.x 
xxx.x 
Day 2 
Yes/No 
yyyy-mm-dd 
xxx.x 
xxx.x 
... 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
xxx.x 
xxx.x 
Day 2 
Yes/No 
yyyy-mm-dd 
xxx.x 
xxx.x 
... 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.6.3 
Nasal Oxygen (O2) Administration 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Study Day 
Nasal 02 Prescribed 
Date of Nasal 02 
Administration 
O2 Flow Rate 
(L/min) 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
xxx.xx 
Day 2 
Yes/No 
yyyy-mm-dd 
xxx.xx 
... 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
xxx.xx 
Day 2 
Yes/No 
yyyy-mm-dd 
xxx.xx 
... 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
xxx.xx 
Day 2 
Yes/No 
yyyy-mm-dd 
xxx.xx 
... 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.6.4 
CPAP Use, ECMO Prescription, ICU Admission 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Study Day 
CPAP Prescribed Date of CPAP Use Maximal Daily 
Level of End 
Expiratory 
Pressure 
Delivered by 
CPAP 
(cm) 
Was ECMO 
prescribed? 
Date of ECMO 
prescription 
Was patient 
admitted to ICU? 
Date of ICU 
Admission 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
xxx.xx 
Yes/No 
yyyy-mm-dd 
Yes/No 
yyyy-mm-dd 
Day 2 
Yes/No 
yyyy-mm-dd 
xxx.xx 
Yes/No 
yyyy-mm-dd 
Yes/No 
yyyy-mm-dd 
... 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
xxx.xx 
Yes/No 
yyyy-mm-dd 
Yes/No 
yyyy-mm-dd 
Day 2 
Yes/No 
yyyy-mm-dd 
xxx.xx 
Yes/No 
yyyy-mm-dd 
Yes/No 
yyyy-mm-dd 
... 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
xxx.xx 
Yes/No 
yyyy-mm-dd 
Yes/No 
yyyy-mm-dd 
Day 2 
Yes/No 
yyyy-mm-dd 
xxx.xx 
Yes/No 
yyyy-mm-dd 
Yes/No 
yyyy-mm-dd 
... 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 
 
 


 
 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.6.5 
SARS-COV-2 IgM Antibody Titer and Response 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Study Day 
Date of Assessment 
Titer 
xxxxxx 
Day 1 
yyyy-mm-dd 
xxx 
Day 7 
yyyy-mm-dd 
xxx 
xxxxxx 
Day 1 
yyyy-mm-dd 
xxx 
Day 7 
yyyy-mm-dd 
xxx 
xxxxxx 
Day 1 
yyyy-mm-dd 
xxx 
Day 7 
yyyy-mm-dd 
xxx 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.7.1 
Adverse Events 
 
Treatment: GLS-1027 120 mg 
 
Subject ID System Organ Class/ 
Preferred Term/ 
Verbatim Term 
Start Date 
(Study Day) 
End Date 
(Study Day) 
Severity Relationship 
Action Taken 
Serious Outcome 
Study 
Discontinuation 
Treatment 
Required 
 
xxxxxx 
xxxxxxxxxxxxxxx/ 
yyyy-mm-dd 
(xx) 
yyyy-mm-dd 
(xx) 
Grade x xxxxxxxxxx 
xxxxxxxxxx 
Yes/No xxxxxxxxxx Yes/No 
Yes/No 
 
xxxxxxxxxxxxxx/ 
xxxxxxxxxxxxx 
 
xxxxxx 
xxxxxxxxxxxxxxx/ 
yyyy-mm-dd 
(xx) 
yyyy-mm-dd 
(xx) 
Grade x xxxxxxxxxx 
xxxxxxxxxx 
Yes/No xxxxxxxxxx Yes/No 
Yes/No 
 
xxxxxxxxxxxxxx/ 
xxxxxxxxxxxxx 
 
xxxxxx 
xxxxxxxxxxxxxxx/ 
yyyy-mm-dd 
(xx) 
yyyy-mm-dd 
(xx) 
Grade x xxxxxxxxxx 
xxxxxxxxxx 
Yes/No xxxxxxxxxx Yes/No 
Yes/No 
 
xxxxxxxxxxxxxx/ 
xxxxxxxxxxxxx 
 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. Sort by Treatment, Subject ID, AE start date and end date. 
 
Repeat Layout of Listing 16.2.7.1 for: 
 
Listing 16.2.7.3 Adverse Events Leading to Study Discontinuation 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.7.2 
Serious Adverse Events 
 
Treatment: GLS-1027 120 mg 
 
Subject ID System Organ Class/ 
Preferred Term/ 
Verbatim Term 
Start Date 
(Study Day) 
End Date 
(Study Day) 
Severity Relationship Action Taken SAE Criteria 
Outcome 
Study 
Discontinuation 
Treatment 
Required 
 
xxxxxx 
xxxxxxxxxxxxxxx/ 
yyyy-mm-dd 
(xx) 
yyyy-mm-dd 
(xx) 
Grade x 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx Yes/No 
Yes/No 
 
xxxxxxxxxxxxxx/ 
xxxxxxxxxxxxx 
 
xxxxxx 
xxxxxxxxxxxxxxx/ 
yyyy-mm-dd 
(xx) 
yyyy-mm-dd 
(xx) 
Grade x 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx Yes/No 
Yes/No 
 
xxxxxxxxxxxxxx/ 
xxxxxxxxxxxxx 
 
xxxxxx 
xxxxxxxxxxxxxxx/ 
yyyy-mm-dd 
(xx) 
yyyy-mm-dd 
(xx) 
Grade x 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx Yes/No 
Yes/No 
 
xxxxxxxxxxxxxx/ 
xxxxxxxxxxxxx 
 
xxxxxx 
xxxxxxxxxxxxxxx/ 
yyyy-mm-dd 
(xx) 
yyyy-mm-dd 
(xx) 
Grade x 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx 
xxxxxxxxxx Yes/No 
Yes/No 
 
xxxxxxxxxxxxxx/ 
xxxxxxxxxxxxx 
 
 
SAE = Serious Adverse Event 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. Sort by Treatment, Subject ID, AE start date and end date. 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.7.4 
Deaths 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Death Date 
(Study Day) 
If Death is Due to Adverse Event, AE # 
xxxxxx 
yyyy-mm-dd (xx) 
xx 
xxxxxx 
yyyy-mm-dd (xx) 
xx 
xxxxxx 
yyyy-mm-dd (xx) 
xx 
xxxxxx 
yyyy-mm-dd (xx) 
xx 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. Sort by Treatment, Subject ID. 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.8.1 
Hematology 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Study Day 
Date 
(Study Day) 
Lab Test 
Result 
xxxxxx 
Day 0 
yyyy-mm-dd (xx) 
xxxxxxxxxx 
xx.x 
xxxxxxxxxx 
xx.x 
xxxxxxxxxx 
xx.x 
xxxxxxxxxx 
xx.x 
xxxxxxxxxx 
xx.x 
xxxxxxxxxx 
xx.x 
xxxxxxxxxx 
xx.x 
xxxxxxxxxx 
xx.x 
Study Day 4 
yyyy-mm-dd (xx) 
xxxxxxxxxx 
xx.x 
xxxxxxxxxx 
xx.x 
Baseline is the last non-missing value prior to first dose of study treatment. 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 
Repeat for Listing 16.2.8.2 Chemistry 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.8.3 
Vital Signs 
 
Treatment: GLS-1027 120 mg 
 
Subject ID Study Day Date/Time of Test Min/Max Systolic BP 
(mmHg) 
Min/Max Diastolic BP 
(mmHG) 
Min/Max Heart Rate 
(beats/min) 
Min/Max 
Respiratory Rate 
(breaths/min) 
Min/Max Temperature 
(◦C) 
 
 
 
 
 
 
xxxxxx 
Day 1 
yyyy-mm-dd hh:mm 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
Day 2 
yyyy-mm-dd hh:mm 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
Day 3 
yyyy-mm-dd hh:mm 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
Day 4 
yyyy-mm-dd hh:mm 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
Day 5 
yyyy-mm-dd hh:mm 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
Day 6 
yyyy-mm-dd hh:mm 
xx.x 
xx.x 
xx.x 
xx.x 
xx.x 
... 
 
 
 
 
 
 
 
 
 
 
 
Baseline is defined as the last non-missing value prior to the first dose of study treatment. 
SBP=Systolic Blood Pressure, DBP=Diastolic Blood Pressure. 
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.8.4 
12-Lead Electrocardiogram 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Study Day 
ECG Date/Time 
Parameter 
Result 
Overall Interpretation 
Abnormal CS Findings 
xxxxxx 
Hospital Admission yyyy-mm-dd hh:mm 
xxxxxxxxxxxx 
xx.x 
Normal/Abnormal NCS/Abnormal CS 
xxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxx 
xx.x 
xxxxxxxxxxxx 
xx.x 
xxxxxxxxxxxx 
xx.x 
xxxxxxxxxxxx 
xx.x 
xxxxxxxxxxxx 
xx.x 
xxxxxxxxxxxx 
xx.x 
xxxxxxxxxxxx 
xx.x 
Day 2 
yyyy-mm-dd hh:mm 
xxxxxxxxxxxx 
xx.x 
Normal/Abnormal NCS/Abnormal CS 
xxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxx 
xx.x 
xxxxxxxxxxxx 
xx.x 
xxxxxxxxxxxx 
xx.x 
xxxxxxxxxxxx 
xx.x 
xxxxxxxxxxxx 
xx.x 
xxxxxxxxxxxx 
xx.x 
xxxxxxxxxxxx 
xx.x 
... 
N(CS)=(Not) Clinically Significant  
 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.8.5 
Physical Examination 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Study Day 
Exam 
Completed 
Date 
Any Clinically Significant 
Findings 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
Yes/No 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
Yes/No 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
Yes/No 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
Yes/No 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.8.6 
Urine Pregnancy Test  
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Study Day 
Test Completed 
Date/Time of Test 
Result 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
Negative/Positive 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
Negative/Positive 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
Negative/Positive 
xxxxxx 
Day 1 
Yes/No 
yyyy-mm-dd 
Negative/Positive 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 
 
 


 
 
GeneOne Life Science Inc. 
Page 1 of x 
Protocol: GLS27-005 
 
Listing 16.2.8.7 
Chest X-Ray Score 
 
Treatment: GLS-1027 120 mg 
 
Subject ID 
Study Day 
Chest X-Ray Performed 
Date of Chest X-Ray 
CXR Score 
xxxxxx 
Hospital Admission 
Yes/No 
yyyy-mm-dd 
xxx.xx 
xxxxx 
Yes/No 
yyyy-mm-dd 
xxx.xx 
xxxxxx 
Hospital Admission 
Yes/No 
yyyy-mm-dd 
xxx.xx 
xxxxx 
Yes/No 
yyyy-mm-dd 
xxx.xx 
xxxxxx 
Hospital Admission 
Yes/No 
yyyy-mm-dd 
xxx.xx 
xxxxx 
Yes/No 
yyyy-mm-dd 
xxx.xx 
Source: \\xx\xxx\xxx\xxx\xxxxxx\xxxxxxxxxxxxxxxx\xxxx\xxxxx.sas  
date 
 time 
 
Programming Note: Repeat for each treatment group. 
 
 


Certificate Of Completion
Envelope Id: 809EB1C2727A4834A85933CC3530ED1B
Status: Completed
Subject: Please DocuSign: GeneOne_GLS27-005_SAP_v1.0_Catalyst_03Dec2021.pdf
Source Envelope: 
Document Pages: 91
Signatures: 2
Envelope Originator: 
Certificate Pages: 5
Initials: 0
Ahmed Tariq
AutoNav: Enabled
EnvelopeId Stamping: Disabled
Time Zone: (UTC-05:00) Eastern Time (US & Canada)
5826 Fayetville Rd
Suite 202
Durham, NC  27713
ahmed.tariq@catalystcr.com
IP Address: 74.71.122.151  
Record Tracking
Status: Original
             12/3/2021 3:17:54 PM
Holder: Ahmed Tariq
             ahmed.tariq@catalystcr.com
Location: DocuSign
Signer Events
Signature
Timestamp
Ahmed Tariq
ahmed.tariq@catalystcr.com
Catalyst Clinical Research - Part 11
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signature ID: 
8A9AFFC7-511B-4804-9134-C7E9728C3D84
Using IP Address: 74.71.122.151
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I am the author of this document
Sent: 12/3/2021 3:21:57 PM
Viewed: 12/3/2021 3:22:31 PM 
Signed: 12/3/2021 3:23:17 PM
Electronic Record and Signature Disclosure: 
      Not Offered via DocuSign
Susan E. Spruill
sspruill@appstatsconsulting.com
Security Level: Email, Account Authentication 
(Required)
Signature Adoption: Pre-selected Style
Signature ID: 
6B44CB45-B795-4FD5-B700-ED25E98AB084
Using IP Address: 99.197.222.18
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this document
Sent: 12/3/2021 3:21:57 PM
Viewed: 12/5/2021 8:53:06 AM 
Signed: 12/5/2021 8:54:12 AM
Electronic Record and Signature Disclosure: 
      Accepted: 12/5/2021 8:53:06 AM
      ID: e8e1e6ba-5d8e-4116-b669-e9d992005840
In Person Signer Events
Signature
Timestamp
Editor Delivery Events
Status
Timestamp
Agent Delivery Events
Status
Timestamp
Intermediary Delivery Events
Status
Timestamp
Certified Delivery Events
Status
Timestamp


Carbon Copy Events
Status
Timestamp
Witness Events
Signature
Timestamp
Notary Events
Signature
Timestamp
Envelope Summary Events
Status
Timestamps
Envelope Sent
Hashed/Encrypted
12/3/2021 3:21:57 PM
Certified Delivered
Security Checked
12/5/2021 8:53:06 AM
Signing Complete
Security Checked
12/5/2021 8:54:12 AM
Completed
Security Checked
12/5/2021 8:54:12 AM
Payment Events
Status
Timestamps
Electronic Record and Signature Disclosure


ELECTRONIC RECORD AND SIGNATURE DISCLOSURE  
From time to time, Catalyst Clinical Research - Part 11 (we, us or Company) may be required by 
law to provide to you certain written notices or disclosures. Described below are the terms and 
conditions for providing to you such notices and disclosures electronically through the DocuSign 
system. Please read the information below carefully and thoroughly, and if you can access this 
information electronically to your satisfaction and agree to this Electronic Record and Signature 
Disclosure (ERSD), please confirm your agreement by selecting the check-box next to ‘I agree to 
use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign 
system. 
 
Getting paper copies  
At any time, you may request from us a paper copy of any record provided or made available 
electronically to you by us. You will have the ability to download and print documents we send 
to you through the DocuSign system during and immediately after the signing session and, if you 
elect to create a DocuSign account, you may access the documents for a limited period of time 
(usually 30 days) after such documents are first sent to you. After such time, if you wish for us to 
send you paper copies of any such documents from our office to you, you will be charged a 
$0.00 per-page fee. You may request delivery of such paper copies from us by following the 
procedure described below. 
 
Withdrawing your consent  
If you decide to receive notices and disclosures from us electronically, you may at any time 
change your mind and tell us that thereafter you want to receive required notices and disclosures 
only in paper format. How you must inform us of your decision to receive future notices and 
disclosure in paper format and withdraw your consent to receive notices and disclosures 
electronically is described below. 
 
Consequences of changing your mind  
If you elect to receive required notices and disclosures only in paper format, it will slow the 
speed at which we can complete certain steps in transactions with you and delivering services to 
you because we will need first to send the required notices or disclosures to you in paper format, 
and then wait until we receive back from you your acknowledgment of your receipt of such 
paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to 
receive required notices and consents electronically from us or to sign electronically documents 
from us. 
 
All notices and disclosures will be sent to you electronically  
Electronic Record and Signature Disclosure created on: 9/25/2019 1:03:37 PM
Parties agreed to: Susan E. Spruill


Unless you tell us otherwise in accordance with the procedures described herein, we will provide 
electronically to you through the DocuSign system all required notices, disclosures, 
authorizations, acknowledgements, and other documents that are required to be provided or made 
available to you during the course of our relationship with you. To reduce the chance of you 
inadvertently not receiving any notice or disclosure, we prefer to provide all of the required 
notices and disclosures to you by the same method and to the same address that you have given 
us. Thus, you can receive all the disclosures and notices electronically or in paper format through 
the paper mail delivery system. If you do not agree with this process, please let us know as 
described below. Please also see the paragraph immediately above that describes the 
consequences of your electing not to receive delivery of the notices and disclosures 
electronically from us. 
 
How to contact Catalyst Clinical Research - Part 11:  
You may contact us to let us know of your changes as to how we may contact you electronically, 
to request paper copies of certain information from us, and to withdraw your prior consent to 
receive notices and disclosures electronically as follows: 
To contact us by email send messages to: shawnegerton@catalystcr.com 
 
To advise Catalyst Clinical Research - Part 11 of your new email address  
To let us know of a change in your email address where we should send notices and disclosures 
electronically to you, you must send an email message to us at shawnegerton@catalystcr.com 
and in the body of such request you must state: your previous email address, your new email 
address.  We do not require any other information from you to change your email address.  
If you created a DocuSign account, you may update it with your new email address through your 
account preferences.  
 
To request paper copies from Catalyst Clinical Research - Part 11  
To request delivery from us of paper copies of the notices and disclosures previously provided 
by us to you electronically, you must send us an email to shawnegerton@catalystcr.com and in 
the body of such request you must state your email address, full name, mailing address, and 
telephone number. We will bill you for any fees at that time, if any. 
 
To withdraw your consent with Catalyst Clinical Research - Part 11  
To inform us that you no longer wish to receive future notices and disclosures in electronic 
format you may: 


i. decline to sign a document from within your signing session, and on the subsequent page, 
select the check-box indicating you wish to withdraw your consent, or you may; 
ii. send us an email to shawnegerton@catalystcr.com and in the body of such request you must 
state your email, full name, mailing address, and telephone number. We do not need any other 
information from you to withdraw consent..  The consequences of your withdrawing consent for 
online documents will be that transactions may take a longer time to process.. 
 
Required hardware and software  
The minimum system requirements for using the DocuSign system may change over time. The 
current system requirements are found here: https://support.docusign.com/guides/signer-guide-
signing-system-requirements.  
 
Acknowledging your access and consent to receive and sign documents electronically  
To confirm to us that you can access this information electronically, which will be similar to 
other electronic notices and disclosures that we will provide to you, please confirm that you have 
read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for 
your future reference and access; or (ii) that you are able to email this ERSD to an email address 
where you will be able to print on paper or save it for your future reference and access. Further, 
if you consent to receiving notices and disclosures exclusively in electronic format as described 
herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before 
clicking ‘CONTINUE’ within the DocuSign system. 
By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm 
that: 
 
You can access and read this Electronic Record and Signature Disclosure; and 
 
You can print on paper this Electronic Record and Signature Disclosure, or save or send 
this Electronic Record and Disclosure to a location where you can print it, for future 
reference and access; and 
 
Until or unless you notify Catalyst Clinical Research - Part 11 as described above, you 
consent to receive exclusively through electronic means all notices, disclosures, 
authorizations, acknowledgements, and other documents that are required to be provided 
or made available to you by Catalyst Clinical Research - Part 11 during the course of 
your relationship with Catalyst Clinical Research - Part 11.